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Abstract 
 
Background:  Inpatient psychiatric care is a scarce and expensive resource in the National 
Health Service (NHS), with chronic bed shortages being partly driven by high re-admission 
rates.  People often need to go into hospital when they have a mental health crisis due to 
overwhelming distressing psychotic symptoms, such as hearing voices (hallucinations) or 
experiencing unusual beliefs (delusions).  Brief talking therapies may be helpful for people 
during an acute inpatient admission as an adjunct to medication in reducing re-admission 
rates, and despite promising findings from trials in the USA, there have not yet been any 
clinical trials on this kind of intervention within NHS settings. 
Objectives:  The primary objective of the study was to find out whether it was possible to 
carry out this kind of trial successfully within UK inpatient settings in terms of successfully 
recruiting and retaining patients in the trial.  The secondary objective was to collect pilot data 
on clinical outcome measures, including re-admission rates at 6-month follow-up. 
Method:  The amBITION study (BrIef Talking therapIes ON wards; ISRCTN376253384) 
was a parallel groups, feasibility randomised controlled trial (RCT) of a manualised brief 
talking therapy (Mindfulness-Based Crisis Intervention; MBCI).  Inpatients on acute 
psychiatric wards were eligible for the study if they reported at least one positive psychotic 
symptom, and were willing and able to engage in a talking therapy.  In addition to treatment 
as usual (TAU), participants were randomly allocated to receive either MBCI or a control 
intervention (Social Activity Therapy; SAT) which involved doing activities on the ward with 
the therapist.   
Results:  Fifty participants were recruited to the trial (26 MBCI; 24 TAU).  No participants 
dropped-out during the therapy phase, and everyone in the trial received at least one therapy 
session.  The average number of sessions per participant was 3 in both arms of the trial. 
Retention in the trial was excellent, and exceeded the pre-set benchmark of no more than 
20% loss to follow-up at trial end-point (6-month follow-up after discharge).  The follow-up 
rate at 6-month follow-up was 98% for service use data extracted from clinical notes, and 
86% for self-report questionnaire measures.  Three participants experienced adverse events, 
but none of these were considered to be related to their participation in the trial. 
Conclusions:  It is feasible to recruit and retain participants in the trial.  The therapy was 
acceptable to patients, and satisfaction ratings with therapy was high.  Progression to a further 
trial is warranted based on these encouraging feasibility outcomes.   
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 Acute inpatient care, CBT for psychosis and impact on reducing risk of 
relapse 
 
1.1 Overview 
 
Acute inpatient care for mental health in the National Health Service (NHS) is a scarce and 
expensive resource.  Bed occupancy is too high and length of admission is increasing.  
Service user satisfaction with inpatient care is generally low.  A common source of 
dissatisfaction with acute inpatient care is the lack of access to talking therapies.  The 
Schizophrenia Commission Report suggested that greater access to talking therapies during 
hospitalisation might be helpful in reducing short-term readmission rates.  However, the 
current gold-standard psychological therapy, Cognitive-Behavioural Therapy for psychosis 
(CBTp), whilst effective in reducing psychotic and affective symptoms, has not generally 
proven effective in reducing relapse.  There have been some randomised controlled trials 
(RCTs) of CBTp within acute inpatient settings, however they also failed to show a 
convincing effect in reducing relapse.  Furthermore, interventions tested in the 3 largest in-
patient RCTs comprised many treatment sessions (16-20), however, most participants did not 
complete a set minimum of sessions, let alone the full therapy course.  Given that the average 
length of an inpatient admission is around 4 weeks, what is required is a briefer intervention 
which is tailored to fit the setting.  This is preferable to trying to implement a standard CBTp 
protocol, which has been primarily designed and evaluated in community settings for people 
with residual psychotic symptoms, rather than for people experiencing a mental health crisis.  
There have been 2 promising pilot trials in the United States (US) of a mindfulness-based 
intervention (Acceptance and Commitment Therapy; ACT), specifically adapted to be 
delivered within inpatient settings.  It is a brief therapy (1-5 sessions), with stand-alone 
sessions to accommodate unpredictable lengths of stay, and targets the underlying 
psychological processes implicated in crisis.  Pilot trial results suggest that the ACT 
intervention reduced the risk of re-admission by 50% at 4-month follow-up, compared to 
treatment as usual.  It is not yet known whether such an approach would also be effective 
within NHS acute inpatient settings for people with psychosis. 
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1.2 Acute inpatient care: Expensive, inadequate and in short supply 
 
 
There is a crisis in acute inpatient care in the United Kingdom (UK). Bed occupancy in the 
NHS is too high (>85% safety threshold), length of stay is increasing, and costs are rising 
(Figure 1).  The rising tide of demoralization and dissatisfaction, which Craig refers to in the 
quote above, is all too apparent in the findings of service user surveys and studies (Csipke et 
al., 2014, Csipke et al., 2016, Rose et al., 2015).  A frequent complaint amongst service users 
is that there is inadequate access to psychological therapies during inpatient admissions 
(Wood and Alsawy, 2016).  
 
 
 
Figure 1  NHS Mental Health Benchmarking Summary (Network, 2017) 
  
“The reduction in acute hospital beds might be viewed as a tremendous success for 
deinstitutionalization in the UK, were it not that the demand for inpatient care now 
grossly outstrips supply, accompanied by a rising tide of demoralization and 
dissatisfaction with care among hospital staff and patients” p. 91 (Craig, 2016) 
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In addition to the academic literature, charity reports have also played a vital role in giving a 
voice to service user concerns.  For example, a report from the mental health charity Mind 
(2011) high-lighted concerns about a therapeutically impoverished environment on wards and 
an undue emphasis on a medical model of care (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These findings were later mirrored in the Schizophrenia Commission Report (2012), which 
noted:- “We were particularly concerned about the lack of access to CBT and other 
psychological therapies which are recommended in the NICE guidelines and can be very 
valuable in helping people deal with the impact of symptoms and in keeping them out of 
hospital.” (p. 33).  This quote draws attention to another critical issue, which is intrinsically 
linked to the bed-shortage crisis; high re-admission rates.  Sometimes people are successfully 
stabilised in hospital, only to relapse again in the community shortly after discharge, leading 
to another admission.  This sometimes attracts the stigmatising label of being a “revolving-
door” patient.  Frequent hospital admissions are distressing and disruptive to service users 
and their families, as well as placing a high economic burden on NHS services (Lloyd-Evans 
et al., 2010).  The Schizophrenia Commission is correct of course in its assertion that CBTp 
is recommended in clinical guidelines (NICE, 2014).  However, does the evidence support its 
role in keeping people out of hospital for longer? 
  
Figure 1 Service user quotes from Mind report (2011) 
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1.3 CBTp; Effective in symptomatic reduction but not for reducing risk of relapse 
 
NICE clinical guidelines (2014) recommend both CBTp and Family Intervention (FI) as 
evidence-based psychological therapies which should be widely available to service users 
(CG178 – Psychosis and Schizophrenia in adults: prevention and management).  The 
guidelines further stipulate that CBTp should be delivered as an individual therapy, of at least 
16 planned sessions, and should focus on helping people to establish links between thoughts, 
emotions and behaviours, and to promote alternative ways of coping with the target 
symptom.  The aims of the intervention should include reducing distress and improving 
functioning. CBT can be started “either during the acute phase or later, including in inpatient 
settings” (recommendation 1.4.4.1).  Although the evidence reviewed for the 2014 NICE 
guidelines clearly showed CBTp to be an effective treatment, this was based on evidence that 
it helped reduce psychotic symptoms, and associated affective symptoms such as depression 
and anxiety e.g. (Wykes et al., 2004).  There is no specific recommendation for the provision 
of CBTp as an effective treatment to keep people out of hospital for longer, or to reduce 
overall admission rates.   
 
There has been a proliferation of meta-analyses for CBTp over the 15 years, however only 
CBTp meta-analyses that report data relating to impact on hospital admissions will be 
discussed here.  This is also a timely point to note the distinction that is made between 
relapse and readmission in the literature.  A person may relapse, in that there is a recurrence 
or exacerbation of symptoms, but this will not necessarily always lead to an admission.  
Given the acute shortage of inpatient beds, admissions are often driven by additional factors 
such as the presence of a perceived risk to self or others. Conversely, readmission can occur 
in the absence of a relapse of psychotic symptoms.  For example, admissions may be to re-
start or stabilise people on medication regimes, particularly with the introduction of 
Community Treatment Orders (CTOs), which allow a person to be recalled to hospital if they 
do not comply with medication in the community even in the absence of a relapse in mental 
state.  For this reason, some trials have defined relapse only in relation to a deterioration in 
mental state, or a recurrence of psychotic symptoms.  This can either be assessed by using 
scores on symptom rating scales to define a significant deterioration over a defined period, or 
systematically reviewing clinical notes for indications of re-emergence of psychotic 
symptoms, and subsequent changes to clinical management such as increased keyworker 
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visits (e.g. Bebbington et al. (2006)).  Readmission (for whatever reason) is then usually 
reported as a separate outcome. Some trials have used a composite definition, such as 
defining relapse in terms of admission to hospital, but only in the context of a worsening of 
psychotic symptoms (Drury et al., 2000). 
 
An early meta-analysis of 8 RCTs of CBTp concluded there was no evidence that CBTp 
prevented relapse or readmission during treatment, but trials with longer follow-up periods 
were lacking at the time (Pilling et al., 2002).  A later review by Lynch and colleagues argued 
that if only well-controlled trials were included in a meta-analysis, CBTp was not effective in 
reducing symptoms or in preventing relapse (Lynch et al., 2010).  Specifically, in relation to 
relapse, this review included 8 RCTs with follow-up periods of 6 months to 3 years, and 
reported a pooled odds ratio (OR) of 1.17 (95% CI 0.88-1.55, p=0.29).  Finally, a Cochrane 
review of CBTp compared to other psychological therapies also concluded that there was no 
evidence that it reduced risk of relapse, or readmission (Jones et al., 2012).  Only 5 RCTs 
were found eligible for their review, and they included studies with follow-up periods of up 
to 5 years.  They reported a non-significant risk ratio (RR) of 0.91 (95% CI 0.63-1.32, n=183) 
for relapse over the long-term, and 0.86 for re-admission over the long-term (95% CI 0.62-
1.21, n=294).  Comparable results were found for RRs over the short- and medium-term.  It is 
important to note at this point that the field of CBTp meta-analyses is not without its 
controversies, mainly relating to how the inclusion/exclusion criteria for studies is set, and 
how risk of bias is assessed and accounted for in the results (Thomas, 2015).  However, the 
overall picture relating to reducing risk of relapse/readmission is clear; CBTp is not effective.   
 
Exploring one of the key studies in the area may be helpful at this stage in helping us to 
understand why this might be, from an individual trial perspective. The Psychological 
Prevention of Relapse in Psychosis trial (PRP) was the first large-scale (n=301) and robustly 
designed RCT to explicitly focus on relapse as key outcome.  The aim was to test the 
effectiveness of CBT and FI in reducing relapse in people who had recently relapsed 
(whether or not this had led to a hospital admission).   This contrasted with many of the 
previous trials which had focused mainly on people with chronic distressing psychotic 
symptoms in the community.  The trial had 2 pathways within the study, for service users 
with and without carers (as people without carers could not be randomised to FI).  CBTp in 
the trial was delivered over the course of 9 months, and had a minimum of 12 and a 
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maximum of 20 planned therapy sessions. The primary outcomes were relapse (rated using 
case-note review), and hospital admission (collected through hospital notes).  They found that 
neither CBT nor FI reduced the risk of relapse or hospital admission at 12 or 24-month 
follow-up (Garety et al., 2008).  This was a somewhat unexpected finding, as one of the key 
hopes for CBTp was that it might help keep people well for longer, or reduce the number of 
relapses, as well as improving symptoms over the course of treatment.  To explore this 
finding further, the PRP team later published a subsequent sub-group analysis (Dunn et al., 
2012).  They looked at 102 participants with sufficient therapy rating data, and divided them 
into 3 groups.  The ‘No Therapy’ group were defined as having received <5 sessions (n=21).  
The ‘Partial Therapy’ group (n=39) were defined not by the number of sessions they 
received, but rather by the content of the sessions.  Partial therapy was defined as only 
including the initial stages of a manualised CBTp approach (i.e. engagement and assessment).  
The ‘Complete Therapy’ group (n=42) were defined as having also progressed to the later 
stages of therapy, including specific work on relapse prevention, reinterpreting the meaning 
of delusional beliefs and hallucinations and schema work.  They found that the people who 
had completed therapy showed statistically significant increases in the number of months in 
remission, and also showed significant improvements in psychotic and affective symptoms.  
By contrast, partial or no therapy was found not to be effective in reducing relapse or 
improving symptoms.  Furthermore, these sub-groups in the treatment arm were compared to 
three comparable groups in the TAU group, controlling for key demographic and clinical 
variables in the analysis of outcomes.  Although this is an interesting finding, the sub-group 
analysis was carried out post-hoc, and so should be interpreted with an appropriate degree of 
caution.    It also leads to further questions about why only 40% in this sub-group analysis 
met the criteria for having completed therapy, even with CBTp delivered to a high standard 
by highly trained therapists in the trial.   
 
1.4 CBTp within inpatient settings also does not show any evidence of impact on risk of 
relapse/readmission 
 
Although the NICE guidelines state that CBTp may be started in hospital, and carried on 
seamlessly post-discharge in the community, there are relatively few trials which evaluate 
therapy started in the acute phase in hospital. It is also important to note that most services in 
the NHS have a clear division between inpatient and community psychology provision, 
although there are variations in service models across the country.  The meta-analyses 
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discussed above have included inpatient trials, including trials set in long-stay wards 
(Valmaggia et al., 2005) and trials with a mixture of participants in inpatient and outpatient 
settings (Haddock et al., 2009, Pinto et al., 1999).  In addition to these, there are also some 
RCTs conducted in the UK that have investigated delivering CBTp within an acute inpatient 
setting, with a focus on working with people with psychotic symptoms in the acute phase 
(Drury et al., 1996a, b, Lewis et al., 2002, Startup et al., 2004).   Although there were 
reported benefits in the remission of psychotic symptoms, again there was no evidence that 
CBTp in the acute phase provided benefits in reducing risk of relapse over the longer-term. 
 
Drury and colleagues conducted a trial of cognitive therapy for acute psychosis in an inner 
city psychiatric hospital in Birmingham.  The strengths of this study are that it was set in a 
typical acute ward, and it had a credible control arm (ATY; recreational therapy) which was 
matched for therapy hours with the active treatment arm (CT; cognitive therapy). New 
admissions to the ward were screened within a week, and people with positive psychotic 
symptoms (hallucinations and/or delusions) in the context of a psychosis diagnosis were 
eligible to participate.  Although 62 people in total were randomised into the trial, a third of 
the sample were excluded after randomisation (10 in CT arm; 12 in ATY) for several reasons 
including not admitting to symptoms, inadequate medication compliance and refusal to 
engage in therapy.  Only the remaining 40 participants (20 in each arm) were included in the 
analysis, meaning that the analysis was effectively per protocol rather intention-to-treat 
(ITT).  The package of care in the CT arm was complex and intense.  It included not only 
individual CT sessions, but also group and family work.  The aim was to provide an average 
of 8 hours of total therapy time a week, for a maximum of 6 months.  The authors do not 
report the actual number of sessions participants completed, or the average therapy time 
(although people who did not engage at all were excluded from the analysis as outlined 
above).  The aim of the study was to investigate the effectiveness of CT in hastening the 
resolution of positive symptoms, and reducing residual symptoms.  The results indicated a 
relatively greater decline in positive psychotic symptoms in the CT compared to the control 
group, with only 5% of people in the CT group showing moderate or severe symptoms at 9-
month follow-up, compared to 56% in the control group (Drury et al., 1996a).  They also 
found that there was a significant reduction in time to recovery at 6-month follow-up in the 
CT group compared to the control group (Drury et al., 1996b).  Although risk of 
relapse/readmission was not a primary outcome measure for the trial, participants were 
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followed up 5 years later to examine any longer-term impact of the intervention (Drury et al., 
2000).  Readmission data were collected through hospital records and were available for 
37/40 participants (18 in CT group; 19 in ATY group).  In addition to looking at hospital 
admissions, the research team also rated rates of relapse, which was defined as i) admission 
to hospital or home treatment team, with an exacerbation of acute psychotic symptoms, or ii) 
documentation of early relapse followed by an increase in medication and/or increased 
keyworker visits.  The results showed no significant difference between the CT and control 
group in terms of relapse rate, positive symptoms or insight at 5-year follow-up.  In fact, the 
mean number of admissions was 1.2 in both the CT and control group, and the mean number 
of relapses was also virtually identical between the groups (1.4 in CT group vs. 1.2 in ATY 
group).  In summary, the intensive CT intervention in this trial was found to be effective in its 
primary aims of symptom reduction in the acute phase, but had no longer-term positive 
impact on risk of relapse/readmission. However, the results should be interpreted with 
caution due to the small sample size and lack of ITT analysis. 
 
Drury’s study demonstrated the feasibility of running a CBTp trial in an acute inpatient 
setting, despite some methodological limitations.  A subsequent inpatient study by Haddock 
and colleagues in Manchester extended this work by focusing only on people with a more 
recent diagnosis of psychosis, who had been first treated for psychosis less than 5 years ago 
(Haddock et al., 1999c) .  Although in the Drury study, 2/3 participants were described as 
experiencing their first or second episode of psychosis, the sample also included some people 
with more chronic difficulties.  It is of course possible that inpatient CBTp may have a more 
positive impact in the early stages of psychosis, and would fit in with the general early 
intervention model of trying to prevent longer-term disability and the development of 
secondary difficulties over time.  The Haddock trial was designed as a pilot study, so the 
sample size was small.  There were 10 people in the CBTp arm, and 12 people in the control 
arm, which was supportive counselling (SC).  The treatment protocol was simpler than the 
Drury study, as it only included individual therapy sessions, and not additional group and 
family sessions.  They designated a therapy envelope of 5 weeks, to fit in with a typical 
length of admission, with 4 booster sessions offered at monthly intervals post-discharge. The 
mean average of sessions completed was 10 in the CBTp arm and 9 in the SC arm during the 
inpatient phase.  However, the authors noted there was considerable variability in the number 
of therapy sessions people received, with a range of 3-18 sessions over the inpatient phase.  
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Take-up of the post-discharge booster sessions was generally poor.  People in the CBTp 
group attended an average of 1.67 booster sessions, but only 2/10 attended all 4 sessions, and 
3/10 did not attend any booster sessions at all.  Similarly, in the SC group, the average 
number of booster sessions attended was 0.91, no-one attended all 4 sessions, and 7/12 did 
not attend any at all.  The primary outcome for the trial was reduction of psychotic symptoms 
at 4 months post-discharge.  Data on the main outcome measure (Brief Psychiatric Rating 
Scale; BPRS; Overall and Gorham (1962)) was only available for 8 people in the CBTp 
group and 10 in the SC group, so group comparisons should be treated with caution due to the 
small sample size.  The results showed a significant reduction on the BPRS in both groups, 
but no significant differences between groups.  Although not a primary outcome, the 
researchers also looked at relapse/readmission data at 2-year follow-up.    Relapse was 
defined as a change in clinical management resulting from an increase in psychotic 
symptoms.  They found that the mean number of relapses in the CBT group was lower than 
the SC group (44% vs. 73% respectively), but that the time to 1st readmission was shorter in 
the CBTp group (mean 316 days vs. 639 days in the SC group).  These differences were not 
found to be statistically significant, probably due to the small sample size. 
 
Given that this pilot study indicated that a larger trial would be feasible, and the therapy was 
acceptable to an inpatient population, the research team progressed onto a larger efficacy trial 
(SoCRATES; Study of Cognitive Realignment Therapy in Early Schizophrenia, Lewis et al. 
(2002)).  There was a similar focus on an early intervention population, in that the trial 
recruited people who were mostly in their first admission (83%), with the remainder only 
having had 1 other previous admission (which had to be within the past 2 years).  The study 
again tested CBTp vs. SC as the active control arm, but also added in an additional treatment 
as usual arm (TAU). The aim of the study focused on whether CBTp would speed up 
remission of acute psychotic symptoms, with prevention of future relapse as a secondary aim.  
This was a much larger multi-site trial, with 101 participants randomised into the CBTp arm, 
106 in the SC arm, and 102 in the TAU arm.  They used the same therapy envelope of 5 
weeks as in the pilot trial, aiming to provide 15-20 hours of intervention within this time, 
with booster sessions offered at 2, 4 and 8 weeks post-discharge.  The findings showed that 
the mean number of sessions attended were comparable in the CBTp (16.1) and SC groups 
(15.7), although the CBTp group received significantly longer therapy time overall (8.6 
hours) compared to the SC group (7.1 hours).  Interestingly, the average number of therapy 
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hours (as opposed to therapy sessions) was still only about 50% of the target number of hours 
stated in the protocol.  This may reflect the clinical setting, in that people in acute crisis may 
only be able to engage with therapy sessions of shorter duration than the standard therapy 
hour.  This therefore calls into question how realistic it is to aim to deliver 15-20 therapy 
hours within an acute inpatient setting.  Acute phase outcomes showed a similar picture to the 
pilot trial, in that people in all 3 groups showed significant improvement in psychotic 
symptoms over the course of the trial, with a trend to faster improvement in the CBTp 
compared to the TAU group, although this was not statistically significant (Lewis et al., 
2002).  There was no evidence of faster improvement in the CBTp compared to the SC group.  
At 18-month follow-up, they found that both the CBTp and SC groups scored lower on 
symptom measures compared to TAU, but there was no group difference on relapse or re-
hospitalisation (Tarrier et al., 2004).  Hospital admission data was available for 99% of the 
original sample, and clinical notes for 95% of the sample.  Relapse was defined as change in 
clinical management in response to a worsening of psychotic symptoms lasting at least a 
week.  In the CBTp group, 33% had at least one re-admission, and 55% had at least one 
relapse.  The figures were similar in the SC group (29% readmission; 52% relapse) and the 
TAU group (36% re-admission; 51% relapse).  The higher rates of relapse compared to re-
admission in each group validates the approach of using both a case-note review as well as 
looking at hospital admission alone, as clearly not all relapses in the community lead to an 
admission. 
 
The most recent large inpatient RCT was the North Wales trial of CBTp for acute psychosis 
(Startup et al., 2004).  The authors noted that the SoCRATES trial found less positive 
outcomes for CBTp over the acute-phase compared to the Drury trial, which could probably 
be explained by a larger sample size and the use of an ITT analysis in the SoCRATES trial.  
However, Startup and colleagues also noted the intensity of the therapy intervention in 
previous trials, and questioned the generalisability of such an approach in routine clinical 
practice given that therapist time is a highly scarce resource. They therefore took a slightly 
different approach to treatment delivery, and offered participants in the trial up to a maximum 
of 25 weekly sessions, with participants being asked to commit to at least 12 sessions.  In 
contrast to the previous trials, they also explicitly stated that therapy could be continued 
without interruption following discharge.  They recruited people with acute psychotic 
symptoms within the first 28 days of their admission, but did not limit the inclusion criteria to 
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only people experiencing their first-or second episode of psychosis.  In contrast to the Drury 
and Lewis trials, they did not use an active control condition, just TAU.  In total, 47 people 
were randomised to CBTp and 43 to TAU.  The primary outcomes were positive and negative 
symptoms and social functioning, at 6 and 12-month follow-up. The mean average number of 
therapy sessions of CBTp was 12.9, however, there was an interesting pattern of engagement 
in therapy (for people who attended at least 1 session) which the authors described as 
trimodal (like the findings of the PRP study; Garety et al, 2008).  There was a bottom group 
of participants who only had 2-3 sessions, a middle group who completed approximately the 
minimum agreed of 12 sessions, and a top group who continued up to the maximum of 25 
sessions.  Treatment was prematurely terminated in 21/47 (45%) of the participants in the 
CBTp arm for various reasons including not attending sessions, and discharging themselves 
early from hospital.   In summary, a minimum therapy dose was conservatively defined as 
50% of the maximum allowed sessions, but only just over half of participants met this 
threshold. Although therapy could be continued in the community after discharge without 
interruption, the trial paper does not report how many sessions on average were completed 
pre- or post-discharge for each participant, or the proportion of participants who carried on 
with therapy after discharge.  Therefore, it is not possible to know whether most therapy 
sessions were in fact conducted in the inpatient or outpatient setting (or if it was fairly 
balanced between settings).  
 
At 12-month follow-up, a significantly larger proportion of people in the CBTp group 
showed reliable and clinically important change as assessed by the Global Assessment of 
Functioning Scale (GAF; American Psychiatric Association (1994)), and the CBTp group 
showed greater improvement on psychotic symptom scales compared to the TAU group.  
However, these findings should be interpreted with caution, as there was no active control 
group for non-specific therapy factors such as therapist time and attention, and the follow-up 
assessments were not blind rated.  At 2-year follow-up, there was no significant difference in 
the average number of admissions between the CBTp and TAU groups (0.4 vs. 0.7 
respectively), proportion of people with at least 1 re-admission (0.61 vs. 0.7) or total number 
of days in hospital (Startup et al., 2005).  They did not rate relapse separately from hospital 
admission. 
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In summary, although these inpatient trials have some mixed findings, they tell a consistent 
story in terms of the impact of CBTp delivered during the acute phase within an inpatient 
setting.  There is no evidence of benefit in terms of reducing the risk of relapse or 
readmission, up to 5 years post-treatment.  Startup and colleagues (2005) note: - 
 
“The fact that 61% of the CBT group were readmitted to hospital at least once 
(70% of the TAU group) shows that CBT was not effective in maintaining patients in the 
community once treatment was terminated, despite the large improvement in symptoms and 
social functioning that were obtained during treatment.” (p. 1314) 
 
This echoes the comments of Garety and colleagues, who concluded from the results of the 
PRP trial that they could not recommend CBTp for routine prevention of relapse, and “CBT 
targeted at this acute population requires development” (Garety et al, 2008, p. 412).  What 
might this development be?  To re-cap, NICE guidelines recommend CBTp should consist of 
at least 16 planned sessions, and the inpatient trials to date have tried implementing this 
within various therapy envelopes, ranging from 5-25 weeks.  However, given that the average 
length of an acute inpatient admission in the UK is now 33 days (NHS Benchmarking 
Network, 2017), what if a different kind of approach was needed; a brief, crisis-focused 
intervention that was tailored to an inpatient setting, and specifically targeted the underlying 
psychological processes that bring people into crisis, to reduce future risk of relapse.   
 
1.5  Brief Acceptance and Commitment Therapy (ACT) for acute psychosis shown to 
reduce risk of relapse in US pilot trials 
 
In recent years there have also been promising findings in applying mindfulness-based 
interventions to psychosis (see Chapter 3).  These therapeutic approaches all share a common 
goal in focussing on reducing distress and disability associated with psychotic symptoms.  
However, mindfulness-based interventions differ from conventional cognitive therapies in 
that they focus exclusively on changing people’s relationship to their thoughts and feelings, 
and do not aim to modify content directly.  This focus makes them ideally suited to brief 
interventions, as  they do not attempt any cognitive restructuring that typically requires a 
longer period of engagement and building therapeutic rapport. Furthermore, patients in a 
mental health crisis are experiencing high levels of suffering.  The core principles of a 
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.mindfulness-based approach (e.g. compassion, non-judgement, acceptance, here-and-now 
focus) are particularly relevant in meeting this suffering during a crisis. 
 
Mindfulness-based brief crisis-focused interventions are also ideally placed to reduce the risk 
of future relapse and re-admission, as they can help a person understand how their 
maladaptive coping strategies have brought them into crisis, and to develop skills in 
alternative coping strategies.  Two pilot RCTs (Bach and Hayes, 2002, Gaudiano and 
Herbert, 2006) have been conducted in the USA evaluating a type of mindfulness-based 
intervention known as Acceptance and Commitment Therapy (ACT).  The core ACT 
principle is that much maladaptive behaviour is the result of unsuccessful attempts to 
suppress or avoid unwanted thoughts, feelings or bodily sensations (Hayes et al., 2011).  This 
is particularly relevant to understanding what brings people into crisis culminating in an 
inpatient admission. For example, people may cope with unpleasant voices (auditory 
hallucinations) by drinking alcohol or using illicit drugs to block them out.  Someone 
experiencing persecutory delusions may choose to avoid the anxiety they feel when they go 
out in public by isolating themselves at home.  These behaviours not only stop the person 
from being able to function normally in their everyday life, they also increase the risk of 
serious self-neglect and possible risk to self and others under the influence of drugs and 
alcohol.  Once people stop taking care of themselves, their compliance with their anti-
psychotic medication regime also tends to deteriorate along with everything else, leading to a 
spiral of increased symptoms and a decreased capacity to cope effectively.  
 
Bach & Hayes (2002) and Gaudiano & Herbert (2006) both conducted RCTs of ACT vs. 
TAU for inpatients with distressing psychotic symptoms in the USA. The need for brief 
interventions is even more urgent in the USA, where there is no national health service, and 
acute inpatient admissions are generally only funded for up to 7 days. The aim of the ACT 
intervention was to help people:- 
a) to identify and abandon internally oriented control strategies 
b) to accept the presence of difficult thoughts or feelings 
c) to learn to “just notice” the occurrence of these private experiences, without 
struggling with them, arguing with them, or taking them to be literally true 
d) to focus on overt behaviours that produce valued outcomes 
- (Bach & Hayes, 2002, p. 1130) 
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Bach & Hayes (2002) used a manualised 4-session treatment, with the last session 
occasionally being delivered post-discharge in the case of early or unexpected discharge.  
Gaudiano & Herbert (2006) used a slightly different approach, to take into account that 
length of stay is often variable and unpredictable, by offering people between 1 and 5 
sessions, all of which followed a single-session, self-contained format.  The median number 
of sessions people completed was 3.  In contrast to the UK trials reviewed in the previous 
section, these ACT trials were specifically targeted at reducing relapse/readmission rather 
than symptom reduction over the acute phase. 
  
Bach & Hayes (2002) randomised 40 people each to the ACT and TAU arms respectively.  
The trial was open to all participants admitted with psychotic symptoms, and most 
participants had previous admissions (80%), rather than being a predominantly early 
intervention population.  They reported that the re-hospitalisation rate at 4-month follow-up 
for the ACT group was half that of the TAU group (20% vs. 40% respectively), a statistically 
significant difference. This significant advantage for ACT over TAU in reducing readmission 
rates was also maintained at 1 year follow-up (Bach et al., 2012).  Gaudiano & Herbert 
(2006) report the same trend of results (28% ACT vs. 45% TAU respectively), but this did 
not reach statistical significance.  This could partly be accounted for by a smaller sample size 
in this later study (n=19 ACT; n=21 TAU), meaning it was likely to be underpowered. Bach 
& Hayes additionally reported self-report psychotic symptom measures at baseline and 4-
month follow-up, and Gaudiano & Herbert reported the same measures at baseline and post-
treatment (discharge), but not at follow-up.  They asked people to identify their most 
distressing psychotic symptom (either voices or beliefs) and then to rate it on frequency, 
distress and believability.  Believability as a dimension is not common within CBTp trials, 
and is sometimes confused with conviction, e.g. as measured in the PSYRATS (Psychotic 
Symptom Rating Scales; (Haddock et al., 1999b).  However, ACT researchers conceptualise 
believability as a slightly different concept to conviction, more related to cognitive defusion, 
i.e. how much people are ‘buying into’ their experiences, or to what degree they can step 
back and view them as mental events.  This idea of being able to step back from internal 
experiences and ‘de-fuse’ is also covered in the curriculum of a standard mindfulness-based 
cognitive therapy course (MBCT) in week 6, which refers to this theme as ‘Thoughts are not 
Facts’ (Segal et al., 2013).   The data from the two trials were later combined for the purposes 
of a mediation analysis, and it was found that the reduction in readmission rate at 4-month 
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follow-up was mediated by symptom ‘believability’, but not symptom-related distress (Bach 
et al., 2013).  This finding was in line with the underlying model of the intervention, in that 
the key target is a person’s relationship with their experience, rather than the content or form 
of the experience itself.  Given that distressing psychotic symptoms are likely to reoccur 
frequently for people who have required hospital admission in the past, perhaps the most 
important thing is not to try to get rid of symptoms faster, but to change the behavioural 
impact of such experiences when they arise in the future.  Finally, brief, crisis-focused 
interventions such as those trialled by Bach and colleagues may also be successful because 
they specifically target the problematic behaviours which have brought people into crisis (e.g. 
maladaptive attempts to block out distressing experiences) at a time when people are willing 
to explore them.  This window of opportunity may be lost as the crisis resolves, particularly 
for people with a “sealing over” recovery style who prefer not to think about their psychotic 
experiences after admission (Mcglashan et al., 1975). 
 
A 50% reduction in readmission is an encouraging result in a field which so far has singularly 
failed to demonstrate any positive impact of psychological therapies on reducing the risk of 
relapse.  These results have not yet been replicated in other countries though, or in a larger 
multi-site trial in the US. Results such as these, which seem almost too good to be true, are 
often treated cautiously and with an understandable degree of scepticism. Öst (2008) 
published a systematic review and meta-analysis of so-called ‘third-wave’ behavioural 
therapies, an umbrella terms for therapy approaches including acceptance and commitment 
therapy (ACT).  The findings were rather critical of the methodological quality of studies in 
the review in general.  In fact, Öst concludes by stating that “none of the third wave therapies 
fulfilled the criteria for empirically supported treatments” (p. 296).  A subsequent update of 
the review reached similar conclusions (Öst, 2014).  He singles out the Bach/Gaudiano 
inpatient trials as being examples of trials with limited generalisability as all therapy was 
delivered by a single therapist, and there was a limited description of the ‘enhanced’ TAU 
condition used as the comparator.  However, prominent researchers in the ACT field later 
published a robust response to the review, which was critical of its methods (Atkins et al., 
2017).  Almost 10 years on from the first Öst review the controversy continues. Are these 
unreliable findings arising from studies with significant methodological limitations; or 
whether in fact, these are credible brief therapies for inpatient settings, warranting further 
investigation within a UK NHS setting. 
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1.6 Summary 
 
Current clinical guidelines in the UK recommend CBTp, but there is little evidence on which 
to recommend treatment within inpatient settings.  Inpatient trials have suggested that few 
people complete a full course of CBTp even when it is offered, and the intensity and cost of 
such an approach is unlikely to be generalisable to routine clinical practice.  Furthermore, 
although CBTp provided during an inpatient admission may be helpful for speeding up 
symptom remission, there is no evidence it reduces the risk of relapse of readmission, either 
in the short or longer-term.  Briefer interventions, which are designed to be crisis-focused, 
rather than condensed versions of a full CBTp intervention, may be more feasible and 
effective at reducing relapse.  Two pilot trials from the USA have tested out brief, 
mindfulness-based interventions which reduced re-admission rates by 50% at 4-month 
follow-up.  Such approaches have not yet been tested in the UK.  The next chapter will put 
these findings into a broader context by way of a systematic scoping review of psychological 
therapies for psychosis delivered within acute inpatient settings, both in the UK and 
internationally.  This review includes all study designs, and all therapy models, to give a 
better overall picture of the state of the evidence base for inpatient therapies for psychosis.  
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 A Systematic Review of Psychological Therapies for Psychosis within Acute 
Psychiatric Inpatient Settings 
 
2.1 Overview 
 
The provision of psychological therapies on acute wards is recommended by good practice 
guidelines, and welcomed by service users.  However, provision varies widely both 
nationally and internationally.  This chapter describes a systematic review which was 
designed to scope out the current evidence base for psychological therapies for psychosis 
delivered within acute inpatient settings.  All study designs, and therapy models, were 
eligible for inclusion in the review.  A total of 65 studies were included in the final review.  
The search strategy and review protocol is described.  The results are reported according to 
the 5 main review questions, which were set in advance.  The findings are discussed with 
regards to implication for clinical practice, challenges in conducting research within inpatient 
settings, and suggestions for future research. 
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2.2 Introduction 
 
As discussed in Chapter 1, the Schizophrenia Commission Report highlighted concerns that 
people often did not have access to talking therapies during acute inpatient admissions.  
These concerns are mirrored in a report by the Care Quality Commission (CQC) which found 
that less than a third of respondents reported having access to any kind of talking therapy 
during inpatient admissions, and the majority of people who wanted to access a talking 
therapy during an admission were unable to (CQC, 2009).  First-person accounts of inpatient 
care frequently highlight boredom on wards, and the detrimental impact of not having access 
to therapies e.g. (Antoniou, 2007). 
 
Good practice guidelines for inpatient wards all make reference to the importance of the 
provision of regular activities and therapies.  This includes the Royal College of Psychiatry’s 
Accreditation for Inpatient Mental Health Services framework (AIMS-AT; RCPsych (2014)) 
and the service-user led initiative StarWards (www.starwards.org.uk).  The AIMS-AT 
standards for example recommend “all patients are offered specific psychosocial 
interventions appropriate to their presenting needs and in accordance with national clinical 
guidelines (e.g. NICE and SIGN)” (section 53.6) and that “at least one staff member based on 
the ward/unit is trained and supervised to deliver one basic, low intensity evidence-based 
psychological intervention (U53.7) AND/OR  one problem-specific, high intensity evidence-
based psychological interventions (U53.8)”. 
 
However, if we examine further this suggestion that ward staff should be delivering 
“evidence-based interventions”, a key question arises; to what evidence base should we refer?  
The NICE guidelines for psychosis recommend CBT for psychosis (CBTp) and Family 
Interventions (FI) (NICE, 2014).  However, these recommendations are largely based on 
trials conducted in community settings.  Furthermore, when CBTp has been evaluated within 
inpatient settings, the large number of sessions, and the intensity of delivery required, does 
not fit well with the constraints of an admission which may only last up to 30 days, and the 
limited number of staff available to provide such therapies within routine acute care.  There 
are other key differences between the delivery of psychological therapies within inpatient and 
community settings.  For example, CBTp may be more likely to be delivered as a group, 
rather than an individual intervention, within inpatient settings.  However, a recent systematic 
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review of group therapy for psychosis in acute care highlighted the small number of studies 
published overall in this area, and in particular the paucity of randomised controlled trials in 
the literature (Owen et al., 2015b). 
 
At the time of writing the review protocol, there were no existing systematic reviews or meta-
analyses focusing solely on psychological interventions for psychosis within inpatient 
settings.  There were also no protocols of reviews underway according to the PROSPERO 
database, the international prospective register of systematic reviews 
(https://www.crd.york.ac.uk/PROSPERO/).  Given the lack of existing reviews in the area, 
the aim of this review was intended mainly as a ‘scoping’ review.  This kind of review is 
used to find out what the potential size and scope is of the available research literature, and 
may include ongoing or planned research (Grant and Booth, 2009).  Scoping reviews are 
particularly relevant to areas of healthcare where it is not clear whether the evidence exists to 
answer a more precise question, such as the effectiveness of a particular therapy for a 
particular population.  Scoping reviews are therefore “useful for examining emerging 
evidence when it is still unclear what other, more specific questions can be posed and 
valuably addressed”  - pg. 6, Joanna Briggs Institute Reviewer’s Manual (2015). 
 
The aim of this review was therefore to explore and map out the evidence base for 
psychological therapies for psychosis within acute inpatient settings. Five review questions 
were set in advance: - 
 
1) What is the current state of the evidence base for psychological therapies for 
psychosis within acute psychiatric inpatient settings? (Primary) 
2) What study designs are used to evaluate psychological therapies for psychosis within 
acute inpatient settings? 
3) How are psychological therapies for psychosis within acute psychiatric inpatient 
settings evaluated, and what are considered to be the key outcome measures? 
4) What health care professionals are involved in delivering psychological therapies for 
psychosis, and in which roles (e.g. sole therapist, group co-facilitator, clinical 
supervisor)? 
5) How are psychological therapies for psychosis adapted for use within acute 
psychiatric inpatient settings? 
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2.3 Method 
 
2.3.1 Search Strategy 
 
A review protocol was written and registered in the public domain before searching and data 
extraction began (PROSPERO Registration:  CRD 42015025623). The review team was as 
follows:- 
 
Dr. Pamela Jacobsen, IOPPN, King’s College London (Primary reviewer) 
Dr. Kathleen Hodkinson, Webster University, Vienna (Secondary reviewer) 
Professor Paul Chadwick, IoPPN, King’s College London 
Dr. Emmanuelle Peters, IoPPN, King’s College London 
 
We included only studies published in English, with no date restrictions on searches.  
Searches were initially run in September 2015, and updated in December 2016.  We planned 
to include a wide range of different study types to address the main review question as to the 
current state of the evidence base.  We anticipated that there would be relatively few eligible 
randomised controlled trials (RCTs), and the majority of studies would be small-scale, 
uncontrolled, non-randomised studies. Eligible studies therefore included:- 
 
 Randomised Controlled Trials (RCT) 
 Non-RCT study designs (e.g. uncontrolled studies, observational studies) 
 Case studies 
 Study protocols for future studies 
 Reviews/meta-analyses 
 Qualitative studies 
 Book chapters  
 Dissertations/theses  
 Conference abstracts  
 
Electronic databases PubMed and PsychINFO were used to search for peer-reviewed journal 
articles, and EThOS and ProQuest for theses or dissertations. Clinical Psychology Forum 
33 
 
 
(professional body publication of the British Psychological Society) was hand-searched.  The 
Conference Proceedings Citation Index - Science (CPCI-S) was searched for conference 
abstracts. Trials were searched for on 3 different trial registries (ISRCTN registry; 
clinicaltrials.gov; Cochrane Central Register of Controlled Trials).  Existing reviews in the 
area were searched for in the Cochrane Library.  Finally, the Trip database 
(www.tripdatabase.com) and Open Gray database (www.opengray.eu) were searched for grey 
literature.  We also checked the reference lists of eligible studies for further possible studies 
which had not already been identified. We contacted experts in the field to ask for 
information on any other potentially eligible studies.  This was done by contacting the 
corresponding author on all relevant papers from the past 10 years. 
 
Eligible studies were identified by the primary (PJ) and secondary (KH) reviewer. In the 1st 
stage, PJ independently screened all titles and abstracts identified from searches to determine 
which met the inclusion criteria. In the 2nd stage, PJ and KH both independently screened 
full text articles for inclusion or exclusion, with discrepancies resolved by discussion. For 
included studies, we linked multiple reports from the same study, so that each study (rather 
than each report) was the unit of interest in the review.  The search strategy and search terms 
for each resource is outlined in Table 1. 
 
2.3.2 Condition or domain being studied 
 
Psychological therapies for psychotic symptoms within acute psychiatric inpatient care. 
2.3.3 Definition of acute care 
 
The recent Commission on Acute Adult Psychiatric Care provides a helpful definition of 
acute care (CAAPC, 2015):- ‘Acute psychiatric inpatient services provide treatment and care 
in a safe and therapeutic setting for patients in the most acute and vulnerable stage of mental 
illness, and whose circumstances or acute care needs are such that they cannot, at that time, 
be treated and supported appropriately at home or in an alternative, less restrictive setting.' 
In line with this definition, we defined acute psychiatric care as including triage/acute 
assessment wards, general acute wards and psychiatric intensive care units (PICU).  Non-
acute inpatient care settings were excluded (e.g. rehabilitation wards, specialist units, 
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residential therapy units).  Non-inpatient acute services were also excluded (e.g. day 
hospitals, crisis/home treatment teams).  There were some challenges in defining acute care 
for the purposes of this review, as care settings vary from country to country, and also over 
time within the same country.  We therefore adopted a liberal definition of acute care, and 
erred on the side of being over-, rather than under-inclusive.  In circumstances where the care 
setting was unclear, or did not easily fit into standard categories of inpatient care, we focused 
on assessing the eligibility of the intervention itself, and included interventions which seemed 
feasible to deliver within an average 30-day admission.   
 
2.3.4 Participants/ population 
 
Inclusion:  
1) People experiencing an acute mental health crisis (defined by having been admitted to 
an acute psychiatric ward) 
2) People taking part in a psychological therapy for psychosis regardless of their 
diagnosis (or whether they have received a psychiatric diagnosis) 
3) Adults only (defined as receiving treatment on an adult ward) 
4) Under a section of the Mental Health Act (MHA) or admitted informally 
Exclusion:  
1) People not experiencing an acute mental health crisis (defined as receiving care in 
settings other than an acute psychiatric ward) 
2) Children or adolescents  
 
2.3.5 Intervention 
 
Any psychological intervention/therapy aimed at alleviating distress or impairment to 
functioning arising from psychotic symptoms (e.g. voices, delusions) or aimed at emotional 
difficulties commonly associated with psychotic symptoms (e.g. anxiety, depression). We 
included individual, family and group therapies, delivered by any health care professional, of 
any length, frequency or duration. We included CBT-based psychological therapies, broadly 
defined as a talking therapy based on an underlying theoretical model of the relationship 
between thoughts, emotions and behaviours.  Third-wave cognitive therapies including 
mindfulness, acceptance and commitment therapy (ACT), meta-cognitive therapy (MCT), 
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dialectical-behavioural therapy (DBT) and compassion-focused therapy were included and 
classified as sub-types of CBT. Non-CBT based therapies such as psychodynamic therapy 
were also included.  Cognitive-remediation therapy (CRT) was excluded on the basis that it is 
aimed primarily at remediating cognitive deficits rather than emotional difficulties associated 
with psychotic symptoms (likewise any intervention such as social skills training which is 
focussed solely on the remediation of functioning).  We also excluded compliance therapy, 
any intervention focused primarily on improving psychiatric ‘insight’, staff-based 
interventions, therapeutic community or milieu therapy.  Arts therapies including art, drama 
and movement therapy were also excluded. Any therapies started within the acute inpatient 
setting were included, whether or not the therapies continued post-discharge.  Therapies 
initiated outside of acute inpatient settings were excluded (even if the therapy was continued 
during an inpatient admission for an individual). 
 
2.3.6 Comparator(s)/ control 
 
Studies with any, or no control conditions, were included.  Possible control conditions 
included treatment as usual (TAU), waiting list control, plus other psychosocial interventions. 
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Table 1 Search Terms 
Category Database/resource 
searched 
Search Terms Stage 2 
(Full 
Text 
Review) 
Retained 
for 
inclusion 
in review 
1. Electronic 
Databases 
Combination of searches 
with 3 concepts: - 
Concept 1 – 
PSYCHOTHERAPY 
(includes all sub-types 
of therapy) 
AND 
Concept 2 – 
SCHIZOPHRENIA 
(includes psychosis) 
AND 
Concept 3 – 
ACUTE/INPATIENT 
psychiatric setting  
 
PsychINFO Keyword searches: - 
 brief 
psychotherapy 
 hospital 
admission 
 psychiatric 
hospital 
admission 
 psychiatric 
hospitalization 
 psychiatric 
hospitals 
 psychiatric units 
 psychotherapy 
 schizophrenia 
(.tw.) qualifier used to 
search following terms 
in title and/or abstract:- 
 acute 
 hospita* 
 inpatient? 
 psychosis 
 psychotic 
 psychoses 
 schizo* 
 therap* 
227  
PubMed ((inpatient) AND 
psychosis) AND 
(psychotherapy OR 
therapy) 
18  
Total (without duplicates)   241 69 
2. Theses/Dissertations EThOS (any word)=psychosis 
OR schizophrenia AND 
(acute OR inpatient) 
  
ProQuest   
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Total (without duplicates)   3 2 
3. Professional 
Body Publication 
Clinical Psychology 
Forum 
Hand-searched 1 1 
4. Conference 
abstracts 
Conference 
Proceedings 
Citation Index - 
Science (CPCI-S) 
 
(Topic 
Heading=(psychosis 
OR psychotic OR 
schizo*) AND 
TS=(acute OR hospita* 
OR inpatient*) AND 
TS=therap*) 
 
3 1 
5. Trial Registries ISRCTN registry Condition=psychosis 
OR schizophrenia 
Inclusion 
criteria=inpatient OR 
acute 
Interventions=therapy 
OR behavioral 
  
 Clinicaltrials.gov   
 Cochrane Central 
Register of 
Controlled Trials  
  
Total (without duplicates)   10 8 
6. Existing 
Reviews 
Cochrane Library TOPIC=mental health 
OR 
schizophrenia/psychosis 
AND therapy 
7 0 
7. Grey Literature Trip Database (Area of Clinical 
Practice = Medicine OR 
Psychology OR 
Psychiatry OR Mental 
Health) AND 
(Psychotherapy OR 
Psychological 
therapies) AND 
(Inpatient OR Hospital) 
5 0 
 Open Gray 0 0 
8. Misc Sources   24 21 
TOTAL   294 102 
TOTAL (after linking 
records) 
   65 
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2.3.7 Data Extraction 
 
A standard data extraction template was used to record relevant information from each 
included study (see Appendix 1).  Data for each study was extracted by either PJ or KH, with 
each reviewer cross-checking each of the other reviewer’s forms to ensure consistency and 
accuracy of data extraction.  We assessed the quality of eligible studies using the Mixed 
Methods Appraisal Tool (MMAT; Pluye (2013)). The MMAT is designed to assess 
quantitative, qualitative and mixed methods studies using a single integrated tool which also 
incorporates criteria for assessing RCTs in line with the Cochrane criteria (Higgins et al., 
2011). Each study was assessed using the MMAT by either PJ or KH, then cross-checked by 
the other reviewer, with any discrepancies agreed by discussion to reach a consensus score. 
We did not conduct a meta-analysis due to the wide variety of outcome measures used by 
different studies and the small number of eligible RCTs which were anticipated.  A narrative 
approach was taken in synthesising and describing the findings in line with the aims of the 
review.  
 
2.4 Results 
 
2.4.1 Search Results 
 
As shown in Figure 3, we identified 65 studies for inclusion in the narrative synthesis.  We 
used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines in summarising the search results (Moher et al., 2009).  Fourteen of the 65 studies 
were linked to at least one other record (e.g. Drury et al (1996b) was published as 3 peer-
reviewed journal articles as well as a PhD thesis).  In this case, where at least one of the 
records was a peer-reviewed journal article, this was taken as the ‘primary’ reference.  In the 
case of RCTs which often published acute-phase and follow-up data in separate journal 
articles, the paper which had been published first was designated as the primary paper.  
However, the data extraction form was completed using all relevant information across all 
linked studies. Overall, 58 out of the 65 studies had a peer-reviewed journal article designated 
as the primary paper.  Of the remaining studies, 4 were published solely as book chapters, 1 
was published as a PhD thesis and we could not find any subsequent published journal 
articles (Cholet, 1984)  and the remaining 2 existed only as trial registry records.  One of 
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these had not yet been published in a peer-reviewed journal because the trial was still on-
going (Gaudiano, 2015), and the remaining reported results on the trial registry website but 
we could not find evidence of subsequent publication in a peer-reviewed  journal (Boden, 
2013) . 
 
  
Full-text articles excluded 
(n=192) 
- Not interventional study 
(n=119) 
- Not acute setting (n=48) 
- Not psychosis intervention 
(n=22) 
- CRT, arts therapies or 
compliance therapy (n=3) 
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Multiple reports from 
same study linked 
(n=102) 
Unique studies included 
in narrative synthesis  
(n = 65) 
Full-text articles 
assessed for eligibility 
(n =294) 
Additional records identified 
through other sources 
(n = 28) 
Records identified through 
database searching 
(n = 9754) 
Records excluded 
(n = 8948) 
Records screened 
(n =9242) 
Records after duplicates removed 
(n =9242) 
Figure 2  PRISMA Flowchart 
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2.4.2 Review Question 1: Current state of evidence base 
 
The sixty-five studies included in the review are summarised in Table 2.  The most common 
type of studies were RCTs (N=21), service evaluation projects (i.e. descriptions or 
evaluations of therapies offered within routine clinical practice, not requiring ethical 
approval; N=18) and non-randomised controlled trials (N=14).  There were a minority of case 
series (N=5), single case studies (N=4) and studies reporting only qualitative data (N=3).  
Quality assessment using the MMAT involved two stages.  The initial stage involved 
assessing each study according to two screening questions, which can be answered ‘yes’, ‘no’ 
or ‘can’t tell’:- 
 
- Are there clear qualitative and quantitative research questions (or objectives), or a 
clear mixed methods question (or objective)? 
- Do the collected data address the research question (objective)?  E.g. consider 
whether the follow-up period is long enough for the outcome to occur (for 
longitudinal studies or study components) 
 
The instructions for the MMAT state that further appraisal may not be feasible or appropriate 
when the answer is 'no' or 'can't tell' to one or both of the screening questions.  Any studies 
which did not report any outcomes (whether quantitative or qualitative) automatically failed 
the screening, and could not be assessed further with the MMAT.  Studies which did report 
some kind of outcome data, but failed both the screening questions were also not assessed 
further.  For other studies which reported outcome data, and only failed 1 of the screening 
questions, we used our discretion as to whether we felt we could make a meaningful quality 
assessment with the MMAT.  The second stage of the MMAT involves assessment under one 
of the following categories: - 
 
1. Qualitative 
2. Quantitative randomised controlled trials (RCTs) 
3. Quantitative non-randomised 
4. Quantitative descriptive 
5. Mixed methods (studies are assessed under section 1, then either 2,3 or 4 depending 
on how the quantitative component of the study is best categorised). 
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Each category has 4 sub-items which are assessed in the same way as the screening questions 
(yes/no/can’t tell).  A summary score may be calculated by dividing the number of criteria 
definitely met (i.e. scored as a ‘yes’) divided by 4, and expressed as a percentage.  Quality 
scores therefore ranged from 0%, 25%, 50%, 75% to 100%.  For ease of interpretation, 
MMAT scores are colour-coded in Table 2, with low quality scores (0%-25%) in red, 
medium scores (50%) in orange and high scores (75%-100%) in green. 
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Table 2 Studies included in review (with quality assessment) 
RANDOMISED CONTROLLED TRIALS (N=21) 
No. Author 
(year) 
 
n=total no. of 
participants 
 
Country 
Study 
Design 
(Record  
type) 
Therapy Model  
(Sub-type) 
Mode of 
Delivery 
Outcome  
Data 
Reported? 
MMAT 
Section 
assessed 
under 
MMAT  
score 
1 Kanas et al. 
(1980) 
 
n=86 
 
USA 
RCT1 
(JA)2 
Non-CBT3 
(Psychodynamic) 
Group Yes 2. RCT 0% 
2 Beutler (1984) 
 
n=176 
 
USA 
RCT 
(JA) 
CBT Group Yes 2. RCT 25% 
3 Cholet (1984) 
 
n=40 
 
USA 
RCT 
(Thesis) 
Non-CBT 
(Humanistic- 
Existential) 
Individual Yes 2. RCT 50% 
4 Glick et al. 
(1985) 
 
n=144 
 
USA 
RCT 
(JA) 
CBT 
(Family 
Intervention) 
Family  Yes 2. RCT 50% 
5 Youssef 
(1987) 
 
n=30 
 
USA 
RCT 
(JA) 
Non-CBT 
(Psychoeducation 
only) 
Family Yes 2. RCT 0% 
6 Drury et al. 
(1996a) 
 
n=62 
 
UK 
RCT 
(JA) 
CBT Individual 
+ Group  
+ Family 
Yes 2. RCT 0% 
7 Wahass and 
Kent (1997) 
 
n=6 
 
Saudi Arabia 
RCT 
(JA) 
CBT 
(Culturally 
adapted) 
Individual Yes – but 
failed MMAT 
screening 
stage 
 
8 Haddock et 
al. (1999c) 
 
n=21 
 
UK 
RCT 
(JA) 
CBT Individual Yes 2. RCT 25% 
  
                                                 
1 RCT=Randomised Controlled Trial 
2 JA=Journal article 
3 CBT=Cognitive-Behavioural Therapy 
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9 Bach and 
Hayes (2002) 
 
n=80 
 
USA 
RCT 
(JA) 
CBT 
(Third-wave) 
Individual Yes 2. RCT 50% 
10 Lewis et al. 
(2002) 
 
n=309 
 
UK 
RCT 
(JA) 
CBT Individual Yes 2. RCT 100% 
11 Hall and 
Tarrier 
(2003) 
 
n=25 
 
UK 
RCT 
(JA) 
CBT Individual Yes 2. RCT 100% 
12 Bechdolf et al. 
(2004) 
 
n=88 
 
Germany 
RCT 
(JA) 
CBT Group Yes 2. RCT 100% 
13 Startup et al. 
(2004) 
 
n=90 
 
UK 
RCT 
(JA) 
CBT Individual Yes 2. RCT 25% 
14 Gaudiano 
and Herbert 
(2006) 
 
n=40 
 
USA 
RCT 
(JA) 
CBT 
(Third-wave) 
Individual Yes 2. RCT 50% 
15 Klingberg et 
al. (2010) 
 
n=169 
 
Germany 
RCT 
(JA) 
CBT Individual 
+ Group  
+ Family 
Yes 2. RCT 50% 
16 Moritz et al. 
(2011) 
 
n=48 
 
Germany 
RCT 
(JA) 
CBT Individual 
+ Group  
Yes 2. RCT 100% 
17 Boden (2013) 
 
n=18 
 
USA 
RCT 
(TR)4 
CBT 
(Third-wave) 
Individual Yes 2. RCT 0% 
  
                                                 
4 TR=Trial Registry 
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18 Gaudiano 
(2015) 
 
n=60 (target) 
 
USA 
RCT 
(TR) 
CBT 
(Third-wave) 
Individual No (trial 
protocol only) 
 
19  Habib et al. 
(2015) 
 
n=42 
 
Pakistan 
RCT 
(JA) 
CBT 
(Culturally 
adapted) 
Individual Yes 2. RCT 50% 
20 Jacobsen et 
al. (2016) 
 
n=60 (target) 
 
UK 
RCT 
(JA) 
CBT (Third-wave) Individual No (trial 
protocol only) 
 
21 Tyrberg et al. 
(2016) 
 
n=21 
 
Sweden 
RCT 
(JA) 
CBT (Third-wave) Individual Yes 2. RCT 75% 
NON-RANDOMISED CONTROLLED TRIALS (N=14) 
No. Author 
(year) 
 
n=total no. of 
participants 
 
Country 
Study 
Design 
(Record  
type) 
Therapy Model  
(Sub-type) 
Mode of 
Delivery 
Outcome  
Data 
Reported? 
MMAT 
Section 
assessed 
under 
MMAT  
score 
1 Feifel and 
Schwartz 
(1953) 
 
n=68 
 
USA 
Non-
randomised 
CT5 
(JA) 
Non-CBT 
(Psychodynamic) 
Group Yes 3. QNR6 50% 
2 Walker and 
Kelley (1960) 
 
n=82 
 
USA 
Non-
randomised 
CT 
(JA) 
Non-CBT 
(Psychodynamic) 
Individual Yes 3. QNR 25% 
3 Bookhammer 
et al. (1966) 
 
n=51 
 
USA 
Non-
randomised 
CT 
(JA) 
Non-CBT 
(Psychodynamic) 
Unclear Yes 3. QNR 0% 
4 Stern et al. 
(1972) 
 
n=75 
 
USA 
Non-
randomised 
CT 
(JA) 
Non-CBT 
(Psychodynamic) 
Individual Yes 3. QNR 50% 
  
                                                 
5 CT=Controlled Trial 
6 QNR=Quantitative Non-Randomised 
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5 Gould et al. 
(1975) 
 
n=17 
 
USA 
Non-
randomised 
CT 
(JA) 
Non-CBT 
(Psychodynamic) 
Group Yes 3. QNR 75% 
6 Serok and 
Zemet (1983) 
 
n=31 
 
Israel 
Non-
randomised 
CT 
(JA) 
Non-CBT 
(Gestalt) 
Group Yes 3. QNR 75% 
7 Levene et al. 
(1989) 
 
n=10 
 
Canada 
Non-
randomised 
CT 
(JA) 
Non-CBT 
(Family Therapy) 
Family Yes 3. QNR 25% 
8 Hodel et al. 
(1998) 
 
n=19 
 
Switzerland 
Non-
randomised 
CT 
(JA) 
CBT 
(Emotional 
Management 
Therapy) 
Individual Yes 3. QNR 75% 
9 Hauff et al. 
(2002) 
 
n=96 
 
Norway 
Non-
randomised 
CT 
(JA) 
Non-CBT 
(Psychodynamic) 
Individual Yes 3. QNR 50% 
10 Veltro et al. 
(2006) 
 
n=502 
 
Italy 
Non-
randomised 
CT 
(JA) 
CBT Group Yes 3. QNR 0% 
11 Schmid and 
Wanderer 
(2007) 
 
n=320 
 
Switzerland 
Non-
randomised 
CT 
(JA) 
Non-CBT 
(Phantasy therapy) 
Group Yes – but 
failed MMAT 
screening 
stage 
 
12 Mortan et al. 
(2011) 
 
n=12 
 
Turkey 
Non-
randomised 
CT 
(JA) 
CBT Group Yes 3. QNR 50% 
13 Owen et al. 
(2015a) 
 
n=112 
 
UK 
Non-
randomised 
CT 
(JA) 
CBT 
(Third-wave) 
Group Yes 5. MM 50% 
14 Witkowska 
(2015) 
 
n=60 
 
Poland 
Non-
randomised 
CT 
(JA) 
Non-CBT 
(Psychoeducation 
only) 
Individual Yes – but 
failed MMAT 
screening 
stage 
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SERVICE EVALUATION (N=18) 
No. Author 
(year) 
 
n=total no. of 
participants 
 
Country 
Study 
Design 
(Record  
type) 
Therapy Model  
(Sub-type) 
Mode of 
Delivery 
Outcome  
Data 
Reported? 
MMAT 
Section 
assessed 
under 
MMAT  
score 
1 Coffey (1954) 
 
n=not stated 
 
USA 
Service 
Evaluation 
(BC)7 
Non-CBT 
(Psychodynamic) 
Group No  
2 Goldberg et 
al. (1955) 
 
n=not stated 
 
USA 
Service 
Evaluation 
(JA) 
Non-CBT 
(Psychodynamic) 
Group No  
3 Canter (1956) 
 
n=60 
 
USA 
Service 
Evaluation 
(JA) 
Non-CBT 
(Psychodynamic) 
Group No 
 
 
4 Chazan 
(1974) 
 
n=not stated 
 
Israel 
Service 
Evaluation 
(JA) 
Non-CBT 
(Psychodynamic) 
Family 
(Group) 
No 
 
 
5 Birckhead 
(1984) 
 
n=not stated 
 
USA 
Service 
Evaluation 
(JA) 
Non-CBT 
(Psychodynamic) 
Group No 
 
 
6 Cole and 
Greene 
((1988) 
 
n=20 
 
USA 
Service 
Evaluation 
(JA) 
Non-CBT 
(Psychodynamic) 
Group Yes 4. QD8 0% 
7 Kelly et al. 
(1990) 
 
n=not stated 
 
UK 
Service 
Evaluation 
(JA) 
Non-CBT 
(Supportive 
Counselling) 
Group No  
8 Aviera (1996) 
 
n=not stated 
 
USA 
Service 
Evaluation 
(JA) 
No clear therapy 
model 
Group No  
 
  
                                                 
7 BC= Book chapter 
8 QD= Quantitative Descriptive 
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CASE SERIES (N=5) 
No. Author 
(year) 
 
n=total no. of 
participants 
 
Country 
Study 
Design 
(Record  
type) 
Therapy Model  
(Sub-type) 
Mode of 
Delivery 
Outcome  
Data 
Reported? 
MMAT 
Section 
assessed 
under 
MMAT  
score 
1 Boyd (1979) 
 
n=3 
 
USA 
Case Series 
(JA) 
Non-CBT 
(Psychodynamic) 
Individual 
+ Group 
No 
 
 
2 Cole 
(1993) 
 
n=3 
 
USA 
Case Series 
(BC) 
CBT 
(Family 
Intervention) 
Family No  
3 Ahmed et al. 
(1997) 
 
n=3 
 
USA 
Case Series 
(JA) 
No clear therapy 
model 
Individual Yes – but 
failed MMAT 
screening 
stage 
 
4 Kerr (2001) 
 
n=4 
 
UK 
Case Series 
(JA) 
Non-CBT 
(CAT)9 
Individual No  
5 Freemantle 
and Clarke 
(2009) 
 
n=2 
 
UK 
Case Series 
(BC) 
CBT 
(Third-wave) 
Individual No  
  
                                                 
9 CAT= Cognitive-Analytical Therapy 
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SINGLE CASE STUDIES (N=4) 
No. Author 
(year) 
 
n=total no. of 
participants 
 
 
Country 
Study 
Design 
(Record  
type) 
Therapy Model  
(Sub-type) 
Mode of 
Delivery 
Outcome  
Data 
Reported? 
MMAT 
Section 
assessed 
under 
MMAT  
score 
1 Dublin (1973) 
 
n=1  
 
USA 
Case Study 
(JA) 
Non-CBT 
(Gestalt) 
Individual No  
2 Ginsburg 
(2000) 
 
n=1  
 
USA 
Case Study 
(JA) 
Non-CBT 
(Supportive 
Counselling) 
Individual No  
3 Mansell and 
Fadden 
(2009) 
n=1  
 
UK 
Case Study 
(BC) 
CBT 
(Family 
Intervention) 
Family No  
4 Cooper (2014) 
 
n=1  
 
UK 
Case Study 
(JA) 
Non-CBT 
(Psychodynamic) 
Group Yes – but 
failed MMAT 
screening 
stage 
 
QUALITATIVE ONLY (N=3) 
No. Author 
(year) 
 
n=total no. of 
participants 
 
Country 
Study 
Design 
(Record  
type) 
Therapy Model  
(Sub-type) 
Mode of 
Delivery 
Outcome  
Data 
Reported? 
MMAT 
Section 
assessed 
under 
MMAT  
score 
1 Holma and 
Aaltonen 
(1997) 
 
n=15 
 
Finland 
Qualitative 
(JA) 
Non-CBT 
(Family Therapy) 
Family Qualitative 
data only 
1. Qual 50% 
2 Gonzalez de 
Chavez et al. 
(2000) 
 
n=32 
 
Spain 
Qualitative 
(JA) 
Non-CBT 
(Psychodynamic) 
Group Qualitative 
data only 
1. Qual 75% 
3 York (2007) 
 
n=8 
 
UK 
Qualitative 
(JA) 
CBT 
(Third-wave) 
Group Qualitative 
data only 
1. Qual 75% 
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Overall, 40% of studies failed the initial MMAT screening stage (26/65).  Of the remaining 
60% which were assessed further, 21.5% were rated as high quality, 20% were medium 
quality and 18.5% were low-quality.  We broadly categorised therapies into CBT, and non-
CBT models, with sub-types of therapy noted where appropriate.  Overall, we found there 
were slightly more CBT studies (N=35) than non-CBT therapies (N=28).  We took a broad 
definition of therapy models, but even so were unable to categorise 2 studies into a 
recognisable therapy model (Dichos therapy (Aviera, 1996) & Computer-facilitated therapy 
(Ahmed et al., 1997)).  Among the CBT studies, there was a noticeable increase in so-called 
third wave cognitive therapies in recent years, with 12 studies categorised as either 
mindfulness, compassion-focused, or acceptance and commitment therapy (ACT).  The 
majority of the non-CBT studies were psychodynamic (N=17).  A clear difference emerged 
between countries in their dominant therapy models.  For the UK studies, over 75% were 
CBT based (16/20). However, the reverse was true for the USA studies, with 62% of studies 
being non-CBT based (16/26).  For other countries (which were predominantly European), 
CBT and non-CBT studies were more evenly balanced (11 CBT and 8 non-CBT).  The first 
CBT studies did not emerge until the 1980s, but they represent the majority of studies 
included in the review published since 2000.   
 
To provide a broad overview of the main findings of the studies in the review, relevant 
studies were identified according to four criteria.  These were 1) the stated aim of the study 
was described as evaluating efficacy/effectiveness 2) the study reported at least one outcome 
measure 3) the study stated which was the primary outcome measure, where multiple 
outcomes were reported and 4) the study passed MMAT screening stage.  Twelve studies in 
total met all these criteria and are summarised in Table 3, in chronological order from oldest 
to most recent. No exclusions were made based on study quality; the findings should 
therefore be interpreted with great caution, and in the context of the associated MMAT 
quality scores shown in Table 2.   
  
50 
 
 
Table 3 Summary of main findings (efficacy studies with primary outcomes only) 
Author 
(year) 
 
Study Design 
 
Country 
Treatment 
 
 
n=no. of 
participants 
Control condition(s) 
 
 
n=no. of 
participants 
Primary Outcome 
Measure 
Main Findings 
Bookhammer et al 
(1966) 
 
Non-randomised 
CT 
 
USA 
Rosen’s Direct 
Analysis 
 
n=14 
Treatment as Usual 
(TAU) 
 
n=37 
Binary outcome of 
improved/unimproved 
as rated by treating 
clinician at 5-year 
follow-up 
No difference in rates 
of improvement 
between the Direct 
Analysis and TAU 
groups  
Serok and Zemet 
(1983) 
 
Non-randomised CT 
 
Israel 
Gestalt group therapy 
 
 
n=16 
Treatment as usual 
(TAU) 
 
n=15 
Neuropsychological 
reality perception test 
Gestalt group showed 
evidence of 
improvement in 
perception of self and 
others 
Beutler 
(1984) 
 
RCT 
 
USA 
1) Behavioural/task 
(BT) 
2) Expressive-
experiential (EE) 
3) Process-oriented 
(PO) 
 
Number of 
participants in each 
group not stated 
(Total n=176 
including controls) 
Treatment as usual 
(TAU) 
Composite symptom 
measure (including 
symptom check-list, 
nurse assessment, and 
group facilitator 
ratings) 
Compared to TAU 
control group: - 
1) no change in BT 
group, 2) 
deterioration in EE 
group 
3) improvement in 
PO group 
Cholet 
(1984) 
 
RCT 
 
USA 
Humanistic-
existential (HE) 
psychotherapy  
 
 
n=20 
Equivalent time as in 
treatment condition 
spent with college 
student  
 
n=20 
Behavioural 
adjustment scale 
(staff rated) 
No difference 
between groups on 
mood, co-operation 
or communication 
sub-scale but 
significant 
improvement on 
social contact scale in 
HE group compared 
to control  
Cole and Greene 
(1988) 
 
Service Evaluation 
 
USA 
Unstructured 
psychodynamic 
group 
 
n=20 (repeated 
measures design –all 
patients did both 
groups) 
Structured 
occupational therapy 
group 
 
n=20 (repeated 
measures design –all 
patients did both 
groups) 
Patient self-report of 
which group they 
preferred 
Patients preferred the 
occupational therapy 
group to the 
psychodynamic 
group 
Bach and Hayes 
(2002) 
 
RCT 
 
USA 
Acceptance and 
Commitment 
Therapy (ACT) 
 
n=40 
Enhanced Treatment 
as Usual (ETAU) 
 
 
n=40 
Re-admission to 
hospital at 4-month 
post-discharge 
Re-admission to 
hospital was 
significantly lower in 
the ACT group 
(20%) compared to 
the ETAU group 
(40%) 
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Hauff et al (2002) 
 
Non-randomised CT 
 
 
Norway 
Specialist therapy 
ward with individual 
psychotherapy + 
psychodynamic 
milieu 
 
n=25 
Standard care on 
acute ward 
 
 
 
 
n=71 
Global mental health 
status at 7-year 
follow-up 
No difference 
between outcomes 
for patients treated on 
the specialist therapy 
ward compared to the 
standard care ward 
Lewis et al 
(2002) 
 
RCT 
 
UK 
Cognitive-behaviour 
therapy (CBT) 
 
n=101 
Supportive 
counselling  
 
n=106 
 
Treatment as usual 
(TAU) 
 
n=102 
Psychotic symptoms 
at 70-day follow-up 
All patients improved 
significantly over 
time, with a trend to 
faster improvement 
in the CBT group 
Startup et al 
(2004) 
 
RCT 
 
UK 
Cognitive-behaviour 
therapy (CBT) 
 
n=47 
Treatment as usual 
(TAU) 
 
n=43 
Psychotic symptoms 
at 12-month follow-
up 
The CBT group 
showed significantly 
greater improvement 
compared to the TAU 
group 
Veltro et al 
(2006) 
 
Non-randomised CT 
 
 
Italy 
Cognitive-behaviour 
group therapy (CBT) 
as part of ward 
routine care 
 
n=352 
Ward routine care 
before introduction of 
CBT programme 
(pre-post design) 
 
n=150 
Total re-admissions 
up to 4-year follow-
up 
The re-admission rate 
was significantly 
lower in the 4 years 
following the 
introduction of CBT 
(24%) compared to 
the year before its 
introduction (38%) 
Klingberg et al 
(2010) 
 
RCT 
 
Germany 
Cognitive 
Behaviorally 
Oriented Service 
(CBOS) – individual, 
group and family 
sessions  
 
 
n=84 
Individual supportive 
treatment – 
individual and group 
sessions based on 
practical and non-
directive emotional 
support 
 
n=85 
Mean time to relapse 
(defined by 
deterioration on 
psychotic symptom 
rating scale) 
Mean time to relapse 
was significantly 
longer in the CBOS 
group (168 days) 
compared to the 
control group (157 
days) 
Moritz et al 
(2011) 
 
RCT 
 
Germany 
Meta-Cognitive 
Therapy (MCT) 
 
 
 
n=24 
Cogpak 
(computerised 
cognitive remediation 
therapy) 
 
n=24 
Delusions severity at 
end of treatment 
Significantly greater 
decline in delusion 
severity in the MCT 
group compared to 
control group 
 
  
52 
 
 
2.4.3 Review Question 2: Types of study design 
 
As expected, a full range of study designs were included in the review, from single case 
studies to large-scale RCTs.  RCTS were much more likely to describe CBT, rather than non-
CBT interventions, and the converse was true for non-randomised controlled trials.  Service 
evaluation, case series/studies and qualitative studies were more evenly matched between 
CBT and non-CBT models (Table 4). 
 
Table 4 Study design by therapy model  
 Therapy model  
 
Total 
 CBT Non-CBT No clear 
therapy model 
RCT 18 3 0 21 
Non-
randomised 
controlled trial 
4 10 0 14 
Service 
Evaluation 
9 8 1 18 
Case 
Series/Case 
study 
3 5 1 9 
Qualitative 
only 
1 2 0 3 
Total 35 28 2 65 
 
Quality assessment scores were variable across different categories of study designs.  For the 
RCTs (N=21), there was evidence of an improvement in quality over time, as all studies 
published pre-2000 were rated as low-medium quality (0-50%), but post-2000 included at 
least 5 studies rated as high quality (75-100%).  This probably reflects improvements in trial 
reporting guidelines arising from the first publication of the CONSORT statement in the 
1990s (Begg et al., 1996), and its subsequent adoption by most major journals.   
 
In addition to the MMAT, we also assessed RCTs using the Cochrane Risk of Bias.  As can 
be seen from Table 5 and Figure 4, randomisation methods, allocation concealment and 
blinding were causes for concern.    Only two of the RCTs clearly stated using the ‘gold 
standard’ of an independent randomisation service with randomly varying block sizes, with a 
large number of studies not specifying the randomisation method at all (N=10).  A minority 
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of studies mentioned blinding of outcome assessors, and blinding of the inpatient and/or 
community teams potentially involved in treatment decisions.  Size of trials was also a 
concern – out of the 19 RCTs with published results, over half (N=10) had fewer than 25 
people in the treatment arm.  Finally, most of the RCTs used TAU (or ‘enhanced’ TAU in the 
Gaudiano trials) as the control arm (N=11), and therefore did not control for non-specific 
therapy factors such as time and attention from a warm, empathic therapist.  A minority of 
trials did use an active control arm.  One of the largest trials had a strong design in this 
respect, and included both a supportive counselling and TAU condition, with over 100 
participants in each arm (Lewis et al., 2002). 
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Table 5 Risk of bias summary for RCTs only using Cochrane Tool 
 
 
Selection Bias Performance 
Bias 
Detection 
Bias 
Attrition 
Bias 
Reporting 
Bias 
Other 
Bias 
Random 
sequence 
generation 
Allocation 
concealment 
Blinding 
(participants 
and 
personnel) 
Blinding 
of 
outcome 
assessment 
Incomplete 
outcome 
data 
Selective 
reporting 
1 Kanas et 
al.(1980) 
 
USA 
      No ITT 
analysis 
2 Beutler 
(1984) 
 
USA 
      No ITT analysis 
3 Cholet 
(1984) 
 
USA 
      Unclear 
if ITT 
analysis 
Small N 
(N=20 in 
treatment 
arm) 
4 Glick et 
al. (1985) 
 
USA 
      Unclear 
if ITT 
analysis 
 
5 Youssef 
(1987) 
 
USA 
      No ITT 
Analysis 
Small N 
(N=15 in 
treatment 
arm) 
6 Drury et 
al. 
(1996a) 
 
UK 
      No ITT 
analysis 
7 Wahass 
and Kent 
(1997) 
 
Saudi 
Arabia 
      Small N 
(N=3 in 
treatment 
arm) 
8 Haddock 
et al. 
(1999c) 
 
UK 
      Unclear 
if ITT 
analysis 
Small N 
(N=10 in 
treatment 
arm) 
9 Bach and 
Hayes 
(2002) 
 
USA 
      No ITT 
analysis 
10 Lewis et 
al. (2002) 
 
UK 
      None 
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11 Hall and 
Tarrier 
(2003) 
 
UK 
      No ITT 
Analysis 
Small N 
(N=12 in 
treatment 
arm) 
12 Bechdolf 
et al. 
(2004) 
 
Germany 
      None 
13 Startup et 
al. (2004) 
 
UK 
      None 
14 Gaudiano 
and 
Herbert 
(2006) 
 
USA 
      Small N 
(N=19 in 
treatment 
arm) 
15 Klingberg 
et al. 
(2010) 
 
Germany 
      Unclear if 
ITT analysis 
16 Moritz et 
al. (2011) 
 
Germany 
      Small N 
(N=24 in 
treatment 
arm) 
17 Boden 
(2013) 
 
USA 
      Unclear if 
ITT analysis 
Small N 
(N=12 in 
treatment 
arm) 
18 Gaudiano 
(2015) 
 
USA 
NOT ASSESSED – TRIAL PROTOCOL ONLY 
19 Habib et 
al. (2015) 
 
Pakistan 
      No ITT 
analysis 
Small N 
(N=21 in 
treatment 
arm) 
20 Jacobsen 
et al. 
(2016) 
 
UK 
NOT ASSESSED – TRIAL PROTOCOL ONLY 
21 Tyrberg 
et al. 
(2016) 
 
Sweden 
      Small N 
(N=11 in 
treatment 
arm) 
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Random sequence allocation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
Low risk of bias Unclear risk of bias High risk of bias
0% 25% 50% 75% 100%
 
Figure 4 Risk of Bias Summary for RCTs 
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2.4.4 Review Question 3: Evaluation and Outcome measures 
 
Most of the studies included in the review reported collecting some kind of outcome measure 
(N=48).  We categorised the outcome measures used into 4 main categories (psychotic 
symptoms, affective symptoms, general/clinical functioning, and readmission/relapse).  The 
results are summarised in Table 6.  Where outcome measures were reported, these were 
usually focused on assessing psychotic symptoms and/or general functioning.  There were 
relatively few studies that reported assessing affective symptoms, such as depression or 
anxiety.  Only 3 of the 65 studies used self-report recovery measures.  Even though they were 
not usually the primary outcome measure, many studies reported readmission/relapse data.  
The timing of outcome assessments was variable, and usually included a combination of 
different time points (e.g. baseline, discharge and 6-month follow-up).  The assessment 
schedule was not specified in 2 studies.  For the remaining 46 studies, 32 reported data at 
baseline, 12 reported outcomes session by session, 4 at mid-therapy and 26 at discharge/end 
of therapy.  Twenty-one studies reported follow-up data beyond the end of therapy.  The 
longest follow-up point was 6 months or less for 10 studies, and longer than 6 months for the 
remaining 11 studies. 
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Table 6 Summary of outcome measures  
 INCLUDED? 
DOMAIN 
(No. of studies including each scale in 
parentheses) 10 
 
N=48 studies (21 RCTs)  
 
Yes (RCTs 
only) 
 
No (RCTs only) 
 
1) Psychotic symptoms 
 
- UNPUBLISHED SCALES (4) 
- PANSS (7) 
- PSYRATS (5) 
- BPRS (5) 
- PAS (2) 
- SAPS/SANS (2) 
- SAHI (1) 
21 (16) 27 (5) 
2) Affective symptoms 
 
- UNPUBLISHED SCALES (3) 
- BAI/BDI (2) 
- HADS (1) 
- DASS (1) 
- HDI (1) 
7 (2) 41 (19) 
3) General/Clinical 
Functioning 
 
- GAF (3) 
- HSRS (1) 
- GAS (3) 
- ADL (1) 
- CORE (34 OR 10 ITEM) (2) 
- CGI-S (1) 
- SFS (3) 
- NOISE (1) 
- OQ-45 (1) 
14 (7) 34 (14) 
4) Recovery 
 
- Self-rating of goals (1) 
- MHCS (2) 
- QPR (1) 
3 (1) 45 (20) 
5) Readmission 
           
    Relapse (defined other than just 
readmission e.g. exacerbation in 
symptoms) 
13 (10) 
 
6 (4) 
35 (11) 
 
42(17) 
                                                 
10 Some studies included more than 1 scale within the same domain 
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Key to abbreviations: PANSS=Positive and Negative Syndrome Scale (Kay et al., 1987); PSYRATS= Psychotic Symptom 
Rating Scales (Haddock et al., 1999a); BPRS=Brief Psychiatric Rating Scale (Overall and Gorham, 1962); PAS=Psychiatric 
Assessment Scale (Krawiecka et al., 1977); SAPS=Scale for the Assessment of Positive Symptoms (Andreasen, 1984b); 
SANS=Scale for the Assessment of Negative Symptoms (Andreasen, 1984a); SAHI=Structured Auditory Hallucinations 
Interview (Kent and Wahass, 1996); BDI=Beck Depression Inventory (Beck et al., 1996); BAI=Beck Anxiety Inventory 
(Beck and Steer, 1993); HADS=Hospital and Anxiety Depression Scale (Zigmond and Snaith, 1983); DASS=Depression, 
Anxiety & Stress Scales (Lovibond and Lovibond, 1995); HDI=Hamilton Depression Inventory (Reynolds and Kobak, 1995); 
GAF=Global Assessment of Functioning (APA, 1994); HSRS=Health Sickness Rating Scale (Luborsky and Bachrach, 1974); 
GAS=Global Assessment Scale (Endicott et al., 1976); ADL=Activities of Daily Living; CORE=Clinical Outcomes in 
Routine Evaluation(Evans et al., 2000); CGI-S=Clinical Global Impression Scale (NIMH, 1985); SFS=Social Functioning 
Scale (Birchwood et al., 1990); NOISE=Nurses’ Observation Scale for Inpatient Evaluation (Honigfeld and Klett, 1965); OQ-
45=Outcome Questionnaire-45 (Lambert et al., 1996); MHCS=Mental Health Confidence Scale (Carpinello et al., 2000); 
QPR=Questionnaire about the Process of Recovery (Neil et al., 2009) 
 
2.4.5 Review Question 4: Delivery of therapies 
 
The most common mode of delivery was group therapy (N=27), followed by individual 
therapy (N=19).  There was a notable difference in the types of trial design between group 
and individual treatment modalities.  The majority of the studies describing individual 
therapies were RCTs (12/19), compared to 3/27 of the group therapy studies.   
As anticipated, a variety of staff groups were involved with delivering psychological 
therapies within inpatient settings, including psychologists, psychiatrists, nurses, occupational 
therapists, social workers, family therapists, CBT therapists and clinical trainees from 
different disciplines.   It was notable however that almost a third of the studies included in the 
review failed to specify the professional group delivering the intervention.  This limits the 
interpretation and replicability of such studies.  The primary, or sole, therapist was described 
as a Clinical Psychologist in the majority of studies where the profession was specified 
(N=14).   
 
Training, supervision and checks on treatment fidelity were generally poorly described or 
entirely absent.  Over 50% of studies included in the review gave no details about training 
and supervision of therapists.  For the 21 RCTs in the review, only a third of studies (N=7) 
clearly reported that the staff delivering the intervention were both trained and supervised.  
An additional third reported either staff training or supervision, but not both.  The final third 
gave no details on either.  The majority of RCTs gave no details on checking treatment 
fidelity.  Only 8 studies reported fidelity checks – this was usually done by an independent 
rater reviewing a sample of audiotapes of therapy sessions (N=6), but the use of direct 
observation (N=1) and videotapes (N=1) was also reported.  
 
60 
 
 
2.4.6 Review Question 5: Adaptations to delivery within acute settings 
 
After an initial review of the included studies, we identified and categorised studies according 
to 5 main adaptations.  These were 1) increased frequency of sessions (≥2 sessions a week), 
2) briefer interventions (≤5 sessions), 3) shorter sessions (<50 minute standard length of 
sessions), 4) use of single session format (i.e. each session is stand-alone, although therapy 
may include more than one session) and 5) continuing therapy post-discharge.  The most 
common adaptation was an increased frequency of sessions. An increased frequency of 
sessions sometimes reflected an attempt to deliver a larger number of sessions within a 
shorter period of time to fit the typical length of an inpatient admission.  Other studies aimed 
to deliver a smaller number of sessions, but still had an increased frequency of sessions to fit 
in with short lengths of admissions (Bach and Hayes, 2002, Gaudiano and Herbert, 2006).  
Only a quarter of studies reported briefer interventions (15/65), with 5 or fewer planned 
sessions.  This is perhaps surprising given concerns that acute admissions are short, and so 
there is limited time to provide psychological therapies.  However, the number of planned 
sessions, or the average number of sessions delivered per patient, was often not stated, and 
we were unable to extract this information for many studies.  We found that the use of the 
standard therapy ‘hour’ (i.e. around 50 minutes) was in fact the most commonly reported 
length of session (41/65).  Over a third of studies reported using a single-session format 
(24/65).  This may be particularly helpful in settings when length of admission is 
unpredictable, and discharges may occur unexpectedly in the middle of treatment.  Single-
session formats may be particularly useful in groups, in meeting the needs of people who may 
attend only 1 session, but also in allowing people to flexibly ‘drop in’ over the course of an 
admission.  In relation to group interventions, the use of single-session formats is of course 
closely linked to whether the group is open (people can join and leave at any session) or 
closed (people can join only at the beginning and are encouraged to stay for the full course).  
We found that open groups were the most common format reported (N=17), with only 2 
studies explicitly reporting a closed group format (Cooper, 2014, Owen et al., 2015a).  It was 
not always clear whether group formats were open or closed.  There was some reference to 
continuing therapy post-discharge in 13 studies.  This was sometimes to allow people to 
complete a set number of sessions, for a group (Bechdolf et al., 2004) or individual 
intervention (Bach and Hayes, 2002).  Some studies offered booster sessions post-discharge, 
but take-up of these was generally low (Haddock et al., 1999c, Lewis et al., 2002). 
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2.5 Discussion 
 
2.5.1 Summary of main findings 
 
We conducted a systematic scoping review of psychological therapies for psychosis within 
acute inpatient settings. We found that there were a broad range of therapies in the published 
literature, delivered in many ways, by different groups of professionals, and evaluated using a 
wide range of approaches.  This makes a coherent synthesis of current evidence challenging.  
For example, out of the 12 efficacy studies with well-defined primary outcome measures, no 
two of them in fact used the same outcome with the same end-point (Table 3).     Quality was 
varied across different study types and over time, but we found significant methodological 
weaknesses in many studies, including in RCTs. Such a high degree of heterogeneity surely 
provides a challenge to any quantitative synthesis of findings by means of a meta-analysis. 
Reporting of diagnosis or symptom profile is also inconsistent in the literature – and indeed, 
in practice often there is no clear diagnosis for inpatients. For this reason, the present review 
took the pragmatic step of selecting studies on the basis of setting (acute inpatient) and type 
of psychological therapy (e.g. CBT for psychosis). We would recommend all future inpatient 
research on psychological therapy for psychosis report diagnostic information on participants 
where available, in addition to symptom profiles using established assessment tools. 
 
Evaluating therapies within inpatient settings is undoubtedly challenging. It is not possible, or 
indeed ethical, to control or keep constant all other elements of treatment each person is 
receiving, such as medication, nursing care or occupational therapy.  Attributing change, 
whether it be improvement or deterioration, to any single component of treatment is therefore 
not normally possible.  There is also the problem of accounting for ‘natural’ recovery after a 
mental health crisis. The added value of any psychological intervention should therefore 
always be carefully assessed.  
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2.5.2 Outcome assessment  
 
The present study focussed on patient outcomes – as opposed for example to change in ward 
milieu or in staff well-being. Direct patient outcomes can relate to well-being during 
admission (e.g. psychotic symptoms, length of admission), or after (e.g. subsequent relapse or 
readmission rates), or both. The studies reviewed included a wide range of primary and 
secondary outcomes and assessment tools, making it difficult to draw conclusions. The field 
may therefore benefit from the development of an agreed standardised set of outcomes, 
known as ‘core outcome sets’ (COS).  A COS can be used as the minimum to be reported for 
any study or trial, and makes it easier to combine and compare the results of studies, over 
time, and from different countries.  The urgent need for a COS in psychosis can be no better 
demonstrated than by the findings of a recent review of schizophrenia intervention trials 
(both drug and psychological therapy trials) which found 2194 different scales were used to 
measure outcomes, with every fifth study introducing a new rating instrument (Miyar and 
Adams, 2013). We would encourage development of COS for inpatient research that address 
core outcomes both during and post admission.  
 
2.5.3 Therapy delivery 
 
Only 3/27 evaluations of group therapies used an RCT design, which may reflect 
methodological challenges in evaluating inpatient groups – in-patient group therapies are 
normally open to everyone on a ward, for ethical and practical reasons, and there is also 
increased risk of treatment “contamination” between conditions on inpatient wards where 
patients are in close proximity. One potential solution is to use a cluster randomised design, 
where individual wards are randomised to a particular intervention, rather than individual 
patients, although there are often important differences between wards (e.g. catchment area, 
therapeutic milieu) and larger sample sizes are needed, which is often a barrier to conducting 
this kind of study in routine clinical practice (Torgerson, 2001).   
 
2.5.4 Adapting therapy protocols for in-patient settings.  
 
Most studies reported having adapted psychological therapy for delivery within inpatient 
settings. Commonly this meant offering traditional numbers of sessions but more frequently, 
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or offering fewer sessions, or developing a single-session format. We would recommend that 
future research describe more clearly the process of adapting therapies and protocols: for 
example, giving a clear rationale for the need to adapt a therapy; a clear rationale for the 
chosen adaptations; a clear statement about if and how the adaptations were piloted (e.g. a 
small case series); being clear about the degree of service user consultation and participation 
throughout the process. Furthermore, future research might examine, perhaps through mixed 
methods, the impact of the specific adaptations made. 
 
2.5.5 Strengths and limitations 
 
As this review was planned as a scoping review, we designed the strategy accordingly, and 
published our search strategy and review questions in advance on the PROSPERO database.   
A particular strength of this review is that we searched for literature from a wide variety of 
sources, including those not readily available (e.g. non-digitised book chapters, unpublished 
PhD theses).  However, work not published in academic journals has not been subject to the 
same degree of peer review or scrutiny, and therefore should be interpreted with caution.  We 
also attempted to search for studies underway as well as completed, by searching trial 
registries for planned or ongoing research, and by contacting experts in the field.  However, 
despite increasing calls for all trials to be pre-registered on a public registry, compliance is 
still variable.  Therefore, we cannot exclude the possibility that there is work underway that 
we would not have found from registry searches.  There were some challenges in defining 
acute care for the purposes of this review, as care settings vary from country to country, and 
over time within the same country.  We therefore adopted a liberal definition of acute care, 
and erred on the side of being over-, rather than under-inclusive.  In circumstances where the 
care setting was unclear, or did not easily fit into standard categories of inpatient care, we 
focused on assessing the eligibility of the intervention itself, and included interventions 
which seemed feasible to deliver within an average 30-day admission.  However, difficulties 
in defining key terms in the search strategy may have led to relevant studies being excluded, 
or less relevant studies being included in the final review. 
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2.5.6 Conclusions and implications for practice 
 
A systematic approach is now clearly needed to develop the evidence base for inpatient 
psychological interventions, and to progress from promising pilot studies to larger, well-
designed RCTs in line with guidelines for developing complex interventions (MRC, 2006). 
Qualitative research (including pre-trial assessment) also has a role to play, for example in 
optimising use of interventions within RCTs and in informing future choice of interventions 
(O’Cathain et al., 2013). Core outcome sets are required to establish common, minimum 
outcomes both during and post admission, and the process of adapting therapies for in-patient 
settings needs greater methodological rigour and clarity. 
 
2.6 Summary 
 
The evidence base for inpatient interventions is mixed, and difficult to interpret in its totality.  
A minority of studies have specifically focused on evaluating impact on readmission/relapse.  
As reviewed in Chapter 1, the most promising intervention in this respect are brief, 
mindfulness-based interventions which are specifically crisis-focused, and have been 
successfully piloted in the US (Bach and Hayes, 2002, Gaudiano and Herbert, 2006).  The 
next chapter will set out the development of mindfulness for psychosis, from its theoretical 
underpinnings, to the first feasibility trials to later RCTs and meta-analyses. 
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 Mindfulness for Psychosis 
3.1 Overview 
 
 
Mindfulness has a rapidly expanding evidence-based across a wide range of physical and 
mental health conditions, in addition to the promotion of well-being in the general 
population.  Historically, there were concerns about whether meditation was safe for people 
experiencing psychotic symptoms, despite little hard evidence to support such concerns.  
Chadwick developed a theoretical model of mindfulness for psychosis, which proposed that 
people are often caught up in a pattern of reacting to psychotic symptoms that perpetuates 
distress.  This is characterised by experiential avoidance, judgement, and struggling or 
fighting against experiences when they enter awareness.  A mindfulness response style is an 
alternative way of relating to experiences, which involves deliberately turning towards 
difficulty, acceptance of what is present in the moment, and letting experiences come and go 
in their own time without reactive engagement.  This model of mindfulness for psychosis is 
consistent with studies linking avoidance-based coping strategies to increased distress 
associated with psychotic symptoms.  Meditation practises in mindfulness for psychosis are 
adapted by making them shorter in length, providing more frequent guidance (including 
reference to the psychotic experience), and using concrete, everyday language in the 
guidance.  Early pilot trials by Chadwick and colleagues confirmed that these adapted 
mindfulness practises were safe and acceptable to service users, and there was no indication 
of any harmful effects.  There is now increasing interest in the effectiveness of mindfulness 
for psychosis, including the recent publication of several meta-analyses and systematic 
reviews.  However, the number of trials in the area remains low, and the quality of such trials 
is variable.  There are no published controlled trials of mindfulness for psychosis within UK 
inpatient settings. 
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3.2 Development of mindfulness for psychosis 
 
3.2.1 Theoretical model 
 
The popularity of mindfulness-based interventions has grown exponentially over recent 
years. Studies have proliferated in mindfulness for both physical (Carlson, 2012, Gotink et 
al., 2015) and mental health conditions (Strauss et al., 2014), and for promoting general well-
being in healthy populations (Khoury et al., 2015).  Mindfulness could be considered as 
having reached the mainstream of NHS provision when Mindfulness-Based Cognitive 
Therapy (MBCT) was recommended in clinical guidelines to reduce risk of depressive 
relapse for the first time in 2009 (guideline updated (2016)).   
 
However, there are historical concerns about using mediation techniques with people 
experiencing current psychotic symptoms, or who might be vulnerable to developing them.  
For example, as far back as the 1970s, a pilot study reported positive benefits of mindfulness 
meditation with people with mood symptoms including depression and anxiety but cautioned 
against their use in with people experiencing “hallucinations, delusions, thinking disorders, 
and severe withdrawal” - (p.331, Deatherage (1975). Subsequent case studies have reported 
people, both with and without a previous history of psychosis, experiencing psychotic or 
manic episodes associated with meditation (Kuijpers et al., 2007, Sethi and Bhargava, 2003, 
Walsh and Roche, 1979, Yorston, 2001).  However, the precipitating events to these episodes 
are often described as particularly intensive bouts of meditation (of varying schools of 
meditation), usually in the context of a retreat. None of the meditation practises described 
would be typical of a mindfulness-based intervention; and additional complex factors 
associated with retreats such as the effects of sleep deprivation and food restriction were 
likely to have played a significant role (Shonin et al., 2014, Walsh and Roche, 1979).  
Ongoing concerns additionally arise from a misunderstanding of the intentions or practice of 
mindfulness.  There is often a misguided idea that somehow encouraging people to focus on 
voices or difficult thoughts could make things worse, or even that due to the cognitive 
difficulties that people with psychosis sometimes also experience, they are simply unable to 
concentrate or to direct the focus of their attention in any way (Lavin, 2015).  This is of 
course not the case.  Mindfulness is not about inducing or creating any kind of internal 
experience, whether that is a paranoid thought, voice, emotion or bodily sensation.  In a 
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mindfulness practice, the intention is to simply turn towards whatever is already present, and 
developing an alternative response style to constant avoidance or struggle. 
 
Despite the scant evidence on harm, and growing evidence of benefit across a wide range of 
mental health conditions, Chadwick’s model of mindfulness for psychosis was still a radical 
development in the field when it was first published (Chadwick et al., 2005).  Chadwick 
noted that the aim of conventional CBTp was to alleviate distress associated with psychotic 
symptoms, rather than to attempt to directly eliminate the symptoms themselves.  
Mindfulness based approaches are therefore theoretically consistent with this approach, in 
that they aim to alleviate distress and suffering, through modification of the relationship we 
have with our internal experiences, rather than changing the form or content of the 
experiences themselves.  Chadwick further noted that people with distressing psychosis often 
struggle to cope with distressing voices or beliefs, and frequently get trapped in cycles of 
either trying to avoid their experiences or getting lost in battling against them.  Mindfulness 
offers an alternative way of being with psychotic experiences; bringing non-judgemental 
awareness, acceptance of the present moment and the letting go of struggling or fighting 
against experiences (Figure 5).  
 
 
Figure 5 Theoretical model of Mindfulness for psychosis; Chadwick (2005) 
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As with other cognitive therapies, the basis for mindfulness for psychosis is an idiosyncratic 
formulation, developed collaboratively between therapist and client, which explicitly 
identifies processes that maintain distress. It is important to normalise wanting to block out or 
avoid our difficult experiences at times; or at the other end of the spectrum, to get caught up 
in struggling or fighting against them.  For example, a study of 40 people with chronic voices 
found that the most common cognitive coping strategies they reported was trying to block 
voices out, telling them to go away, or trying to debate with them (Falloon and Talbot, 1981).  
However, a sole reliance on these response styles can often perpetuate distress and disruption 
to everyday activities as they are usually ineffective over the longer-term   (Howard et al., 
2013, Johns et al., 2002, Rassin and van der Heiden, 2007).  The rationale for a mindfulness-
based intervention is therefore to help people develop an alternative way of relating to their 
experiences, which involves deliberately turning towards the difficult, practising acceptance 
of what is present just in the moment, and letting experiences come and go in their own time.     
 
Experiential avoidance is therefore a key process that is targeted in mindfulness for 
psychosis.  Experiential avoidance (EA) is deﬁned as occurring when a person is unwilling to 
remain in contact with internal events or sensations, and takes steps to alter the form or 
frequency of those events and the context in which they arise (Hayes et al., 2011).  So for 
example, someone may use drugs or alcohol to block voices out, or use cognitive strategies to 
suppress their thoughts as outlined above.  Self-initiated coping strategies are commonly 
reported for people who hear voices, in both clinical and non-clinical populations (Farhall et 
al., 2007).  However, people who report coping poorly with their voices are more likely to 
use avoidance-based, distraction techniques, and to feel less in control of their voices 
compared to people who cope well with voices (Romme and Escher, 1989).  Consistent with 
Chadwick’s model, a cross-sectional study of 50 people who heard voices found that people 
who scored highly on a measure of EA (Acceptance and Action Questionnaire-II (AAQ-II); 
Bond et al. (2011)) were more likely to report behavioural and emotional attempts to resist 
voices (Morris et al., 2014).  Similarly, Varese et al. (2016) surveyed 101 clinical voice-
hearers and found that EA was associated with high levels of voice-related distress, but was 
not related to voice frequency or duration.  Not only is EA linked to less effective coping 
strategies and increased distress in relation to voices, there is also evidence it plays a 
mediating role in the relationship between life hassles and delusional distress.  Goldstone et 
al. (2011) did a questionnaire survey comparing a non-clinical (n=133) and clinical 
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(schizophrenia diagnosis; n=100) sample of people, and measured life hassles (Survey of 
Recent Life Experiences; (Kohn and Macdonald, 1992), delusional ideas (Peters Delusions 
Inventory (PDI); Peters et al. (2004)) , and EA (AAQ-II).  They found that both life hassles 
and EA were significantly correlated with both overall delusion score on the PDI, as well as 
the distress sub-scale, and the relationship was strongest between EA and delusional distress.  
They went on to perform a mediation analysis and found that EA mediated the relationship 
between life hassles and delusions, and delusional distress, in both the clinical and non-
clinical group.  The authors concluded that “the findings suggest that individual (irrespective 
of their diagnostic status) with a tendency to suppress or avoid unwanted thoughts are 
significantly more likely to experience distressing delusions in response to stressful life 
occurrences” - p.260.  The findings should be interpreted with caution because the study was 
cross-sectional, and we therefore cannot infer the direction of causality.  In order to overcome 
some of the limitations of cross-sectional data, Udachina et al. (2014) later conducted an 
experience sampling method (ESM) study, which is a structured diary technique.  They 
recruited people experiencing paranoia in the context of a schizophrenia-spectrum diagnosis 
(n=41) who were asked to rate paranoia, self-esteem and EA, 10 times a day over 6 
consecutive days. They found that EA partially mediated the relationship between low self-
esteem and paranoia.  The authors suggest this would be consistent with a model in which 
“persecutory delusions arise as a result of dysfunctional attempts to avoid unpleasant 
thoughts about the self” – p.442.  They further found that EA was also independently 
associated with low self-esteem, and this was more pronounced at times when participants 
reported feeling under stress related to their daily activities. Both these cross-sectional 
(Goldstone et al., 2011) and contextual data (Udachina et al., 2014) would therefore be 
consistent with a model of crisis in which people who used EA to cope at times of stress 
might be more likely to experience a subsequent exacerbation of psychotic symptoms. 
 
3.2.2 Adaptations in mindfulness for psychosis 
 
Crane and colleagues recently wrote a timely paper on what defines mindfulness-based 
programs (Crane et al., 2016).  The paper discusses the importance of understanding the 
commonalities between different mindfulness based approaches, as well as the specific 
adaptations required for different populations, or settings.  They use an inventive visual 
metaphor for this, of the warp thread and the weft threat on a weaving loom.   The warp 
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thread is a fixed thread which runs vertically through the cloth, whereas the weft is the 
transverse thread which makes every tapestry unique.  They propose that if something is 
defined as a mindfulness-based therapy, it should contain certain commonalities with other 
approaches (the warp thread), whilst also being explicit about what makes the intervention 
unique (weft thread). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As outlined in the previous section, all these central ‘warp threads’ are present within 
mindfulness for psychosis.  It is based on a well-defined psychological model, and this 
includes proposed mechanisms for what causes and maintains human distress and suffering.  
The aim of the intervention is not to get rid of symptoms, or eliminate any kind of internal 
experiences, but rather to help people come into a new relationship with their experience.  
This is done by developing skills in self-regulation of attention, emotions and behaviours and 
cultivating attitudinal qualities of kindness, compassion and curiosity when turning towards 
the difficult.  The approach is based in experiential-learning, and involves an iterative process 
between meditation practice and teacher-led enquiry. 
 
So what of the weft - what are the particular components that make mindfulness for psychosis 
unique, and suited to the needs of people with distressing psychotic experiences?  Whilst 
Warp threads for Mindfulness-Based Interventions (Crane et al., 2016) 
1. Is informed by theories and practices that draw from a 
confluence of contemplative traditions, science, and the major 
disciplines of medicine, psychology and education. 
2. Is underpinned by a model of human experience which 
addresses the causes of human distress and the pathways to 
relieving it 
3. Develops a new relationship with experience characterized by 
present moment focus, decentering and an approach orientation 
4. Supports the development of greater attentional, emotional and 
behavioural self-regulation, as well as positive qualities such as 
compassion, wisdom, equanimity 
5. Engages the participant in a sustained intensive training in 
mindfulness meditation practice, in an experiential inquiry-
based learning process and in exercises to develop insight and 
understanding 
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emphasising that mindfulness meditation can be appropriate for people with psychosis, 
Chadwick and colleagues have also been keen to acknowledge the particular challenges this 
population may face.  People may be experiencing intense symptoms such as distressing 
voices or paranoid thoughts, and people’s concentration levels and attentional flexibility may 
further be affected by cognitive difficulties and the sedating effects of psychiatric medication. 
Chadwick et al. (2005) therefore recommend the following: - 
 
• Limit meditation practices to 10 minutes 
• Avoid prolonged silences, and provide frequent anchors in the guidance  
• Use concrete, everyday language in guidance 
• Give prior permission for the person to stop the practice at any time if needed 
 
For example, a typical 10-minute mindfulness practice may begin with grounding in the body 
through a brief body scan, beginning in the soles of the feet.  The invitation is to just tune into 
whatever bodily sensations are present, with no sense of a right or wrong way to be feeling, 
and taking up a decentred stance of awareness, letting sensations come and go in their own 
time.  The entire practice can be guided as ‘choiceless awareness’, meaning people are 
encouraged to notice and accept whatever is coming up in awareness, moment by moment; 
whether this is a thought, voice, or emotion, and letting things come and go in their own time.  
The level of concentration or focus in the practice can also be adjusted as necessary for the 
individual or group.   For example, the breath can be introduced as an anchor for the 
awareness, so inviting people to come to an awareness of the bodily sensations of breathing, 
whether this is at the nostrils, in the chest or down in the stomach.  If appropriate, guidance 
can also be offered on working with mind-wandering, so simply noticing when the mind has 
wandered away from the breath, whether to voices, thoughts or images in the mind, and to 
gently disengage from struggling or fighting with experience, and to come back to the 
sensations of breathing in the body as a way of re-connecting with the present moment.  As 
for any mindfulness of the breath practice, it is emphasised that the intention is not to force 
the attention to stay on the breath, and not to view mind-wandering as any kind of failure, or 
getting it wrong in some way.  Mind-wandering is emphasised as a normal and healthy part 
of having a human mind, but what is being cultivated is a greater awareness of noticing when 
the mind has wandered, and what it has wandered away to.  Overtime, this can lead to greater 
awareness and familiarity with the habits of the mind; for example, when a critical voice 
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arises in awareness, noticing if there is a tendency to get caught up in pushing the voice away 
or getting caught up in struggling against it. 
 
3.2.3 Early pilot trials of mindfulness for psychosis 
 
The first published study of mindfulness for psychosis was an uncontrolled pilot trial 
published by Chadwick et al. (2005).  They delivered mindfulness for psychosis in a group 
consisting of 6 sessions, with a maximum group size of 6 people.  Each group session 
included 2 x 10-minute mindfulness of the breath meditation, followed by facilitator-led 
inquiry and group discussion.  All participants had been experiencing distressing psychosis 
for at least 2 years (including voices and paranoia), and were current users of secondary 
mental health services.  Fifteen people completed one of 4 groups, and outcome data were 
available from 10 people.   The main outcome used was a general measure of clinical 
functioning (Clinical Outcomes in Routine Evaluation (CORE); Evans et al. (2000)).  The 
results showed a significant improvement on the CORE from pre-post group, and there were 
no adverse effects arising from the meditation practises.   
 
Given these encouraging results, Chadwick and colleagues (2009) went on to conduct a 
randomised controlled trial.  People were eligible for the trial if they had been experiencing 
distressing voices for at least 6 months, and were receiving treatment for a psychotic disorder 
from secondary mental health services.  Twenty-two people were randomised into the study 
(n=11 allocated to mindfulness group intervention, n=11 allocated to wait-list control).  Most 
of the participants experienced distressing paranoid thoughts in addition to voices, all were 
taking anti-psychotic medication, and the mean duration of illness was 17 years.  It is 
therefore important to note that this was a group of people with complex, chronic difficulties 
who were generally representative of people receiving care within secondary services 
(Chadwick, 2014).  The intervention consisted of twice-weekly group sessions for 5 weeks 
plus home practice, followed by 5 further weeks of home practice.  Home practice was not 
formally measured, but all participants reported at least some home practice during the group 
intervention, which they then maintained in the following weeks.    The primary outcome 
measure was again the CORE, and a mindfulness measure, validated for use in psychosis, 
was additionally included as a process measure (Southampton Mindfulness Questionnaire 
(SMQ); Chadwick et al. (2008).  Measures were taken at baseline, and at post-treatment (10 
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weeks).  Data were available on 18 participants, and the primary analysis showed no 
significant difference between the intervention and control group on the CORE.  A secondary 
analysis of all group completers (n=15) indicated significant pre-post improvements on both 
the CORE and mindfulness of thoughts and images (Southampton Mindfulness 
Questionnaire; SMQ). 
 
Chadwick and colleagues later expanded this work into an intervention for distressing voices 
called Group Person Based Cognitive Therapy (PBCT), which integrates CBTp and 
mindfulness.  The therapy included mindfulness practice, guided discovery and behavioural 
experiments.  Data from nine pilot groups indicated a positive benefit for 50 voice-hearers 
who completed pre- and post measures of well-being, distress, control and dependence upon 
the voice (Dannahy et al., 2011).  This led on to a larger randomised controlled trial of 108 
participants who had been hearing voices for at least a year (Chadwick et al., 2016).  
Participants were randomly allocated to received either PBCT in addition to treatment as 
usual (TAU) (n=54), or TAU only (n=54).  The intervention consisted of 12 weekly 90-
minute sessions of group PBCT.  There was no significant difference at post-treatment (4 
months post-randomisation) between the PBCT and TAU groups on the primary outcome 
measure of general psychological distress (CORE).  However, they did find evidence of a 
significant benefit in the PBCT group for depression (HADS; (Zigmond and Snaith, 1983) 
and intensity of distress associated with voices (PSYRATS; (Haddock et al., 1999b).  This 
benefit was only maintained for depression at follow-up (10 months post-randomisation).  
There was more than 20% loss to follow-up at the 10 months time-point however, so this 
latter finding should be interpreted with caution. 
 
Overall, these trials have focused on the acceptability, safety and feasibility of the approach.  
This is a vital first step in any treatment development, particular in an area as contentious and 
controversial as using meditation techniques in psychosis.  There are some methodological 
limitations to these trials, which could be addressed in further trials.  For example, rather than 
using TAU alone as the control condition, an active control could be used to better match for 
non-specific therapy factors such as the general benefits of attending a supportive group for 
several weeks.  The findings also indicate that the most appropriate primary outcome measure 
for future trials is likely to be a more symptom-specific measure (i.e. distress associated with 
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voices/delusions) rather than a general measure of well-being or clinical functioning such as 
the CORE. 
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3.2.4 Qualitative studies of service user experiences of mindfulness for psychosis 
 
In addition to clinical outcome measures, another important source of information from 
mindfulness for psychosis trials is qualitative data, arising from a study of people’s 
experiences within the group.  An exploration of the phenomenology of people’s experiences 
in undertaking a mindfulness intervention has much to contribute to our understanding of the 
processes involved, and whether this is consistent with the underlying theoretical model.  
With the aim of investigating the psychological processes involved, Abba et al. (2008) 
conducted interviews (both in groups, and individually) with 16 people who had completed at 
least 4 sessions of a mindfulness group (as outlined in Chadwick et al. (2005)).  Interviews 
were conducted using a semi-structured interview schedule, and were audio-taped and 
transcribed verbatim.  They were analysed using grounded theory (Glaser and Strauss, 1967), 
with emergent themes grouped into categories of increasing abstraction, which were then 
hierarchically organised resulting in the creation of higher-order categories (Figure 6). 
 
 
 
Figure 6 Grounded theory model of mindfulness for psychosis (Abba et al., 2008) 
 
The core theme was identified as “relating differently to psychosis”, with three sub-themes 
describing the key processes involved.  The first describes the process of decentering, and 
opening towards experience, even when it is unpleasant or unwanted.  The second describes a 
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realisation that there is a choice available in responding to voices, thoughts or images, and 
avoiding or struggling against them are not the only possibilities.  Finally, this wider choice 
of responses provides a vital opportunity to reclaim power through acceptance of psychotic 
symptoms, and building a “sense of self” independent of psychotic symptoms.  The authors 
noted that the findings fitted well not only with Chadwick’s model of mindfulness for 
psychosis (Figure 5), but also with the broader literature on how people without psychosis 
describe learning mindfulness skills (e.g. Allen et al. (2009)).  However, they did note the 
particular importance of reclaiming power for people with psychosis, given people often feel 
bullied or denigrated by voices and other perceived persecutors, and this sense of 
subordination and marginalisation is often mirrored in their other social relationships 
(Birchwood et al., 2000). 
 
Other qualitative studies of mindfulness for psychosis have been conducted within 
community, inpatient and early intervention settings and are summarised in Table 7.  All the 
studies produce slightly different resulting themes, given the different methods and clinical 
samples used.  However, there is an interesting convergence in the results.  Participants 
describe the process of deliberately turning towards difficulty, and in doing so, coming to a 
powerful realisation that they can make an active choice in how to respond to their 
experiences, on a moment-by-moment basis, and this leads to a greater acceptance of 
themselves, and a sense of identity which is no longer dominated by psychosis. 
 
“It’s like, being mindful wipes the fog from your glasses, you know, on a steamy day 
or something, you know, on a rainy day” 
- Participant quoted in Dennick et al. (2013) 
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Table 7 Qualitative studies of participants' experiences of taking part in a mindfulness for psychosis group 
Authors  Setting Intervention Participants Qualitative 
method 
Key themes 
York 
(2007) 
Acute 
inpatient 
Weekly open 
group, 
60mins 
duration, 
included 
mindfulness 
of the breath, 
& walking 
meditation 
n=8 (attended 
at least 2 
sessions) 
Mixed 
diagnostic 
group 
(including 
psychosis ) 
Thematic analysis 1) Cognitive changes 
2) Concentration 
3) Sense of 
peace/relaxation 
4) Acceptance 
5) Exposure to 
problems 
6) Awareness 
7) Self-management 
8) After discharge 
9) Negative 
experiences & 
misunderstandings 
10) Medication 
Ashcroft 
et al. 
(2012) 
Early 
intervention 
for 
psychosis 
service 
(EIP) 
Weekly 
rolling group, 
60 mins 
duration, 
format 
followed 
Chadwick 
(2005) 
n=9 (attended 
at least 6 
sessions, 
commenced 
at least 20 
weeks ago) 
Grounded theory 1) Using 
mindfulness 
2) Making sense and 
coping 
3) Relating to people 
differently 
4) Understanding 
and accepting 
myself 
Dennick 
et al. 
(2013) 
Community 
(day centre) 
Weekly group 
for 6 sessions, 
90 mins 
duration, 
format 
followed 
Chadwick 
(2005) 
n=3 (attended 
all 6 
sessions) all 
were 
experiencing 
distressing 
psychotic 
symptoms 
(voices) 
Interpretative 
Phenomenological 
Analysis (IPA) 
1) Experiencing 
distress 
2) Group as 
beneficial 
3) Mindfulness as 
beneficial 
4) Mindfulness 
groups as part of 
the process of 
recovery 
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3.2.5 Meta-analyses and systematic reviews 
 
Since the early pilot trials, there has been significant interest in the efficacy of mindfulness as 
a treatment for psychosis.  This is reflected in the large number of reviews and meta-analyses 
of mindfulness for psychosis, which have proliferated over recent years (Table 8).  These 
include meta-analyses (Cramer et al., 2016, Khoury et al., 2013, Louise et al., 2017), 
systematic reviews (Aust and Bradshaw, 2017, Lam and Chien, 2016, Strauss et al., 2015) 
and a narrative review (Shonin et al., 2014).  A closer look at the first meta-analysis by 
Khoury et al. (2013) reveals the state of the evidence base and the challenges inherent in 
trying to produce a coherent synthesis of the data.  One considerable source of heterogeneity 
in this review was the type of mindfulness intervention used. Interventions included 
Acceptance and Commitment Therapy (ACT; (Bach and Hayes, 2002, Gaudiano and Herbert, 
2006, Shawyer et al., 2012, White et al., 2011), Compassionate Mind Training (CMT; 
(Laithwaite et al., 2009), Person Based Cognitive Therapy (PBCT; (Dannahy et al., 2011), 
loving-kindness meditation (Johnson et al., 2011) and mindfulness-based psychoeducation 
(Chien and Lee, 2013).  There was also variation in the therapeutic target within each sub-
type of therapy.   For example, the ACT studies were variously focused on reducing risk of 
hospital readmission for acute inpatients (Bach and Hayes, 2002, Gaudiano and Herbert, 
2006), treating post-psychosis depression (White et al., 2011) and reducing compliance with 
harmful command hallucinations (Shawyer et al., 2012).  In terms of the quality of the 
studies, only 7/13 studies were RCTs, with the remainder reporting only pre-post outcomes 
for the intervention group.  There was wide variation in the primary outcome measures used, 
which included general clinical functioning, psychotic symptoms, mood symptoms and 
hospital re-admission.  It is perhaps not surprising that I2 (a measure of heterogeneity) was 
above 75% for the end of treatment effect across all studies, which would be categorised as a 
high degree of heterogeneity (Higgins et al., 2003).  Indeed, the later review by Lam and 
Chien (2016) explicitly stated they did not perform a meta-analysis on the studies they found, 
due to the wide variation in study designs, interventions and outcome measures.    
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Table 8 Reviews of mindfulness for psychosis studies 
Author Type of review Inclusion 
criteria 
Number of 
studies (no. of 
participants)  
Quality 
assessment 
Conclusions 
Khoury et al. 
(2013) 
Meta-analysis Any study 
reporting 
outcome data 
(symptoms 
and/or 
psychosocial 
functioning) 
13 (n=468) 
  
7 RCTs 
6 uncontrolled 
trials 
A composite 
quality scale 
was devised 
(average score 
was 5/10).  4 
studies 
included 
blinded 
assessments. 
Only 1 RCT 
had an active 
control group. 
 
Mindfulness 
moderately 
effective in pre-
post studies 
(smaller effect 
sizes in 
controlled 
studies) 
Shonin et al. 
(2014) 
Narrative Any 
mindfulness 
study reporting 
quantitative or 
qualitative data 
(ACT excluded 
as mindfulness 
considered only 
component of 
treatment) 
11 (n=221) 
 
3 RCTs 
3 uncontrolled 
trials 
1 case series 
4 qualitative  
 
 
No formal 
quality 
assessment 
Mindfulness 
appears to have 
a beneficial 
role, but data 
not yet 
sufficient to 
demonstrate 
clear treatment 
effects for 
psychosis 
Strauss et al. 
(2015) 
Systematic 
review 
Mindfulness for 
people who 
hear voices 
(either 
treatment 
studies or 
cross-sectional 
studies of 
mindfulness 
constructs) 
15 (n=479) 
 
3 RCTs 
2 uncontrolled 
studies 
1 case study 
4 qualitative  
5 cross-
sectional 
No formal 
quality 
assessment 
Mindfulness is 
acceptable and 
safe, but there 
are no 
adequately 
powered RCTs 
to provide 
sufficient data 
on efficacy 
Lam and 
Chien (2016) 
Systematic 
review 
RCTs of 
mindfulness 
(ACT excluded 
as mindfulness 
considered only 
component of 
treatment) 
6 (n=407) 
 
 
Cochrane Risk 
of Bias Tool. 
Most studies 
had high risk of 
bias for 
selection, 
performance 
and detection 
bias due to 
unclear 
description of 
randomisation 
procedures and 
non-blinded 
assessors 
Insufficient 
evidence to 
demonstrate 
promising 
effects based 
on existing 
studies 
Cramer et al. 
(2016) 
Meta-analysis RCTs of 
mindfulness or 
acceptance-
based therapy 
8 (n=434) 
 
 
Cochrane Risk 
of Bias Tool. 
6 RCTs had 
low risk of 
bias, 2 had high 
risk.  Only 3 
No serious 
adverse events 
reported.  
Mindfulness 
and acceptance-
based 
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studies used 
ITT analysis. 
treatments can 
be 
recommended 
in psychosis in 
addition to 
standard care 
Louise et al. 
(2017) 
Meta-analysis RCTs, 
including 
mindfulness, 
acceptance and 
compassion-
based 
interventions 
10 (n=572) 
 
Clinical Trial 
Assessment 
Measure 
(CTAM).  Four 
studies rated as 
high risk of 
bias (score 
<65) 
Overall 
findings 
indicate that 
mindfulness 
and acceptance-
based therapies 
show beneficial 
effects on 
symptoms in 
psychosis 
Aust and 
Bradshaw 
(2017) 
Systematic 
review 
RCTs, 
including 
mindfulness, 
acceptance and 
compassion-
based 
interventions 
11 (n=549) Clinical Trial 
Assessment 
Measure 
(CTAM).  
Three studies 
rated as high 
risk of bias 
(score <65) 
Mindfulness is 
safe and 
appears to have 
therapeutic 
benefits.  
Larger trials are 
now needed. 
 
Given that the number of studies included in these reviews ranges from only 6-15, the 
evidence base is still sparse, and it is always problematic when the number of reviews begins 
to outpace the number of primary research studies.  The number of RCTs included in the first 
published meta-analysis was 7 (Khoury et al., 2013), and this only increased to 10 in the 
latest meta-analysis (Louise et al., 2017).  The strongest conclusion to be drawn from the 
state of the evidence base so far is that more randomised controlled trials need to be 
conducted, particularly with the inclusion of active control arms, rather than just TAU or 
wait-list control.  Only 2 of the RCTs used an active control (befriending) to account for non-
specific therapy factors (Shawyer et al., 2012, Shawyer et al., 2016).  There are no RCTs of 
mindfulness for psychosis within UK inpatient settings in the published literature.  The 2 
ACT for psychosis studies from the US ((Bach and Hayes, 2002, Gaudiano and Herbert, 
2006) have been replicated in a small-scale feasibility study in Sweden (n=22; Tyrberg et al. 
(2016)), however this later study was not included in either the Louise et al. (2017) or Aust 
and Bradshaw (2017) reviews.  Accounting for significant levels of heterogeneity remains a 
challenge; future reviews may have to be more specific about the type of interventions 
included, the clinical setting and the patient population.  Although the reviews summarised in 
Table 8 do vary in terms of whether they included just RCTs, or included other study designs 
as well, and whether they considered acceptance and compassion-focused studies eligible, a 
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clear pattern does appear to emerge.  Mindfulness for psychosis is feasible, acceptable and 
safe.  However, as for establishing clear treatment effects, there is more work to be done. 
 
3.3 Summary and objectives of study 
 
Mindfulness for psychosis is based on a clearly defined theory of how experiential avoidance 
perpetuates distress associated with psychotic symptoms.    The first uncontrolled of trial of 
mindfulness for psychosis was published over 10 years ago.  Pilot randomised trials in 
several different countries followed, which established mindfulness for psychosis as a safe 
and acceptable intervention. The evidence base is still in an early stage of development in 
terms of establishing efficacy.  A major challenge to interpreting the current evidence base 
arises from the wide range of interventions, clinical settings, and outcome measures used.    
The role of mindfulness for psychosis in reducing risk of readmission for people admitted to 
hospital with acute distressing symptoms warrants further study, given promising results from 
pilot trials conducted in the US. 
 
In line with the MRC guidelines for developing and evaluating complex interventions 
(updated (2006)), the focus of this preliminary trial was on establishing feasibility.  This 
includes gathering data relevant to testing procedures, estimating recruitment/retention and 
determining sample size. The primary objective of this study was therefore to find out 
whether it is possible to carry out this kind of trial successfully within inpatient settings and 
to find out whether patients and staff find it an acceptable intervention.  The secondary 
objective was to collect pilot data on clinical outcome measures.  The trial protocol is set out 
in Chapter 4, and the statistical and data management plan in Chapter 5. 
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 Method 
4.1 Overview 
 
This chapter gives an overview of the method for the study.  The trial protocol was written 
using a standard template provided by King’s Clinical Trials Unit, which conforms to the 
SPIRIT 2013 Statement recommendations for clinical trial protocols (Chan et al., 2013).  In 
line with good practice guidelines (MHRA, 2012), the trial was pre-registered prior to the 
start of recruitment on the ISRCTN registry (DOI 10.1186/ISRCTN37625384).  The trial 
protocol was also published in Pilot and Feasibility Trials, a peer-reviewed open-access 
journal (Appendix 2).   
 
The trial design was a single-centre, parallel-groups, feasibility randomised controlled trial.  
Consecutive new admissions to acute wards at the Maudsley Hospital were screened for 
eligibility over the recruitment period.  A full screening log of all admissions was kept, 
including recording the reasons for any patients not entering the trial.  Eligible patients were 
randomly allocated to receive either the intervention or control treatment, both of which 
consisted of between 1-5 sessions of intervention, all within the duration of the inpatient 
admission.  Participants completed self-report measures at baseline, post-therapy and 3- and 
6-month post-discharge follow-up.  Outcome measures included service use data, collected 
by clinical note review and blind-rated, and clinical measures from self-report questionnaires. 
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4.2 Trial identifiers 
 
Title of Trial: Mindfulness-Based Crisis Interventions (MBCI) for psychosis within acute 
inpatient psychiatric settings; A feasibility randomised controlled trial 
Trial Acronym: BrIef Talking therapies ON wards (amBITION study) 
ISRCTN: 376253384 
REC Number: 15/LO/1338 
UKCRN Number: 19490 
Lead Sponsor: King’s College London 
Co-Sponsor: South London and Maudsley NHS Foundation Trust 
 
4.3 Primary and secondary objectives 
 
The primary objective of the study was to find out whether it is possible to carry out this kind 
of trial successfully within inpatient settings and to find out whether patients and staff find it 
an acceptable intervention.  The secondary objective was to collect pilot data on service use 
and clinical outcomes. 
 
4.4 Study design and timeline 
 
This study was a single-centre, parallel-groups, feasibility randomised controlled trial.  Trial 
procedures and the assessment schedule are shown in the study plan (Figure 7).    End of 
therapy was defined as EITHER i) completing 5 sessions of therapy OR ii) discharge from 
acute ward, whichever came first.  Post-therapy measures were taken either at i) discharge 
OR ii) 5 weeks post-randomisation, whichever occurred first. The first follow-up occurred 3 
months (90 days) after discharge, and the second follow-up occurred 6 months (180 days) 
after discharge.  The end of the study for each participant was when the 6-month follow-up 
was completed.  The 3-month mid-point follow-up was included to minimise missing data 
arising from loss to follow-up, and to provide more detailed information on symptom change 
in the short-term after discharge. 
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- Eligibility Screen (all new admissions) 
- Consultant permission to approach eligible patients 
 
- Patient approached and given information sheet 
- Initial consent for screening - final eligibility checks done 
- Patient gives written informed consent 
- Baseline self-report measures 
- Demographic/clinical data collected 
Mindfulness-Based Crisis 
Interventions (MBCI) 
1-5 sessions 
Social Activity Therapy 
(SAT) 
1-5 sessions 
Randomisation 
3-month follow-up 
Re-admission data/Self-
report measures 
3-month follow-up 
Re-admission data/Self-
report measures 
6-month follow-up 
Re-admission data/Self-
report measures 
6-month follow-up 
Re-admission data/Self-
report measures 
Post-therapy 
Self-report measures 
Post-therapy 
Self-report measures 
INTERVENTION CONTROL 
Figure 3 Study Plan 
Post-Discharge 
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4.5 Ethical approval 
 
Ethical approval for the study was given by the London -Camberwell St Giles Research 
Ethics Committee (REC reference number: 15/LO/1338).  See Trial Master File for 
confirmation of favourable opinion letter (dated 29/09/15). 
 
4.6 Participants 
 
4.6.1 Inclusion/Exclusion Criteria 
 
Inclusion Criteria 
i) Aged 18 or above 
 ii) Current psychiatric inpatient on a working-age adult ward 
 iii) Diagnosis of schizophrenia-spectrum disorder or psychotic symptoms in the context of an 
affective disorder (ICD-10 codes F20-39; (WHO, 2010) 
 iv) Reports at least one current positive psychotic symptom (scores >1 on frequency on self-
report symptom scale) 
 v) Able to give informed consent to participate in trial, as assessed by consultant 
psychiatrist/responsible clinician and researcher 
 vi) Willing and able to engage in psychological therapy 
 
Exclusion Criteria 
i) established diagnosis of learning disability, or major cognitive impairment arising from any 
underlying medical condition (e.g. head injury, neurological disorder) resulting in significant 
functional impairment  
ii) unable to engage in a talking therapy in English, or to complete simple written 
questionnaires in English 
 iii) primary diagnosis of substance misuse 
v) lacks capacity to consent to participation in research trial 
 vi) unable to take part in individual therapy due to risk of aggression/violence 
 vii) mental state precludes possibility of engaging in a talking therapy, e.g. significant 
thought disorder, as assessed by clinical team and researcher 
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4.6.2 Recruitment, randomisation and blinding 
 
Participants were recruited from 4 acute inpatient psychiatric wards at the Maudsley Hospital.  
All consecutive new admissions were screened for eligibility by consultation with the 
inpatient care team.  The initial screening criteria were patients presenting with positive 
psychotic symptoms in the context of a psychosis or mood disorder.  Potentially eligible 
patients were then approached to take part with permission of their inpatient Consultant 
Psychiatrist and the nurse in charge of the shift, if it was agreed that they were deemed to 
have capacity to consent to take part in research, and there was no risk to the researcher in 
approaching the person.  Patients could take part in the trial if they were admitted under a 
section of the Mental Health Act (MHA) so long as they were deemed to have retained 
capacity to consent to participation in research.  The researcher asked patients for permission 
to speak to them about the research (with any refusals at this stage recorded on the screening 
log), and provided them with a copy of the brief information sheet to introduce them to the 
main aims of the study.    Further eligibility screening by reference to electronic clinical notes 
was conducted with written consent from patients who had been approached and were 
potentially interested in participating. Once the researcher had confirmed the patient’s 
eligibility, they approached the patient again to give them a copy of the full patient 
information sheet and to talk it over with them and explain the study further.  If for any 
reason the patient was found to be not eligible, for example they did not self-report any 
psychotic symptoms on interview with the researcher, or they had an ineligible diagnosis, 
then the reason was explained to them, and was recorded on the screening log. Eligible 
patients were given at least until the next day to read over the full information sheet, think it 
over, ask questions and to discuss their participation with anyone they may wish to (e.g. 
primary nurse or family member).    Screening and recruitment was overseen by PJ who 
completed all the screening logs.  Patients on the wards were approached either by PJ herself, 
a Clinical Studies Officer (CSO) from the local Clinical Research Network (CRN), or a 
psychologist on a short-term CRN secondment. 
 
After giving informed consent, eligible participants completed baseline measures.  They were 
then randomised using an online computerised service at the Kings Clinical Trials Unit 
(KCTU).  Block randomisation was used, with randomly varying block sizes to ensure 
allocation concealment.   The randomisation sequence was not stratified.  Each participant 
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was randomised at the beginning of their first therapy session, using a laptop computer, and 
participants were shown the process on-screen.  This was done for 2 reasons.  Firstly, it kept 
the time between randomisation and the beginning of the intervention to a minimum, which 
reduced the risk of participants being randomised into the trial, but not receiving any 
intervention.  This is a particularly pertinent issue within acute settings, where unpredictable 
discharges occur frequently.  Secondly, it made the randomisation process as transparent and 
open as possible, with the intention of increasing participants’ sense of trust in the process 
and mitigating against the possibility of any concerns arising from the randomisation process.   
 
As with all psychological therapy trials, both the therapist and participant were aware of the 
treatment condition they were randomised to.  However, the 2 therapies were referred to by 
neutral labels in all participant and staff literature (therapy 1 vs. therapy 2) with the aim of 
promoting equal treatment credibility between the conditions.  The participant’s inpatient and 
community care team were however blinded to treatment allocation, as far as could be 
achieved with conservative measures.  This included not referring to any content of the 
therapy sessions in clinical notes or standard trial letters, and conducting all therapy sessions 
in a private room on the ward.  Key members of the inpatient and community team (e.g. 
inpatient and community consultant psychiatrist, care co-ordinator, psychologist/therapist) 
and GP were notified of the patient’s participation in the trial at i) randomisation and ii) end 
of intervention.  They were informed of how many sessions were attended, and any goals 
arising from the intervention that the participant was happy to be shared.  Participants were 
not explicitly advised against sharing any details of their therapy or treatment allocation with 
other staff.  This was done to assess what, if any, were the major threats to blinding of 
inpatient and community teams that might occur, so these could be mitigated against in the 
planning of any future trials.  The service use data, which included relapse and re-admission 
assessed at 6-month follow-up, were blind rated by an appropriately trained researcher who 
was not otherwise involved in the trial.  Clinical outcome measures were all self-report, rather 
than clinician-rated, to reduce the risk of assessor bias – though risk of demand 
characteristics of course remains.  All questionnaire measures were collected by PJ. 
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4.6.3 Withdrawal of Participants 
 
Participants had the right to withdraw from the study at any time for any reason.  It was 
decided in advance, and documented in the trial protocol, that the researcher may also 
withdraw any participants who i) lose capacity to consent ii) no longer wish to take part in 
therapy iii) their mental state deteriorates to the extent they can no longer engage with 
therapy or iv) there is a risk of harm to self or others arising from their participation in 
therapy. All reasons for withdrawal were recorded.  The trial protocol stipulated that 
participants who wished to withdraw from the study, or who were withdrawn by the 
researcher, would be asked to confirm whether they were still willing to provide clinical self-
report measures at follow-up, and qualitative feedback at the end of the trial. Data on 
relapse/readmission for people who dropped-out were gathered from the clinical note system 
as normal, as this did not require any further contact with the participant.  This was made 
clear on the participant information sheet and the consent form. 
 
4.7 Description of therapies 
 
Therapy sessions in both conditions were delivered on an individual basis in a private room 
on the inpatient wards.  PJ was the trial therapist in both conditions. PJ is a Clinical 
Psychologist registered with the UK Health & Care Professions Council (HCPC) with 
expertise in cognitive behavioural therapy for psychosis (CBTp) and mindfulness 
interventions as well as experience of working in acute settings.   Therapy sessions in both 
conditions ranged from 1-5 sessions, depending on variables such as length of admission, 
with the frequency of sessions adjusted as needed between a minimum of weekly and 
maximum of daily.  All sessions followed a stand-alone, self-contained format, to 
accommodate unpredictable lengths of stay and unexpected discharges.  The treatment phase 
was restricted to the duration of the inpatient admission.  However, treatment did continue if 
a participant was transferred from one acute ward to another (as can frequently happen due to 
bed shortages and other factors).   
 
All participants in the trial continued to receive treatment as usual (TAU) both during their 
inpatient admission and post-discharge.  In theory, this could have included medication, 
attendance at activity and/or therapy groups, individual therapy sessions and family therapy 
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sessions.  Information relating to TAU was recorded on each participant’s Case Report Form 
(CRF). 
 
4.7.1 Mindfulness-Based Crisis Interventions (MBCI) – Experimental Intervention 
 
MBCI was developed in line with the ACT trials conducted in the US and the model of 
mindfulness for psychosis proposed by Chadwick (Chadwick, 2006a).  The treatment 
protocol for the current trial was adapted for use within an acute crisis setting, following 
Bach and Hayes (2002) and Gaudiano and Herbert (2006).  The full therapy manual 
developed for the trial is included in the Trial Master File.  In brief, each session included 3 
key components to be included in each session, with varying amounts of emphasis placed on 
each component depending on the session number and the stage of therapy.  These were: - 
 
i. Developing mindfulness skills (guided practice) 
ii. Making sense of crisis using mindfulness model 
iii. Identifying values and setting goals 
 
The guided practice was always done at the beginning of each session.  The first session 
focused primarily on the development of a crisis-focused formulation, using a standard 
template, which formed the basis of a shared understanding of what brought the person into 
hospital on this occasion.  This formulation then informed any future sessions, focusing on 
key processes that had been identified in the run-up to the crisis, such as experiential 
avoidance.  The therapist also worked with the participant to identify their values (e.g. family, 
work, health, society), and discuss specific behavioural goals consistent with these values.  
Participants were then helped to set a small, achievable goal for homework at the end of each 
session that could be reviewed at the beginning of next session, where possible.  In 
preparation for discharge, longer-term goals were also identified (e.g. starting a college 
course) and were shared with the community care team at the end of therapy in the end of 
therapy letter, to act as a bridge to carrying on the recovery process in the community. 
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4.7.2 Social Activity Therapy (SAT) – Control Intervention 
 
The control condition was taken from the PICASSO trial of CBTp for people with psychosis 
and a history of violence, which was conducted partly on inpatient wards (Haddock et al., 
2009).  SAT involved working collaboratively with the participant to identify activities they 
enjoyed and which they could engage in during and between sessions as they wished (e.g. 
board games, puzzles). The aim was to provide a supportive environment with a therapist 
using non-specific aspects of therapy (e.g. collaboration, feedback, empathy).  The aim was 
to keep the sessions activity focussed, and to be supportive, collaborative and empathic 
without employing any therapy techniques specific to any model of therapy, including CBTp 
or mindfulness-based therapies.   
 
4.7.3 Treatment Fidelity 
 
All participants were asked their permission to audio-tape sessions for the purposes of 
clinical supervision and fidelity checks.  The proportion of people who agreed was recorded, 
as this is important data for assessing the feasibility of audio-recording as the primary method 
of fidelity checking for future trials.  Participants were offered copies of the recordings if they 
so wished.  A sample of therapy sessions was randomly selected for fidelity checking by an 
experienced clinician, who was blind to treatment allocation, and had not been otherwise 
involved in the trial.  Fidelity checks were completed using the adherence and competency 
scale developed for the trial (see Trial Master File). In brief, this comprised 4 sub-scales: - 
 
 
 
A:  Non-specific Cognitive Therapy Scale (essential to MBCI & SAT)  
 From Cognitive Therapy Scale for Psychosis (CTS-PSY; Haddock et al. (2001)) 
 
1) Agenda 
2) Feedback 
3) Understanding 
4) Interpersonal Effectiveness 
5) Collaboration 
6) Homework 
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B:  MBCI-specific Therapy Scale (unique to MBCI)  
 Following Chadwick (2006b) 
 
1) Making sense of crisis using mindfulness model 
2) Developing mindfulness skills 
3) Identifying values and committed action 
 
C:  SAT-specific Therapy Scale (unique to SAT)  
 From PICASSO study (Haddock et al., 2009) 
 
1) Within-session activities 
2) Response to emotion distress 
 
D:  CBT for psychosis Therapy Scale (proscribed for both MBCI & SAT)  
 From Revised Cognitive Therapy for Psychosis Adherence Scale (R-CTPAS; Rollinson et al. (2008)) 
1) Columbo style 
2) Evidence for delusional beliefs 
3) Verbal challenge of delusions 
4) Validity testing 
5) Schemas 
 
Within each sub-scale, each key component was rated for adherence (0=absent, 1=present), 
and then where relevant, further assessed on a 6-point competence scale (0=poor, 
3=satisfactory, 6=excellent).  To maintain a high-level of treatment fidelity over the course of 
the trial, PJ received regular supervision from an independent clinical supervisor with 
expertise in acute care, and mindfulness-based approaches.  Clinical supervision included the 
use of audio recordings from therapy sessions and presentation of case formulations. 
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4.8 Outcome measures 
 
4.8.1 Primary objective – Feasibility/acceptability data 
 
1) Number of eligible participants identified over study period 
2) Total numbers recruited into trial and recruitment rate (benchmark of 80% of target) 
3) Proportion of participants who dropped out during the intervention stage 
4) Range and average number of sessions completed (including number of sessions 
attended as a proportion of those offered) 
5) Reasons for participants dropping out during the intervention stage 
6) Number lost to follow-up and reasons (benchmark of less than 20% to be set in line 
with previous studies) 
7) Any unexpected adverse effects of participating in the trial 
 
4.8.2 Qualitative data on acceptability 
 
1) Participant feedback on trial procedures, randomisation, credibility of two therapies  
2) Staff feedback on trial procedures, recruitment strategies, blinding procedures 
 
At the end of the study, all participants were asked for some brief feedback on a 
questionnaire that was completed with PJ at their 6-month follow-up (see Trial Master File 
for topic guide).  They were also asked if they would be willing to give additional feedback 
around the same topics, via either a follow-up interview or focus group, which would be 
conducted by one of the service user researchers working on the trial. All service user 
researchers were part of the advisory group for the trial, and were recruited from the Trust 
Involvement Register, and had appropriate training.  Staff from the in-patient units where 
patients were recruited were also invited to give feedback on the trial via an individual 
interview or focus group.  Staff interviews were conducted by two assistant psychologists 
who had not otherwise been involved in the trial. The assistant psychologists were working 
for the Trust in the Corporate Directorate, and had previous experience of conducting staff 
interviews and focus groups.  Interviews and focus groups were audio-recorded, with written 
consent from all participants.   
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4.8.3 Secondary objective - Pilot data 
 
Pilot outcome measures were collected, as detailed in Table 9 (service use data) and Table 10 
(clinical measures).   
 
Table 9 Service use outcome data 
Outcome Method Time period 
Main outcome: -   
1) Re-hospitalisation 
(≥1 OBD11)   
Clinical notes  Discharge – 3 & 6 mth 
follow-up 
Additional outcomes: -   
2) Time to re-
admission (days) 
Clinical notes  Discharge – 3 & 6 mth 
follow-up 
3) Total number of 
OBDs 
Clinical notes  Discharge – 3 & 6 mth 
follow-up 
4) Episodes of care 
with crisis/home 
treatment team 
(HTT) 
Clinical notes  Discharge – 3 & 6 mth 
follow-up 
5) Contact with 
CMHT12 (number of 
meetings/contact 
with CMHT 
including care co-
ordinator) 
Clinical notes  Discharge – 3 & 6 mth 
follow-up 
6) Reference to 
therapy goal which 
was shared with 
team 
Clinical notes (free text search 
for goal as defined in end of 
therapy letter shared with team) 
Discharge – 3 & 6 mth 
follow-up 
7) Relapse rate 
 
Defined as a documented 
exacerbation in psychotic 
symptoms, in addition to a 
subsequent change in clinical 
management (change in 
meds/increase frequency of 
visits/referral for admission or 
mental health act 
assessment/admission to HTT or 
inpatient ward) 
Clinical notes  Discharge – 3 & 6 mth 
follow-up 
 
 
                                                 
11 OBD=occupied bed day 
12 CMHT=community mental health team 
94 
 
 
Table 10 Clinical measures outcome data 
Construct assessed Questionnaire Method Time points 
Credibility of 
therapy  
1) Therapy 
credibility 
Self-report Baseline only 
(immediately post-
randomisation) 
In the moment rating 
of stress and 
interference from 
symptoms, and hope 
for the future 
2) Stress 
bubbles 
Self-report At the beginning and 
end of every therapy 
session 
Frequency, distress 
& believability of 
beliefs and/or voices 
3) Self-ratings 
of psychotic 
symptoms 
 
(Based on Bach & 
Hayes, 2002; 
Gaudiano & Herbert, 
2006) 
Self-report Baseline, end of 
therapy, 3 mth mid-
point and 6 mth 
follow-up 
Mood – depression, 
anxiety and stress 
4) DASS-21 
 
(Depression, anxiety 
& stress scale; 
Lovibond & 
Lovibond, 1995) 
Self-report Baseline, end of 
therapy, 3 mth mid-
point and 6 mth 
follow-up 
Self-defined 
recovery 
5) QPR 
 
(Questionnaire about 
the Process of 
Recovery; Neil et al 
2009) 
 
Self-report Baseline, end of 
therapy, 3 mth mid-
point and 6 mth 
follow-up 
Voices (incl. 
frequency, distress, 
interference & 
compliance) 
6) HPSVQ 
 
(Hamilton Program 
for Schizophrenia 
Voices 
Questionnaire; Van 
Lieshout & 
Goldberg, 2007) 
Self-report Baseline, end of 
therapy, 3 mth mid-
point and 6 mth 
follow-up 
Mindfulness 7) SMQ 
 
(Southampton 
Mindfulness 
Questionnaire; 
Chadwick et al, 
2008) 
Self-report Baseline, end of 
therapy, 3 mth mid-
point and 6 mth 
follow-up 
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4.8.4 Description of clinical measures 
 
1) Therapy Credibility 
 
Immediately after randomisation, participants were read a brief description of the therapy 
they had been assigned to.  They were then asked to rate on a scale from 0 (not helpful at all) 
to 10 (extremely helpful) how helpful they thought the therapy sounded. 
 
2) Stress Bubbles 
 
The use of within-session measures can be helpful in measuring change in brief interventions, 
by capturing small shifts in key processes that may occur over the course of a therapy 
session.  Stress bubbles are a form of visual analogue scale, with 6 bubbles gradually 
increasing in size from “not at all” (1) to “extremely” (6).  Participants rated 3 items (stress, 
interference from symptoms, and hope for the future) at the beginning and end of every 
session.  These unpublished scales have been successfully used in a previous study of 
mindfulness interventions for psychosis (Jacobsen et al., 2011). 
 
3) Self-ratings of psychotic symptoms 
 
This is a self-report scale that asks respondents to rate their psychotic symptoms (voices 
and/or distressing beliefs) on a scale of 1-7 (frequency) and 0-10 (distress and believability). 
These scales were used in the ACT inpatient trials (Bach and Hayes, 2002, Gaudiano and 
Herbert, 2006), and were found to be easy for participants to complete, and showed 
sensitivity to change over time. 
 
4) Depression, anxiety and stress scales; (DASS-21) (Lovibond and Lovibond, 
1995) 
 
The DASS-21 is a short-form version of the original 42-item DASS comprising 7 items on 
each of the 3 sub-scales for depression, anxiety and stress.  It is a self-report scale with 
respondents scoring each item on a four-point scale from 0 (never) to 3 (almost always).  The 
DASS-21 has been well-validated in both clinical (Antony et al., 1998) and non-clinical 
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samples (Henry and Crawford, 2005).  The DASS-21 is particularly suitable for this study, 
being relatively quick and easy to complete, and has been shown to have good internal 
consistency and convergent validity in an acute psychiatric population (Weiss et al., 2015) 
and is suitable for use with people experiencing psychotic symptoms (Samson and 
Mallindine, 2014). 
 
5) Questionnaire about the Process of Recovery; QPR (Neil et al., 2009) 
 
The QPR is a 22-item self-report measure based on service user accounts of the process of 
recovery from psychosis.  It has 2 sub-scales assessing both intrapersonal and interpersonal 
processes in recovery.  Each item is rated on a 5-point scale from 0 (disagree strongly) to 4 
(agree strongly).  Neil et al. (2009) report that the scale has good internal consistency, 
construct validity and reliability. 
 
6) Hamilton Program for Schizophrenia Voices Questionnaire; (HPSVQ) (Van 
Lieshout and Goldberg, 2007) 
 
The HPSVQ is a 13-item self-report measure in which respondents rate the first 9 items on a 
five-point Likert scale from zero (lowest severity) to four (highest severity).  The total score 
of these 9 items is intended to indicate the severity of auditory verbal hallucinations, and 
includes items on frequency, distress and interference with daily activities.  There are an 
additional 4 qualitative items, not included for the purposes of this study.  Kim et al. (Kim et 
al., 2010) reported high test-retest reliability and good convergent validity with established 
clinician-rated scales (PSYRATS-AH (Haddock et al., 1999b); PANSS (Kay et al., 1987)) 
when used in a clinical sample of people with a diagnosis of schizophrenia.  
 
7) Southampton Mindfulness Questionnaire; SMQ (Chadwick et al., 2008) 
 
The SMQ is a 16-item self-report measure designed to assess mindfulness of difficult 
thoughts and images.  Each item is scored on a 7-point scale ranging from 0 (totally agree) to 
6 (disagree totally).  The SMQ has been validated in a clinical sample of people experiencing 
distressing psychotic symptoms.  Chadwick et al. (Chadwick et al., 2008) report that the 
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SMQ has good internal reliability, and shows convergent reliability with other established 
mindfulness scales (e.g. MAAS; (Brown and Ryan, 2003)). 
 
4.9 Procedures for Recording and Reporting Adverse Events 
 
Procedures for adverse event recording were detailed in the trial protocol.  In brief, all 
adverse events were recorded for each participant from randomisation, to completion of the 
trial at 6-month follow-up.  In addition to standard adverse events (death, hospitalisation, 
disability, birth defect), several additional adverse events were identified in advance, and 
specified in the trial protocol, which were of particular relevance to this patient group and 
clinical setting.   This is in line with an approach previously successfully applied by Horigian 
and colleagues (2010), who defined additional adverse events of particular relevance to a trial 
of a behavioural intervention for adolescent drug abuse, including arrests and school 
suspensions.  Taking this approach can be helpful in making adverse event reporting 
guidelines more relevant to psychological therapy trials.  Standard definitions of adverse 
events are focussed on occurrences of physical harms, because the criteria for defining an 
adverse event were designed primarily for drug trials (Duggan et al., 2014).  However, other 
events, such as emotional harms, or occurrences of potentially risky behaviour, are often 
more relevant to monitoring harm for psychological therapy trials.  Additional adverse events 
were therefore identified in the trial protocol for this study, which consisted of self-harm, 
absconsion from the ward, and harm to or from others (e.g. assault).  All adverse events were 
reported to the independent chair of the Trial Steering Committee, who ratified the project 
team’s assessment of whether they could be related to trial participation and would require 
reporting to the ethics committee and Trust R&D department. 
 
4.10 Stopping Rules 
 
Stopping rules were defined in advance in the trial protocol, and were as follows.  The trial 
could have been prematurely discontinued by the Sponsor or Chief Investigator based on new 
safety information or for other reasons given by the Ethics Committee, Trial Steering 
Committee or other regulatory authority concerned.  The trial could also have been 
prematurely discontinued due to lack of recruitment or upon advice from the Trial Steering 
Committee, who would advise on whether to continue or discontinue the study and make a 
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recommendation to the sponsor.  If the study were to have been prematurely discontinued, 
active participants would have been informed and no further participant data would have 
been collected. 
 
4.11 Trial Steering Committee (TSC) 
 
Membership of the TSC: - 
 
 Katherine Berry – Independent Chair 
 Pamela Jacobsen – Chief Investigator 
 Paul Chadwick – Co-Investigator 
 Emmanuelle Peters – Co-Investigator 
 Service User Representatives 
 Emily Robinson - Trial Statistician (representing King’s Clinical Trials Unit) 
 
The TSC met 3 times over the course of the study (28/04/16, 13/03/17, & 02/11/17).  The 
minutes for each meeting are included in the Trial Master File. 
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 Statistical Analysis and Data Management Plan 
 
5.1 Overview 
 
This chapter details the statistical analysis and data management plan for the trial. A 
statistical analysis plan was written in advance, using a King’s Clinical Trials Unit (KCTU) 
template.  The analysis plan was written by PJ, with support from the advising statistician 
from KCTU, Emily Robinson.  A data management plan was written using DMPonline, an 
online service provided by the Digital Curation Centre, which provides template plans 
according to both funder and institutional requirements (see Trial Master File). 
 
The focus of the analysis plan was on data description for the main feasibility outcomes, and 
description of participant flow through the trial using a standard CONSORT diagram.  The 
data management plan outlined what data would be collected as part of the trial, and how it 
would be stored, backed-up and archived according to the requirements of the funder, 
sponsor and NHS ethics committee.  Finally, strategies for ensuring high quality data, and 
maintaining good data ‘hygiene’ throughout the trial are outlined. 
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5.2 Duration of the treatment period 
 
The treatment phase was restricted to the period of time the participant spent as an inpatient.  
End of therapy was defined as EITHER i) completing 5 sessions of therapy OR ii) discharge 
from acute ward, whichever came first.   
 
5.3 Frequency and duration of follow-up 
 
Participants completed follow up measures at 3- and 6-month post-discharge from hospital.  
The due date for the 3-month follow-up was calculated as discharge date +90 days, and the 
due date for the 6-month follow-up was calculated as discharge date +180 days.  This 
definition was used to make the study consistent with the previous inpatient trials conducted 
in the US which also used re-admission as a primary outcome, and calculated the follow-up 
period from discharge date rather than randomisation date (Bach and Hayes, 2002, Gaudiano 
and Herbert, 2006)  This was to accommodate the fact that trial participants had varying 
lengths of admission, and the duration of treatment window would be more variable 
compared to trials conducted in community settings.  For example, it would be theoretically 
possible for a participant to still be in hospital 6 months post-randomisation therefore 
reducing the probability of them being re-admitted to 0, if randomisation was used as the 
anchor date rather than discharge. 
 
5.4 Visit windows 
 
The assessment window was defined as +/- 28 days from the due date of the 3- and 6-month 
follow-up. Outcomes were treated as missing for any time-point if no data had been collected 
within the 28-day window.  
 
5.5 Sample size estimation 
 
A power calculation to determine a sample size is not appropriate for a feasibility trial such as 
this one, as the purpose of the trial is not to establish efficacy. However, the data from this 
trial could be used to inform a sample size calculation for a later efficacy pilot trial. The 
target recruitment for this feasibility trial was set at N=60 (30 in each arm).  This was 
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determined with reference to existing studies in the field, and is consistent with good practice 
recommendations for feasibility studies (Lancaster et al., 2004). 
 
5.6 Data analysis plan – data description 
 
5.6.1 Recruitment and representativeness of recruited patients 
 
Flow through the trial was presented in a standard CONSORT diagram (Schulz et al., 2010), 
showing total number of new admissions screened, number meeting initial eligibility criteria, 
reasons for potentially eligible participants being excluded, number randomised, drop-outs 
before the end of treatment, and numbers retained in the trial at 3- and 6-month follow-up.   
Descriptive statistics were presented for key feasibility outcomes, including proportion of 
target sample size achieved (≥80% benchmark), proportion of initially eligible patients who 
were randomised, and proportion of participants lost to follow-up (≤20% benchmark). 
 
5.6.2 Baseline comparability of randomised groups 
 
Descriptive statistics were reported for the baseline clinical and demographic characteristics 
of participants, by treatment group, with means, standard deviations, or numbers and 
proportions reported as appropriate.   
 
5.6.3 Adherence to allocated treatment and treatment fidelity 
 
A minimum ‘dose’ of therapy was defined as 1 therapy session.  The proportion of 
participants in each arm receiving at least 1 therapy session was reported, with reasons given 
for any participants who were randomised into the trial, but who did not receive any 
intervention.  Any reasons for withdrawals from treatments were summarised.  A random 
sample of 20% of recorded therapy sessions (evenly split between treatment and control 
arms) were checked for treatment fidelity by an independent rater using the trial adherence 
and competency scale (see Trial Master File).  Fidelity data were summarised, including 
proportion of sessions which were correctly identified as coming from the intervention or 
control arm. 
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5.6.4 Loss to follow-up and other missing data 
 
The proportions of participants missing each variable were summarised in each arm and at 
each time point.  The baseline characteristics of those missing follow up were compared to 
those with complete follow up.  The reasons for withdrawal from the trial were summarised. 
 
5.6.5 Adverse event reporting 
 
Adverse events (AE), adverse reactions (AR), serious adverse events (SAE) and serious 
adverse reactions (SAR) were summarised.  AEs were monitored and recorded from 
randomisation to final follow-up (6 months post-discharge). 
 
5.6.6 Assessment of outcome measures (unblinding) 
 
PJ, as the trial therapist, was not blind to treatment allocation, nor were the trial participants, 
as would be normal for a psychological therapy trial.  The service use outcome data, 
including re-admission and relapse rate at 6-month follow-up, which was blind-rated by an 
independent researcher using clinical note data, extracted and anonymised in advance by PJ.  
Complete notes were extracted for review without further editing, other than that necessary to 
anonymise names.  Any unanticipated threats to ‘unblinding’ using this method were 
reported.  Follow-up interviews were conducted with ward staff to explore the feasibility of 
keeping them blinded to treatment condition.  For example, they were asked if they could 
easily guess which condition participants were in, or whether trial participants discussed any 
details of their therapy sessions with them, which could lead them to infer which treatment 
condition they were in. 
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5.7 Data analysis plan – inferential analysis 
 
5.7.1 Main analysis of treatment differences 
 
All analyses were conducted on an intention-to-treat (ITT) basis, analysing participants as 
randomised, regardless of actual treatment received.  The main statistical analyses estimated 
the difference in mean outcomes between patients randomised to MBCI and SAT by ITT at 
the various post-treatment observation time points. Group difference estimates and associated 
confidence intervals were reported.   
 
5.7.2 Analysis of service use outcomes 
 
Pilot data on re-hospitalisation at 6-month follow-up were analysed using survival analysis. 
The proportion n (%) with odds ratio (95% CI) of patients readmitted were reported in 
separate contingency tables for data at 3- and 6-month follow-up, with the difference in time 
to re-admission between intervention and control groups being formally compared using 
Kaplan-Meier / Log rank survival analysis. 
 
A secondary analysis on the re-admission data was planned in advance, using randomisation 
date as the anchor date for the follow-up period, rather than the discharge date.  This was to 
allow for a comparison of the two approaches, to see if there was a difference in results 
between using randomisation or discharge date.  This was to help inform whether to use 
randomisation or discharge date as the anchor for defining the follow-up window in 
subsequent trials. 
 
5.7.3 Analysis of clinical outcome measures (questionnaires) 
 
Pilot data on clinical measures, which were all continuous outcomes, were analysed using a 
general linear model on an intention-to-treat (ITT) basis, co-varying for baseline score and 
treatment condition. As this was a feasibility study, no adjustment was made for any 
difference in demographic characteristics at baseline. 
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5.7.4 Stratification and clustering 
 
There was no stratification or clustering in the randomisation.  The data collected in this trial 
would be helpful in planning a stratification strategy for a subsequent larger trial however:  
For example, whether there should be stratification for demographic factors (e.g. gender), or 
clinical factors (e.g. number of previous admissions), which might be predictor variables for 
risk of re-admission at 6-month follow-up. 
 
5.7.5 Missing items in scales and subscales 
 
The number (%) with complete data was reported.  If any of the self-report measures had 
missing items, the missing value guidance published for each scale was followed.  Where 
scales did not have published guidance to deal with missing items, scales were pro-rated for 
an individual if 20% or fewer items were missing.  For example, in a scale with 10 items, 
prorating was applied to individuals with 1 or 2 items missing.  The average value for the 8 or 
9 complete items was calculated for that individual and used to replace the missing values.  
The scale score was calculated based on the complete values and these replacements. 
 
5.7.6 Missing baseline data 
 
It was not anticipated that missing baseline data would be an issue for the primary analysis.  
In the case of any extensions to this analysis using other baseline variables, if these contained 
missing data, the number with complete data was reported and an appropriate method of 
imputation was used. 
 
5.7.7 Missing outcome data 
 
Where there were two or more outcome time points, missing post-randomisation assessments 
were dealt with by fitting linear mixed models to all the available data using maximum 
likelihood methods. Such an approach provides valid inferences under the assumption that 
the missing data mechanism is ignorable (or MAR; missing at random).   
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5.7.8 Method for handling multiple comparisons 
 
There was no correction for multiple comparisons as this was a feasibility study and therefore 
it was not powered to test for efficacy based on a specified outcome. However, care should be 
given to the interpretation of inference in group differences on primary or secondary outcome 
measures on this basis. 
 
5.7.9 Model assumption checks  
 
The models assume normally distributed outcomes; this was checked when describing the 
data and where substantial departures from normality occurred, transformations were 
considered.  Residuals were plotted to check for normality and inspected for outliers. 
 
5.8 Data management plan 
 
The full data management plan can be found in the Trial Master File. The main points are 
summarised below. 
 
The primary data for each trial participant was recorded on individual Case Report Forms 
(CRFs), in Microsoft Word format.  Weekly screening logs from each ward were saved in 
Microsoft Excel format.  The main trial database was created and saved using IBM SPSS 
(version 24).  Audio recordings, of therapy sessions and feedback interviews, were saved in 
mp3 format and saved securely.  A Trial Master File (TMF) was compiled, which was 
indexed and organised according to a standard format.  PJ took responsibility for keeping the 
TMF up-to-date over the course of the trial.  In terms of general file management, file names 
were generated in a standard format, and organised into clearly labelled folders, to ensure a 
consistent approach, and to make key files easy to locate and identify.  For example, the 
CRFs were labelled using a standard format so that the participant ID number was clearly 
identifiable at the beginning of each file name.  All electronic data were saved on the 
secure networked server at King's College London (KCL). KCL file servers are managed by 
IT and provide regular backups.  In addition to the on-site and off-site back-ups provided by 
KCL IT, study files were also backed up using OneDrive for Business (remote cloud storage) 
on a weekly basis. 
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The storage of data containing sensitive or confidential information was kept to a minimum. 
The only file for the whole trial containing personally identifiable information (the ID key 
that linked names to participant identification numbers) was password-protected and stored 
only on the secure KCL network drive.  Audio-recordings of therapy sessions and feedback 
interviews were downloaded (and then deleted) from the digital recorder as soon as possible 
(usually on the same day) and were saved as digital files with anonymous identification 
codes.  The paper files for each participant containing hard copies of questionnaires and 
therapy session records were identified only by anonymous identification code and 
were stored securely in a locked filing cabinet in a locked office.  They were not taken out of 
the office or stored elsewhere under any circumstances. 
 
The funder of this trial, NIHR, does not specify when and for how long data should be 
archived.  However, NIHR guidelines do stipulate that "Data generated through participation 
of patients and the public should be put to maximum use by the research community and, 
whenever possible, translated to deliver patient benefit.”  It was therefore planned to deposit 
any data that supported published research or had long-term value with the King’s RDM 
system, after consultation with the NIHR.  King’s is committed to preserving research data 
for a minimum of 10 years since last use of the data. 
 
5.9 Data quality control 
 
Ensuring the quality of data and documentation in a clinical trial is a key part of adherence to 
Good Clinical Practice (MHRA, 2012).  The general approach taken was to try to ensure 
good data ‘hygiene’ from the very start, to minimise the need for data cleaning at a later stage 
due to missing or inaccurate data.  Some of the key steps that were taken are outlined below. 
 
 Use of a standard KCTU template for the CRF, and careful piloting to identify and 
rectify any potential problems early in the trial.  For example, pre-defined categories 
and corresponding check-boxes were used, in order to eliminate “free-text” as much 
as possible.  This made it easier to later generate and code the variables on the trial 
database on SPSS, and aided faster and more accurate data-entry from CRF to 
database. 
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 Use of checklists on CRFs to ensure that all relevant data were collected at each 
assessment point (or where data were missing, or incomplete, this was also recorded 
accurately). 
 Minimising the potential for transcription errors by keeping the data chain to a 
minimum.  Data were entered directly into the electronic CRFs wherever possible, 
and from there entered onto the SPSS database. 
 Paper questionnaires were checked for completeness and accuracy at the time of 
completion, and any discrepancies rectified immediately with the participant wherever 
possible (for example, participants occasionally missed out items by accident, or 
circled 2 responses by mistake on the same item). 
 Raw data for each questionnaire were entered onto scoring templates, created using 
excel spreadsheets.  The scoring spreadsheets included safe-guards against data entry 
mistakes such as setting maximum and minimum value limits for relevant cells.  The 
use of standard formulas guarded against simple calculation mistakes, particularly 
those that can arise from mistakes in reverse-scoring items. 
 All questionnaire scores were double-scored, so that any mistakes in entry or scoring 
could be easily identified and rectified.  In addition to scoring using excel 
spreadsheets, all raw questionnaire data were also entered onto SPSS.  The calculate 
function on SPSS was then used as a double-check of questionnaire scores, and any 
discrepancies were corrected and resolved by reference back to the hard copies. 
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  Results: Feasibility Outcomes 
 
6.1 Overview 
 
This chapter reports feasibility outcomes for the trial.  Participants were recruited from 4 
acute wards over a 15-month period.  Approximately 50% of new admissions met the initial 
eligibility criteria for the trial (302/590).  Of these, 175 were assessed further, and 65 were 
eligible to participate.  Fifty participants were randomised into the trial (83% of pre-set 
target).  All participants received at least one therapy session, and no-one dropped out during 
the intervention stage.  The average number of sessions completed was 3 (range 1-5) in both 
arms of the trial.  Overall, 76% of offered appointments were attended (146/191 sessions).  At 
6-month trial end-point, only one participant was lost to follow-up as they moved abroad 
immediately upon discharge.  Data on hospital re-admission were available for the remaining 
49 participants (98% follow-up).  Follow-up rate for self-report questionnaire measures was 
86%, which exceeded the 80% benchmark set in the trial protocol.  Three participants 
experienced adverse events, none of which was judged to be related to their participation in 
the trial. 
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6.2 Screening and Recruitment 
 
Participants were recruited for the trial from 4 acute inpatient wards at one hospital site in 
South London.  At the time of the study, there were 3 male wards and 1 female ward at the 
hospital.  Each ward had 18-22 beds open at any one time, and bed occupancy was always 
high (95-100%).    Recruitment started on Ward A in November 2015, then expanded to 
subsequent wards in approximately 3-month intervals (Table 11). Recruitment was gradually 
rolled out in this way to try and achieve an average recruitment rate of 5 participants per 
month (Figure 8).  The admission rate was fairly consistent on the male wards, at between 3 
and 4 admissions a week, however it was considerably higher on the female ward at over 6 
admissions a week on average.   
 
Table 11 Recruitment on participating wards 
 Gender First week 
of 
recruitment 
Last week 
of 
recruitment 
Total 
number of 
weeks 
recruitment 
open 
Number of 
admissions 
screened 
Average 
admission 
rate/week 
Ward 
A 
Male 16/11/15 16/01/17 56 207 3.70 
Ward 
B 
Female 22/02/16 09/01/17 45 274 6.09 
Ward 
C 
Male 23/05/16 16/01/17 31 106 3.42 
Ward 
B 
Male 08/08/16 16/01/17 24 89 3.71 
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Figure 8 Recruitment rate by month 
 
Figure 9 (CONSORT diagram) presents patient flow through the study. Each ward had its 
own Consultant Psychiatrist, who was the leader of the multi-disciplinary inpatient team that 
included junior doctors, nurses, health-care assistants and occupational therapists.  In line 
with the trial protocol, consecutive admissions were screened with the consultant psychiatrist 
and clinical team for eligibility for the trial.  As the aim was to screen all potential 
participants in the acute phase of their admission, a ‘new’ admission was defined as someone 
within the first 14 days of their admission.  People who had been transferred from other 
wards or hospitals, and were no longer in the first 14 days of their admission, were excluded 
and not assessed further for eligibility (13% of all admissions screened; see Figure 9).  The 
initial eligibility criteria for the trial were defined as people presenting with positive 
psychotic symptoms in the context of a F20-39 diagnosis.  Just over 50% of all acute 
admissions were identified by the clinical team as meeting these criteria (302/590).  People 
who were identified by the clinical team as lacking capacity, being too unwell in mental state, 
or posing a risk to the researcher were not assessed further.  Some potentially eligible 
participants were not assessed further as they were discharged from the ward or went absent 
without leave (AWOL) before they could be approached.   
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Once identified as eligible, there was a 2-stage consent process to the study.  Participants who 
were initially approached about the study were asked if they were interested in having a 
talking therapy on the ward, given a brief information leaflet and asked to give written 
permission for the researcher to check their clinical notes to further assess eligibility for the 
study (stage 1).  The main reason people did not want to take part at this stage was because 
they were not interested in a talking therapy (n=70).  People who were interested in taking 
part, and confirmed as eligible from a clinical notes check, were then given the full 
information sheet.   Everyone was given the opportunity to ask questions, discuss the study 
with the ward team, and to think it over before making a final decision to participate.  
Participants then signed the full consent form (stage 2), and completed the baseline 
questionnaires.  Overall, 65 out of the 175 people assessed further (37%) were confirmed as 
eligible for the trial.  Fourteen of these did not go on to participate further as they were 
discharged from hospital before they could give consent and be randomised.  Additionally, 
one person changed their mind about taking part at this stage.  This resulted in 50 people 
being randomised into the trial, 26 in the MBCI arm and 24 in the SAT arm.  Participants 
were randomly allocated to treatment condition at the beginning of their first therapy session, 
to try to minimise any drop-out between randomisation and the start of therapy. This was a 
highly successful strategy, as everyone randomised into the trial (100%) ended up receiving 
at least one session of intervention, which was pre-defined as the ‘minimum’ dose. 
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6.3 Flow through trial (CONSORT diagram) 
 
 
  
Consecutive admissions screened (n=676) 
Not eligible after further assessment 
- Not interested in talking therapy (n=70) 
- Too unwell in mental state (n=15) 
- Requires interpreter (n=11) 
- No psychotic symptoms (n=10) 
- LD/cognitive impairment (n=3) 
- Not F20-39 diagnosis (n=1) 
 
Allocated to intervention (MBCI) (n=26) 
- Received allocated intervention (n=26) 
- Did not receive allocated intervention (n=0) 
- Discontinued intervention (risk to therapist) 
(n=1) 
 
 
 
Allocated to control (SAT) (n=24) 
- Received allocated intervention (n=24) 
- Did not receive allocated intervention 
(n=0) 
- Discontinued intervention (n=0) 
Allocation 
Randomized (n=50) 
Enrolment 
Met initial eligibility criteria (n=302)   
Acute admissions (n=590) 
Inpatient Transfers (n=86) 
 (Initial admission >14 days)  
 
- Already participated 
(n=4) 
- Did not meet initial 
eligibility criteria 
(n=284) 
Assessed further (n=175)   
Not assessed further for eligibility  
- Discharged/AWOL before researcher could 
approach (n=37) 
- Too unwell to approach (n=51) 
- Declined to meet with researcher (n=39) 
 
 
Eligible to participate (n=65)   
Eligible but not randomised  
- Discharged before could consent (n=14) 
- Changed mind (n=1) 
 
 
Lost to follow-up at 3 months (MBCI):-  
Service Use Outcomes (readmission) (n=1) 
Clinical outcomes (questionnaire data) (n=6) 
- Not able to contact (n=2) 
- DNA follow-up appointment (n=1) 
- Too unwell (n=1) 
- Moved abroad (n=1) 
- In prison (n=1) 
 
 
 
Lost to follow-up at 3 months (SAT):- 
Service Use Outcomes (readmission) (n=0) 
Clinical outcomes (questionnaire data) (n=2) 
- Not able to contact (n=1) 
- DNA follow-up appointment (n=1) 
- Too unwell (n=0) 
- Moved abroad (n=0) 
- In prison (n=0) 
 
 
 
Follow-up 
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Lost to follow-up at 6 months (MBCI):-  
Service Use Outcomes (readmission) (n=1) 
Clinical outcomes (questionnaire data) (n=5) 
- Not able to contact (n=1) 
- DNA follow-up appointment (n=2) 
- Too unwell (n=0) 
- Moved abroad (n=1) 
- In prison (n=1) 
 
 
 
Lost to follow-up at 6 months (SAT):- 
Service Use Outcomes (readmission) (n=0) 
Clinical outcomes (questionnaire data) (n=2) 
- Not able to contact (n=1) 
- DNA follow-up appointment (n=1) 
- Too unwell (n=0) 
- Moved abroad (n=0) 
- In prison (n=0) 
 
 
 
Analysed at 3-month follow-up (MBCI):- 
Service Use Outcomes (readmission) (n=25) 
Clinical outcomes (questionnaire data) (n=20) 
- Excluded (outside 28-day window) (n=0) 
 
 
 
Analysed at 3-month follow-up (SAT):- 
Service Use Outcomes (readmission) (n=24) 
Clinical outcomes (questionnaire data) (n=22) 
- Excluded (outside 28-day window) (n=1) 
 
 
Analysis 
Figure 4 CONSORT diagram 
Analysed at 6-month follow-up (MBCI):- 
Service Use Outcomes (readmission) (n=25) 
Clinical outcomes (questionnaire data) (n=21) 
- Excluded (outside 28-day window) (n=0) 
 
 
 
Analysed at 6 month follow-up (SAT):- 
Service Use Outcomes (readmission) (n=24) 
Clinical outcomes (questionnaire data) (n=22) 
- Excluded (outside 28-day window) (n=2) 
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6.4 Loss to follow-up 
 
Loss to follow-up at both 3 and 6 months follow-up was low, and did not exceed the 20% 
predefined benchmark (Table 12).  Only one person was lost to follow-up, as they left the 
country immediately upon discharge from hospital.  One person was taken into police 
custody immediately on discharge, and subsequently was sent to prison.  Information on 
hospital admissions was obtained from the prison healthcare team for this participant.  In 
Table 12, follow-up rates are reported separately for the service use outcomes (readmission), 
which could be obtained from clinical notes, and clinical measure outcomes, which required 
direct contact with participants to complete questionnaires.  Most clinical measures were 
completed face to face with the participant, although three participants also returned 
questionnaires via post (at their own request).  Participants were usually seen for follow-up at 
their community mental health team, at the hospital outpatient department, or on the ward for 
people who were inpatients at the time of their follow-up.  One person did not want to be 
seen within a NHS setting, and so the follow-up was done in the local library at their request.  
 
Table 12 Follow-up rates 
 Service use (Readmission) 
N (%) 
Clinical measures 
(Self-report 
questionnaires) 
N (%) 
3-month follow-up (F1) 49 (98%) 42 (84%) 
6-month follow-up (F2) 49 (98%) 43 (86%) 
Participants completing 
both F1 + F2 
49 (98%) 39 (78%) 
Participants completing at 
least 1 follow-up 
49 (98%) 46 (92%) 
Participants not 
completing any follow-ups 
1 (2%) 4 (8%) 
 
The assessment window was pre-defined as +/- 28 days from the due date of the 3- and 6-
month follow-up.  A generous visit window is helpful with this clinical population, who can 
be challenging to follow-up.  It frequently took several attempts to contact people, and 
sometimes appointments had to be re-scheduled several times.  Despite this, only 2 
participants had follow-ups outside the 28-day window.  One participant completed their 3-
month follow-up 29 days after the due date, and completed their 6-month follow-up 47 days 
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after the due date.  Another participant completed their 6-month follow-up 51 days after the 
due date.  In line with the statistical analysis plan, these 3 data points were excluded from the 
analysis. For those follow-ups completed within the visit window, the average number of 
days between the due date and completed date was +4 for 3-month follow-up, and +3 for 6-
month follow-up.  
 
6.5 Baseline Data 
 
Baseline data for participants are shown in Table 13 (demographic characteristics) and Table 
14 (clinical characteristics). No statistical significance tests or confidence intervals were 
calculated for the difference between randomised groups on any baseline variables.  The 
randomisation of intervention groups to participants should have ensured that any imbalance 
over all measured and unmeasured baseline characteristics is due to chance (Altman and 
Dore, 1991).  Characteristics that varied between group, and which might be hypothesised to 
predict a greater risk of readmission in the follow-up period (e.g. prior history of 
hospitalisations), were entered as predictor variables in the Cox regression analysis (Chapter 
7). 
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Table 13 Demographic Characteristics of Participants at Baseline  
 SAT (N=24) MBCI (N=26) OVERALL 
(N=50) 
DEMOGRAPHIC CHARACTERISTICS 
Age 
 
- Mean (range) 
 
 
33 years (19-65) 
 
 
35 years (18-52) 
 
 
34 years (18-65) 
 
Gender 
 
- Male 
- Female 
 
 
17 (71%) 
7 (29%) 
 
 
17 (65%) 
9 (35%) 
 
 
34 (68%) 
16 (32%) 
Ethnicity 
 
- White 
- Asian 
- Black 
- Mixed Race 
- Other 
 
 
8 (33%) 
3 (13%) 
9 (37%) 
3 (13%) 
1 (4%) 
 
 
8 (30%) 
3 (12%) 
12 (46%) 
3 (12%) 
0 (0%) 
 
 
 
16 (32%) 
6 (12%) 
21 (42%) 
6 (12%) 
1 (2%) 
Highest educational 
qualification 
 
- No formal qualifications 
- GCSE (or equivalent) 
- A-Levels (or equivalent) 
- Graduate 
- Post-Graduate 
- Vocational Qualification 
- Not known 
 
 
 
3 (13%) 
6 (25%) 
7 (29%) 
6 (25%) 
1 (4%) 
1 (4%) 
0 (0%) 
 
 
 
 
5 (18%) 
8 (31%) 
8 (31%) 
2 (8%) 
1 (4%) 
1 (4%) 
1 (4%) 
 
 
 
8 (16%) 
14 (28%) 
15 (30%) 
8 (16%) 
2 (4%) 
2 (4%) 
1 (2%) 
Employment status 
 
- Working (full/part-time) 
- Studying 
- Retired 
- Looking after family 
- Unemployed 
- Disability benefits 
 
 
7 (29%) 
3 (13%) 
1 (4%) 
1 (4%) 
2 (8%) 
10 (42%) 
 
 
 
 
2 (8%) 
4 (15%) 
0 (0%) 
0 (0%) 
6 (23%) 
14 (54%) 
 
 
9 (18%) 
7 (14%) 
1 (2%) 
1 (2%) 
8 (16%) 
24 (48%) 
Currently in a relationship 
 
- Yes 
- No 
 
 
5 (21%) 
19 (79%) 
 
 
1 (4%) 
25 (96%) 
 
 
6 (12%) 
44 (88%) 
 
117 
 
 
Accommodation status 
 
- Council tenant 
- Private tenant 
- Own property 
- Living in family home 
- Supported 
accommodation 
- Temporary 
accommodation/homeless 
 
 
10 (41%) 
3 (13%) 
2 (8%) 
5 (21%) 
3 (13%) 
  
1 (4%) 
 
 
11 (42%) 
0 (0%) 
0 (0%) 
11 (42%) 
2 (8%) 
 
2 (8%) 
 
 
21 (42%) 
3 (6%) 
2 (4%) 
16 (32%) 
5 (10%) 
 
3 (6%) 
Live alone 
 
- Yes 
- No 
 
 
11 (46%) 
13 (54%) 
 
 
15 (58%) 
12 (42%) 
 
 
26 (52%) 
24 (48%) 
 
The acute wards were general working-adult age services, and the age range of participants in 
the study reflects this, spanning the full range from 18-65 years old.  As noted earlier, there 
was only 1 female ward open at the hospital during the recruitment period, which led to a 
two-thirds majority of men in the final sample (68%).  The participants reflected the diverse 
and multi-cultural nature of the local community.   Around a third of participants (15/50) had 
migrated to the UK from other countries, and almost a quarter spoke English as an additional 
language (11/50).  It is well-documented that people from black and minority ethnic 
backgrounds (BME) are over-represented within inpatient populations at a national level, 
particularly for those being treated under a section of the Mental Health Act (Bhui et al., 
2003).  Data for the London borough in which recruitment took place confirmed this was also 
the case at a local level (Figure 10).  Figure 10 shows the latest available census data from 
2011 for the borough where recruitment took place, alongside the figures from the most 
recent equality and diversity report, which provides a snapshot of all admissions over a 
selected month (September 2016).  As can be seen in the graph, people from a BME 
background represent 42% of people living in the borough, but represent 64% of acute 
psychiatric admissions.  However, Figure 10 also shows that the ethnic backgrounds of 
participants in the current study were representative of the population on the ward in general, 
with 68% of people coming from a BME background.  There was therefore no indication of 
over-or under-representation of any particular ethnic group in the final sample, using the 
general ward population as a comparator. 
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Figure 10 Ethnicity data for local London borough 
 
Table 13 also shows data indicating the social and occupational functioning of the participant 
group.  In general, there was a range of people’s overall level of functioning.  Some 
participants were functioning very well prior to their crisis, for example, working or studying 
full-time.  However, the majority of participants were either unemployed, or were unable to 
work due to their mental health difficulties and were in receipt of disability benefits.  Most 
participants were not in a relationship, but some were single parents with dependent children.  
Approximately half of all participants lived alone.  
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Table 14 Clinical Characteristics of Participants at Baseline 
 
 SAT (N=24) MBCI (N=26) ALL 
PARTICIPANTS 
(N=50) 
CLINICAL CHARACTERISTICS 
Diagnosis 
 
- F20-29 
(Schizophrenia-
spectrum) 
- F30-39 (Mood 
disorder) 
 
 
17 (71%) 
 
 
7 (29%) 
 
 
20 (77%) 
 
 
6 (23%) 
 
 
37 (74%) 
 
 
13 (26%) 
Psychotic symptoms 
(self-report) 
 
- Delusions only 
- Voices only 
- Delusions + voices 
 
 
 
12 (50%) 
1 (4%) 
11 (46%) 
 
 
 
14 (54%) 
0 (0%) 
12 (46%) 
 
 
 
26 (52%) 
1 (2%) 
23 (46%) 
Legal status on 
admission 
 
- Informal 
- MHA Sec 2 
- MHA Sec 3 
- MHA Sec 37 
 
 
 
6 (25%) 
13 (54%) 
5 (21%) 
0 (0%) 
 
 
 
8 (31%) 
14 (54%) 
3 (11%) 
1 (4%) 
 
 
 
14 (28%) 
27 (54%) 
8 (16%) 
1 (2%) 
Open to CMHT on 
admission 
 
- Yes 
- No 
 
 
 
 
12 (50%) 
12 (50%) 
 
 
 
 
10 (38%) 
16 (62%) 
 
 
 
 
22 (44%) 
28 (56%) 
 
Psychiatric 
medication on 
admission 
 
- Prescribed at least 
one medication 
- Prescribed anti-
psychotic  
- Prescribed an anti-
depressant 
- Prescribed a mood-
stabilizer 
 
 
 
 
20 (83%) 
 
 
18 (75%) 
 
3 (13%) 
 
5 (21%) 
 
 
 
 
19 (73%) 
 
 
18 (69%) 
 
4 (15%) 
 
1 (4%) 
 
 
 
 
39 (78%) 
 
 
36 (72%) 
 
7 (27%) 
 
6 (12%) 
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Years known to 
services 
 
- <1 year 
- 1-5 years 
- 6-10 years 
- 11-15 years 
- >15 years 
 
 
 
5 (21%) 
4 (17%) 
6 (25%) 
2 (8%) 
7 (29%) 
 
 
 
4 (15%) 
6 (23%) 
8 (31%) 
2 (8%) 
6 (23%) 
 
 
 
9 (18%) 
10 (20%) 
14 (28%) 
4 (8%) 
13 (26%) 
Previous admissions 
 
- Yes 
 
 
 
- No 
 
 
14 (58%) 
(mean = 5.64, 
range 1-14) 
 
10 (42%) 
 
 
21 (81%) 
(mean= 4.00, range 
1-10) 
 
5 (19%) 
 
 
35 (70%) 
(mean = 4.66, range 
1-14) 
 
15 (30%) 
Admission in previous 
12 months 
 
- Yes 
- No 
 
 
 
7 (29%) 
17 (71%) 
 
 
 
8 (31%) 
18 (69%) 
 
 
 
15 (30%) 
35 (70%) 
Reported suicidal 
thoughts/acts on 
admission   
 
- Yes 
- No 
 
 
 
 
6 (25%) 
18 (75%) 
 
 
 
 
 
3 (12%) 
23 (88%) 
 
 
 
 
9 (18%) 
41 (82%) 
 
Psychological therapy 
in past 5 years 
 
- None 
- Offered 
- Received 
 
 
 
11 (46%) 
3 (12%) 
10 (42%) 
 
 
 
 
12 (46%) 
4 (15%) 
10 (39%) 
 
 
 
23 (46%) 
7 (14%) 
20 (40%) 
 
The majority of participants had schizophrenia-spectrum diagnoses (F20-29).  The 
participants with F30-39 diagnoses had either a bipolar affective disorder diagnosis, or a 
depressive disorder diagnosis with psychotic symptoms.  As part of the eligibility assessment 
for the trial, people had to self-report at least one positive psychotic symptom.  All but one 
participant reported delusions, half of whom additionally reported hearing voices.  Only one 
participant reporting voices only with no delusions.  The most common delusion type was 
persecutory (61%), followed by grandiose beliefs (22%).   
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In terms of understanding triggers for admission for this group, risk of harm to self was not a 
major feature, as fewer than 20% of people in the sample reported suicidal thoughts when 
assessed in the admission clerking interview with the ward doctor.  The majority of 
participants were admitted under a section of the mental health act, indicating that most 
people either did not agree with the need for inpatient care, or lacked capacity to make their 
own treatment decisions.  People’s routes into hospital were often complex, including 
multiple assessments and involvement from different teams including community mental 
health teams (CMHTs), home treatment teams, A&E and the police.  Most participants were 
already known to mental health services, with 78% on psychiatric medication prior to 
admission, although only 44% were open to their community mental health team (secondary 
services).  This may reflect service changes over recent years, with open-ended periods of 
care with CMHTs being phased out even for those service users with longer-term histories of 
mental health difficulties.  Most participants had a history of previous hospital admissions, 
with approximately a third having had an admission within the 12 months prior to the current 
admission. There was also a subset of participants who were less well-known to services, and 
were on their 1st or 2nd admission, and so met criteria for psychosis early interventions 
services on discharge (which now has no age restrictions within local services).  Since this 
was a group of people who agreed to have a talking therapy, rates of previous therapy were 
quite high, with 40% having documented evidence of previous psychological therapies in the 
past 5 years, most of which was individual CBT.  However, the majority of participants had 
not had any therapy in the past 5 years (although some had been previously offered it).  This 
indicated that people were interested in taking up the offer of a talking therapy during an 
acute admission even if they had previously declined therapy in the community, or indeed 
had never been offered any.  
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6.6 Description of treatment 
 
Treatment variables are shown in Table 15.   Therapy credibility, assessed just after 
randomisation, was high in both treatment conditions, with participants rating the therapy on 
average between 7 and 8 on a scale of 0-10, where 10 is extremely helpful.  Therapy 
credibility did not differ significantly between treatment condition (t (48) =-0.09, p=0.93).  
Consent to audio-taping was high, with almost three-quarters of participants consenting to the 
recording of at least 1 session.  Written consent to audio-tape was given at the beginning of 
the study along with general consent, but verbal consent was also sought at the beginning of 
each therapy session. Participants were informed they could change their mind at any time, or 
ask for the recorder to be turned off at any point in a session, in order to try and promote a 
sense of control over the process.  Participants were also offered a copy of the therapy 
recordings, but take-up of this offer was low (less than 10%). 
 
The average number of sessions people attended was 3 (range 1-5), and this was comparable 
between treatment conditions. A record was also kept of appointments offered but not 
attended.  The overall ‘Did Not Attend’ rate was low (less than 1 scheduled session per 
participant).  Whilst 100% of participants attended at least 1 session, the proportion decreased 
with each subsequent therapy session.  Approximately half of all participants attended at least 
3 sessions, and a quarter of participants attended the maximum of 5 sessions.  The main 
determinant of number of sessions was the length of admission, with some participants 
having admissions of less than a week, with others running into several months.    In order to 
account for varying and unpredictable lengths of admission, the trial protocol designated a 
maximum ‘therapy envelope’ of 35 days (i.e. maximum of 5 sessions, spaced at maximum of 
weekly intervals).  As can be seen in Table 15, this was successfully achieved, with the 
maximum therapy envelope being 28 days. Most admissions were residents in the local 
borough, however due to bed shortages, sometimes people living in neighbouring boroughs 
were also admitted.  If people were admitted ‘out of borough’ they were sometimes 
transferred to their resident borough hospital part-way through their admission.  People were 
also sometimes transferred to a specialist early intervention ward at another hospital site.  
Internal transfers between wards in the same hospital sometimes also occurred due to bed 
shortages or other clinical reasons.  In line with the trial protocol, participants continued to be 
offered therapy sessions if they were transferred to a different ward within the same trust 
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(including to different hospital sites).  Overall, 6 participants (3 in each arm) were transferred 
to another hospital site after enrolment in the trial, and all continued with their treatment 
sessions, so this did not lead to any drop-out during the treatment phase.  Therapy had to be 
suspended for one participant who became disinhibited towards the therapist, but who was 
then discharged the next day, before safety for any further sessions could be assessed. 
 
The maximum length of a therapy session was 60 minutes, but the length of session was 
adaptable to meet the needs of participants.  The average length of session 1 was 42 minutes 
in the SAT group, and 45 minutes in the MBCI condition.  The average length of each 
session did not differ much over the course of subsequent session in the SAT group.  
However, in the MBCI group, the average length of session decreased by a few minutes with 
each subsequent session, with the average length of session 5 being 28 minutes.  There were 
occasionally reasons why sessions had to be ended early.  This was usually due to 
participants being called out of therapy sessions to attend other clinical meetings (such as 
ward round), or to see other visitors.  The maximum frequency of therapy sessions was daily, 
and the minimum frequency was weekly.  Occasionally there was a gap of longer than 7 days 
between sessions, which arose from participants missing sessions which were offered, which 
was sometimes due to them being transferred to other wards.  However, the most common 
interval between sessions was 1-3 days. 
 
For the purposes of the trial, therapy was provided in addition to treatment as usual (TAU), 
and this could include any of the standard range of interventions available on an acute ward.  
This included additional group or individual therapy, including the continuation of therapy 
that had been started in the community prior to admission.  In reality, TAU mainly consisted 
of medication (98% of participants were prescribed at least one medication), and rates of 
other psychological interventions were low.  It is important to note that for the duration of the 
recruitment period for the study (15 months), there was no regular ward psychologist 
assigned to any of the wards where recruitment took place.  There was one Band 7 Clinical 
Psychology post based at the hospital site, which covered all 4 wards plus a psychiatric 
intensive care unit (PICU), however the post-holder was on long-term sick-leave.  There was 
occasional cover from a Consultant Psychologist, but as the post covered an additional 3 
hospital sites in addition to the recruitment site, input was very limited and was usually in 
response to direct referrals from ward teams, which were made infrequently.  Psychological 
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therapy groups (as opposed to general activity/occupational therapy groups) were not widely 
available.  The Consultant Psychiatrist on Ward A ran a weekly psychodynamic therapy 
group with the ward manager, but a record of group attendance was not routinely made in 
patient’s notes, so it was difficult to record reliably which participants from Ward A attended 
this group.  A trainee clinical psychologist occasionally ran groups with the Consultant 
Psychologist, but this was only for limited periods over the recruitment period.  As can be 
seen in Table 15, only 6/50 participants (12%) attended therapy groups during their 
admission. 
 
Finally, participants were asked to rate their satisfaction with therapy at the end of the trial 
(6-month follow-up).  Satisfaction was very high in both groups (10 being completely 
satisfied).  The average satisfaction rating was very slightly higher in the MBCI group 
compared to the SAT group (9.11 vs. 8.27) but this difference was not statistically significant 
(t (39) =-1.68, p=0.10). 
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Table 15 Treatment Details 
 SAT (N=24) MBCI (N=26) ALL 
PARTICIPANTS 
(N=50) 
Therapy credibility 
 
 Mean (SD) 
 Range 
0=Not helpful at all 
10=Extremely helpful 
 
 
7.71 (2.79) 
1-10 
 
 
7.77 (2.08) 
3-10 
 
 
7.74 (2.42) 
1-10 
Agreed to audio-
taping at least one 
session 
 
- Yes 
- No 
 
 
 
 
18 (75%) 
6 (25%) 
 
 
 
 
18 (69%) 
8 (31%) 
 
 
 
 
36 (72%) 
14 (28%) 
Number of therapy 
sessions 
 
Attended 
- Mean (SD) 
- Range 
 
Offered 
- Mean (SD) 
- Range 
 
Did not attend 
- Mean (SD) 
- Range 
 
 
 
 
 
3.04 (1.49) 
1-5 
 
 
3.96 (1.60) 
1-8 
 
 
0.92 (1.02) 
0-4 
 
 
 
 
2.81 (1.47) 
1-5 
 
 
3.69 (1.78) 
1-8 
 
 
0.88 (0.95) 
0-3 
 
 
 
 
2.92 (1.47) 
1-5 
 
 
3.82 (1.7) 
1-8 
 
 
0.90 (0.97) 
0-4 
Number of 
participants 
attending each 
session number 
 
- Session 1 
- Session 2 
- Session 3 
- Session 4 
- Session 5 
 
 
 
 
 
24 (100%) 
20 (83%) 
14 (58%) 
8 (33%) 
7 (29%) 
 
 
 
 
 
26 (100%) 
20 (77%) 
13 (50%) 
9 (35%) 
5 (19%) 
 
 
 
 
 
50 (100%) 
40 (80%) 
27 (54%) 
17 (34%) 
12 (24%) 
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Duration of 
therapy sessions 
(minutes) 
 
Session 1 
- Mean (SD) 
- Range 
 
Session 2 
- Mean (SD) 
- Range 
 
Session 3 
- Mean (SD) 
- Range 
 
Session 4 
- Mean (SD) 
- Range 
 
Session 5 
- Mean (SD) 
- Range 
 
 
 
 
 
42 (10) 
21-55 
 
 
41 (12) 
7-57 
 
 
43 (9) 
24-59 
 
 
42 (14) 
15-59 
 
 
42 (12) 
21-58 
 
 
 
 
 
45 (9) 
20-60 
 
 
39 (13) 
5-57 
 
 
40 (12) 
15-57 
 
 
34 (6) 
26-45 
 
 
28 (6) 
19-33 
 
 
 
 
 
44 (9) 
20-60 
 
 
40 (13) 
5-57 
 
 
42 (11) 
15-59 
 
 
38 (11) 
15-59 
 
 
36 (12) 
19-58 
Average gap 
between therapy 
sessions 
 
Sessions 1-2 
- 1-3 days 
- 4-7 days 
- 8-14 days 
- >14 days 
 
Sessions 2-3 
- 1-3 days 
- 4-7 days 
- 8-14 days 
- >14 days 
 
Sessions 3-4 
- 1-3 days 
- 4-7 days 
- 8-14 days 
- >14 days 
 
Sessions 4-5 
- 1-3 days 
- 4-7 days 
- 8-14 days 
 
 
 
 
 
10 
8 
0 
2 
 
 
11 
3 
0 
0 
 
 
5 
3 
0 
0 
 
 
5 
1 
0 
 
 
 
 
 
13 
7 
0 
0 
 
 
6 
4 
3 
0 
 
 
6 
2 
1 
0 
 
 
2 
3 
0 
 
 
 
 
 
23 
15 
0 
2 
 
 
17 
7 
3 
0 
 
 
11 
5 
1 
0 
 
 
7 
4 
0 
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- >14 days 1 0 1 
Therapy Envelope 
 
Number of days 
between 1st and last 
therapy sessions 
 
- Mean (SD) 
- Range 
 
 
 
 
 
 
 
8 (7) 
0-28 
 
 
 
 
 
 
7 (7) 
0-23 
 
 
 
 
 
 
7 (7) 
0-28 
 
Description of 
Treatment as Usual 
(TAU) during 
admission  
 
- Prescribed at 
least one 
medication 
- Prescribed anti-
psychotic  
- Prescribed an 
anti-depressant 
- Prescribed a 
mood-stabilizer 
- Attended 
therapy group 
on ward 
- Attended 1:1 
psychology 
session (in 
addition to trial 
therapy) 
 
 
 
 
 
23 (96%) 
 
 
21 (88%) 
 
5 (21%) 
 
4 (17%) 
 
2 (8%) 
 
 
0 (0%) 
 
 
 
 
 
26 (100%) 
 
 
25 (96%) 
 
5 (19%) 
 
1 (4%) 
 
4 (15%) 
 
 
0 (0%) 
 
 
 
 
 
 
 
 
49 (98%) 
 
 
46 (92%) 
 
10 (20%) 
 
5 (10%) 
 
6 (12%) 
 
 
0 (0%) 
 
Duration of 
inpatient admission 
(days) 
 
- Mean (SD) 
- Range 
- Admission 
≤30 days 
- Admission 
>30 days 
 
 
 
 
 
32 (23) 
9-93 
17 (71%) 
 
7 (29%) 
 
 
 
 
31 (20) 
4-9713 
15 (60%) 
 
10 (40%) 
 
 
 
 
31 (21) 
4-97 
32 (65%) 
 
17 (35%) 
                                                 
13 One participant in the MBCI arm had an admission of 160 days, and so was excluded from 
descriptive statistics for this variable on the basis it was a clear outlier (more than 60 days 
longer than next longest admission) 
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Satisfaction with 
therapy at 6-month 
follow-up 
 
- Mean (SD) 
- Range 
 
0=Not satisfied at all 
10=Completely satisfied 
 
 
 
 
8.27 (1.91) 
2-10 
 
 
 
 
9.11 (1.1) 
7-10 
 
 
 
 
 
8.66 (1.62) 
2-10 
 
6.7 Treatment Fidelity & Adherence 
 
A sample of tapes was checked for fidelity and adherence by an independent rater.  The rater 
was blind to treatment condition, and was not otherwise involved in the trial.  They were a 
senior Clinical Psychologist, with many years’ experience of training and assessing 
competencies in CBT for psychosis.  One-hundred and eight recorded sessions were available 
(52 MBCI; 56 SAT).  Twenty sessions were randomly selected (10 from each condition), 
representing 16 different participants (some sessions were from the same participant, but no 
more than 2 per participant).  Sessions from 1-5 were all represented at least once in the 
random sample, ensuring that fidelity was assessed from later as well as earlier sessions.   As 
outlined in Chapter 4, there were 4 sub-scales to the adherence and competency scale.  Scale 
A was on non-specific therapy factors, which should have been present in both treatment 
conditions (agenda, feedback, understanding, interpersonal effectiveness, collaboration & 
homework).  These factors were rated as ‘present’ in all sessions. Scale B was on MBCI-
specific components (formulation, mindfulness skills & values).  These components were 
rated as present in all of the MBCI sessions rated, and absent in all the SAT sessions rated.  
The converse was true for Scale C, which was on SAT-specific components (activities & 
response to distress).  Scale D was on components from CBT for psychosis that would be 
proscribed in both treatment conditions (Columbo style, evidence for beliefs, verbal 
challenge, validity testing, schemas).  These factors were rated as ‘absent’ in all sessions.  For 
all therapy components which were rated as ‘present’, the minimum competency rating was 
always at least 3 (‘satisfactory’).  All 20 sessions were correctly identified as coming from 
either a SAT or MBCI session.  In summary, fidelity to treatment model was 100% across all 
sessions rated, and competency was at least satisfactory for all therapy components that were 
present within a session. 
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6.8 Adverse Events 
 
Three participants experienced adverse events over the course of the trial (2 SAT; 1 MBCI).  
One participant was assaulted by another patient during their admission, but did not require 
medical treatment.  One participant presented to A&E on 2 occasions in the follow-up period, 
reporting having taken a paracetamol overdose in response to social stressors.  They were 
admitted to a general medical ward overnight for observation on both occasions but did not 
require further treatment.  The third participant fractured their shoulder falling down stairs, 
which required a brief hospital admission stay for treatment. This occurred in the follow-up 
period.  A month later the same participant took a medication overdose in response to distress 
associated with persecutory beliefs, and was admitted to a general hospital for observation 
before being medically cleared and transferred to a psychiatric ward.  These adverse events 
were all reported to the chair of the Trial Steering Committee who was in agreement that they 
were highly unlikely to be related to trial participation. 
 
6.9 Qualitative Outcomes 
 
As outlined in Chapter 4 (section 4.8.2), all trial participants were invited to complete a 
feedback questionnaire with PJ at the end of the trial, at 6-month follow-up.  The 
questionnaire asked about their experience of taking part in the study, and their experiences 
of the therapy they received (see Trial Master File, 10.15 for topic guide).  Forty participants 
(80%) completed feedback questionnaires.  Additionally, participants were asked about their 
willingness to complete an additional feedback interview, on the same topics, conducted by a 
service user researcher.  Five participants (10%; three SAT, two MBCI) went on to complete 
an interview with a service user researcher, which was audio-recorded and transcribed 
verbatim for analysis.  Staff from the in-patient units where patients were recruited were also 
invited to give feedback on the trial via an individual interview with two assistant 
psychologists who had not otherwise been involved in the trial (see Trial Master File, 10.16 
for topic guide).  A total of eight staff interviews were conducted, including staff from all 
four wards from which trial participants were recruited (three ward managers, two staff 
nurses and three consultant psychiatrists).  Staff interviews were also audio-recorded and 
transcribed verbatim for analysis.  A full qualitative analysis of participant and staff 
experience of the trial is outside the intended scope of this thesis, and so is not reported.  In 
summary, participants reported finding the opportunity to have a talking therapy during their 
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admission helpful in terms of helping them to understand themselves better, the opportunity 
for self-reflection and expression of feelings within a safe therapeutic relationship.  Several 
participants also mentioned that boredom, or monotony of routine on the ward, was a 
motivation for them being interested in taking part in the study in the first place, and that this 
also provided an impetus to attend sessions regularly once they started therapy.  Staff talked 
about valuing talking therapies as an ‘adjunct’ to standard care on the ward (i.e. medication 
and nursing care).  Nurses also acknowledged that the business of their roles on the wards 
often limited the time they had to talk to patients, so a therapist offering extra 1:1 time was 
seen as very valuable, and something that could take the pressure off the nursing team for 
short periods during a shift. 
 
6.10 Summary of key feasibility outcomes 
 
8) Number of eligible participants identified over study period  
 
65 (22% of patients identified as initially eligible on admission (n=302), and 37% 
of people then assessed further for eligibility, n=175). 
 
9) Total numbers recruited into trial and recruitment rate (benchmark of 80% of target)  
 
50 (83%) 
 
10) Proportion of participants who dropped out during the intervention stage 
 
No participants stated they did not wish to continue with any further sessions 
offered during their admission.  Therapy was suspended for one participant who 
became disinhibited towards the therapist during a session (and who then was 
discharged before safety could be assessed for future sessions).   
 
11) Range and average number of sessions completed (including number of sessions 
attended as a proportion of those offered) 
 
131 
 
 
Range 1-5 sessions, mean number of sessions completed= 3.04 in SAT group, and 
2.81 MBCI group.  Total number of sessions attended/offered= 146/191 (76%). 
 
12) Reasons for participants dropping out during the intervention stage 
 
No drop-out during intervention stage. 
 
13) Number lost to follow-up and reasons (benchmark of less than 20% to be set in line 
with previous studies) 
 
At 6-month trial end-point: - 1 (2%) participant lost to follow-up for service use 
outcomes (readmission), 7 (14%) participants lost to follow-up for clinical 
measure outcomes (self-report questionnaires).  Reasons for loss to follow-up: - 
not able to contact (n=2), DNA follow-up appointment (n=3), moved abroad 
(n=1), in prison (n=1). 
 
14) Any unexpected adverse effects of participating in the trial 
 
Three participants experienced adverse events, none of which was considered 
likely to be related to their participation in the trial. 
  
132 
 
 
 Results: Pilot Outcome Measures 
 
7.1 Overview 
 
This chapter reports the results on the pilot outcome measures for the trial.  Results are firstly 
reported for service use outcomes, collected from clinical notes (see Table 16), and secondly 
for clinical measures (self-report questionnaires; Table 18).  The overall re-admission rate at 
6-month follow-up was 22% (11/49), and there was little difference between groups with 6 
(24%) readmissions in the MBCI group vs. 5 (21%) in the SAT group.  Relapse rate was 
calculated based on clinical note review and was defined as documented evidence of 
exacerbation in psychotic symptoms and associated change in clinical management, with or 
without admission.   There was also little difference between groups on relapse rates – 6 
(25%) in MBCI and 7 (29%) in SAT.  Only 2 people (both in the SAT group) experienced a 
stand-alone episode of care with the home treatment team in the follow-up period (i.e. one 
that did not overlap with an inpatient admission).  Time to first re-admission was slightly 
shorter in the MBCI group (mean of 80 days compared to 101 in the SAT group), and total 
number of occupied bed days was slightly lower (45 vs. 51 in the SAT group).  However, 
95% confidence intervals were large for both these variables, and overlapped between 
groups.  Just over a third of participants were discharged under the care of an early 
intervention service (18/48) and almost all participants were still under the care of secondary 
mental health services at 6-month follow-up (46/48).  A third of participants had at least one 
session of Cognitive Behavioural Therapy or Family intervention during the 6-month follow-
up period.  The number of people who had psychological therapy post-discharge was slightly 
higher in the MBCI group compared to the SAT group (10 (42%) vs. 6 (25%)).   
 
On the clinical measures, in general symptom scores followed a pattern of improvement from 
baseline to post-therapy, but with little or no evidence of additional gains over the 6-month 
follow-up period after discharge.   However, the recovery and mindfulness measures showed 
no change over time in either group.  After adjusting for baseline score, there was little 
difference in mean scores at 6-month follow-up between groups on any measures, except for 
some of the voices measures, which indicated higher ratings of voice frequency in the MBCI 
group.   
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7.2 Service use outcomes 
 
Service Use Outcomes are shown in Table 16. 
 
Table 16 Results - Service Use Outcomes 
 Up to F2 (0-6mths) 
Outcome MBCI (N=2514) SAT (N=24) 
8) Re-
hospitalisation 
(≥1 OBD15) 
   
- Yes 
- No 
 
 
 
 
6 (24%) 
19 (76%) 
 
 
 
 
5 (21%) 
19 (79%) 
9) Time to first re-
admission 
(days) 
 
- Mean (SD) 
- Range 
- 95% CI 
 
 
 
 
 
80 (29) 
41-122 
49-111 
 
 
 
 
101 (56) 
58-176 
32-171 
10) Total number 
of OBDs 
 
- Mean (SD) 
- Range 
- 95% CI 
 
 
 
 
 
45 (38) 
2-83 
4-85 
 
 
 
51 (44) 
4-117 
0-105 
11) Episodes of 
care with 
crisis/home 
treatment team 
(HTT)16 
 
- Yes 
- No 
 
 
 
 
 
 
0 (0%) 
25 (100%) 
 
 
 
 
 
 
2 (8%) 
22 (92%) 
  
                                                 
14 Re-admission data not available for 1 participant (moved abroad) 
15 OBD=occupied bed day 
16 Stand-alone episodes of care only (i.e. not overlapping with inpatient admissions) 
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 MBCI (N=24)17 SAT (N=24) 
12) No. of contacts 
with CMHT18  
 
- Mean (SD) 
- Range 
- 95% CI 
 
 
 
14 (7) 
0-32 
10-17 
 
 
 
13 (7) 
3-34 
10-16 
13) Reference to 
therapy goal, 
which was 
shared with 
team 
 
- Yes 
- No 
 
 
 
 
 
 
21(88%) 
3 (12%) 
 
14) Relapse  
 
Exacerbation in psychotic 
symptoms + change in clinical 
management 
 
- Yes 
- No 
 
 
 
 
 
6 (25%) 
18 (75%) 
 
 
 
 
 
7 (29%) 
17 (71%) 
  
                                                 
17 Notes not available for 2 participants (1 moved abroad/1 in prison) 
18 CMHT=community mental health team; no. of contacts excluding therapy appointments 
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Additional outcomes not pre-specified in trial protocol: - 
15) Received 
therapy in 
community 
 
No therapy 
Any therapy 
CBT only 
Family Intervention only 
CBT + Family 
Intervention 
 
 
 
 
 
14 (58%) 
10 (42%) 
6 (25%) 
3 (13%) 
 
1 (4%) 
 
 
 
 
 
18 (75%) 
6 (25%) 
4 (17%) 
2 (8%) 
 
0 (0%) 
 
16) Open to EIS19 
service on 
discharge 
 
- Yes 
- No 
 
 
 
 
10 (42%) 
14 (58%) 
 
 
 
 
8 (33%) 
16 (67%) 
17) Still open to 
CMHT at F2 
 
- Yes 
- No 
 
 
 
23 (96%) 
1 (4%) 
 
 
 
23 (96%) 
1 (4%) 
 
7.2.1 Readmission rates 
 
The number of people who had at least one hospital re-admission at 6-month follow-up was 
very similar between groups (odds ratio=1.20, 95% CI: 0.312-4.61).  Six people (24%) in the 
MBCI group, and 5 people (21%) in the SAT group were re-admitted to hospital in the 6 
months following discharge. There was little difference in the average total number of OBDs 
between groups (MBCI – 45; SAT - 51).   Episodes of care with home treatment teams 
(HTTs) were relatively rare as stand-alone episodes of care (i.e. not overlapping with an 
inpatient admission).  Only 2 participants in the trial had HTT involvement, but did not 
require inpatient admission (both in the SAT group).  Relapse rates were also similar between 
the 2 groups (odds ratio=0.81, 95% CI: 0.26-2.90).  Six people (25%) in the MBCI group and 
7 (29%) people in the SAT group met criteria for relapse, as assessed through clinical note 
review.  Relapse was defined as an exacerbation in psychotic symptoms followed by a 
documented change in clinical management, as outlined in Chapter 4.  In most cases there 
                                                 
19 EIS=Early Intervention Service 
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was no difference between readmission/relapse ratings, as most relapses of psychotic 
symptoms resulted in an inpatient admission.  There were a few exceptions to this.  One 
participant in the MBCI group experienced 2 very short re-admissions during the follow-up 
period of only 1 bed day each.  This was under a CTO (community treatment order) recall so 
that depot medication could be administered, although the participant was not experiencing 
any relapse in symptoms. Another participant in the MBCI group was judged to be relapsing 
in the community, and so a recommendation was made for a voluntary admission.  However, 
there was a delay as no psychiatric bed could be found.  After a few days, the person’s mental 
state stabilised and they were not re-admitted to hospital in the end.  In the SAT group, 7 
people met criteria for relapse, whereas only 5 people were re-admitted to hospital (the 
additional 2 people being those who had stand-alone episodes of care with the HTT).  These 
data are summarised in Figure 11, which also shows the breakdown in numbers between the 
F1 and F2 period (0-3 months, and 3-6 months), as well as the overall follow-up period (0-6 
months).   
 
 
 
 
Figure 11  Re-hospitalisation, HTT and relapse data by group 
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As described in the analysis plan in chapter 5, the 6-month follow-up period was calculated 
from discharge date, rather than randomisation date, to account for varying lengths of 
admission.  As a secondary analysis, readmission rates at 6-month follow-up were re-
calculated using randomisation date as the anchor, rather than discharge date.  This resulted 
in 5 readmissions in the MBCI group (20%) and 3 readmissions in the SAT group (12%).  
The slightly higher number in the MBCI group reflects the fact that time to readmission was 
somewhat shorter in the MBCI group (mean average 80 days) compared to the SAT group 
(mean average 101 days).   
 
 
 
 
Figure 12 Survival curve of re-admission to hospital: Kaplan-Meier Plot 
 
Time to re-admission is shown in Figure 12 as a Kaplan-Meier plot.  This shows that the 
survival curve is similar for both groups.  The re-admissions in the MBCI group occur 
slightly earlier than in the SAT group (between 41 and 122 days post-discharge for MBCI 
MBCI 
 
SAT 
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compared to between 58 and 176 days post-discharge for SAT).  However, due to small 
numbers this may not be a reliable finding and should be interpreted with caution.  The 
results of a Log Rank test confirmed that there was no statistically significant difference 
between the survival curves for the 2 groups (χ2 (1, N=49)  =0.09, p=0.76). 
 
It is of interest to characterise the clinical and demographic profiles of the 11 people who 
were re-admitted in the 6-month follow-up period, across both groups.  Nine of them lived 
alone (81%), compared to 48% in the overall sample.  Six out of the 11 (55%) had housing 
problems identified on admission (i.e. homelessness, rent arrears), compared to 39% in the 
overall sample.  Almost all of them (10/11 – 91%) had a history of previous inpatient 
admissions at baseline, compared to 70% in the overall sample.  Only 2 out of the 11 were 
open to Early Intervention services on discharge (18%), compared to 30% in the general 
sample.  Overall, this picture points to a group of people experiencing a more adverse social 
environment, with more chronic difficulties including a history of previous hospital 
admissions.    
 
7.2.2 Risk factors for time to readmission 
 
As a secondary analysis, Cox regression was used to explore possible factors associated with 
time to re-admission during the 6-month follow-up period.  In model 1, therapy group (MBCI 
vs. SAT) was entered as a co-variate on its own.  This analysis confirmed that therapy group 
did not significantly predict time to readmission in the 6 months post-discharge (hazard 
ratio=0.83, 95% CI 0.25-2.73, p=0.761).  In model 2, three clinically relevant (binary) 
variables were entered as co-variates.  From the baseline data, 1) any previous admission, and 
2) any admission in the previous 12 months, were both entered on the basis that people with 
previous admissions might be at higher risk for quicker re-admission.  The third variable was 
discharge to an early intervention service, on the basis that people might receive a better 
standard of psychosocial care from such teams compared to standard community health 
teams.  In fact, the results of the Cox regression indicated that none of these 3 variables was a 
significant predictor of time to re-admission (Table 17). 
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Table 17 Cox Regression Model: Clinical variables 
 
 Hazard Ratio 
(95% CI) 
P value 
Any previous 
admissions20  
(yes/no) 
 
0.41 (0.04-3.81) 
 
0.433 
Admission in previous 
12 months20 
(yes/no) 
 
0.41 (0.12-1.48) 
 
0.174 
Discharged to Early 
Intervention Service 
 
2.31 (0.48-11.1) 
 
0.297 
 
 
7.2.3 Contact with services post-discharge 
 
Additional data were collected on participants’ contact with mental health services in the 6 
months post-discharge. This helps to contextualise the re-admission/relapse data (Table 16).  
All participants (100%) were discharged to a CMHT immediately upon discharge.  Only 44% 
of participants were open to a CMHT on admission, so this constituted a new referral, or a re-
referral, for just over half the participants.  Approximately a third of participants were 
discharged to an early intervention service (EIS) (18/48).    The overall number of CMHT 
contacts in the 6 months post-discharge did not differ between EIS and non-EIS participants 
(mean average of 13.7 vs 13.8 respectively).  For the MBCI group, where a goal from therapy 
was shared with their care team on discharge, there was some reference to the goal in the 
notes for most people (21/24).  However, it is important to note that this included any 
reference to the goal in general, rather than being a measure of whether the goal was achieved 
or not.  The vast majority of participants were still under the care of a CMHT at 6-month 
follow-up (46/48).  Two participants (1 in each group) were discharged back to the care of 
their GP by mutual consent with their CMHT as they did not feel they needed continuing care 
from secondary services. 
                                                 
20 Not counting the admission in which they took part in the trial 
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Approximately a third of participants had psychological therapy (either CBT or FI) in the 6 
months after discharge.  Participants in the MBCI group were twice as likely to have therapy 
as those in the SAT group (odds ratio=2.14, 95% CI: 0.63-7.33).  However, the odds ratio 
95% confidence interval is large and includes 1, indicating that this may not be a reliable 
finding. Those in EIS services were 3 times more likely to receive a psychological therapy in 
the 6 months post-discharge, compared to those not in EIS services (odds ratio=3.29, 95% CI: 
0.94-11.5).   However, as the 95% confidence interval includes 1, this may also not be a 
reliable finding. 
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7.3 Clinical measures outcomes 
 
7.3.1 Descriptive Statistics 
 
This section reports the data from the clinical outcome measures (self-report questionnaires).  
As the proportion of missing data was less than 20% at all time points, there was no attempt 
to account for missing data using imputation methods.  Furthermore, everyone in the trial 
received at least one therapy session (minimum therapy dose), therefore treatment 
compliance could not have been a predictor of drop-out/missing data.  In line with the 
statistical analyses plan, all analyses were conducted on an intention-to-treat (ITT) basis, 
analysing participants as randomised, regardless of actual treatment received.  However, for 
this trial, intention-to-treat and per protocol methods of analysis were in fact equivalent, as all 
participants received the minimum therapy dose. Where individual items were missing in a 
scale, pro-rating was successfully applied in every case as no more than 20% of items were 
missing. The number of participants with pro-rated data was low (N=3), and in all cases 
related to a maximum of 1 questionnaire measure per assessment point.   
 
In line with the analysis plan, descriptive statistics were first calculated based on unadjusted 
means, before adjusting for baseline score.  Unadjusted means are shown in Table 18, by 
assessment point and treatment group (MBCI vs. SAT). Data are presented separately for 
beliefs (delusions) and voices for the self-rating psychotic symptom scales. Participants 
reported delusions more commonly than voices, so the sample size is larger for the delusions 
ratings.       
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Table 18 Questionnaire measures (unadjusted means) 
 T1  
(Baseline) 
 
 
 
T2  
(End of 
therapy) 
 
 
F1  
(3-month 
follow-up) 
 
 
F2  
(6-month 
follow-up) 
 
 
 MBCI 
 
N=26 
SAT 
 
N=23 
MBCI 
 
N=23 
SAT 
 
N=23 
MBCI 
 
N=20 
SAT 
 
N=20 
MBCI 
 
N=21 
SAT 
 
N=19 
Self-rating of 
psychotic 
symptoms 
(Beliefs) 
 
Frequency 
(1-7)  
 
Mean 
S.D 
(95% CI) 
 
 
Distress 
(0-10) 
 
Mean 
S.D 
(95% CI) 
 
 
Believability 
(0-10)  
 
Mean 
S.D 
(95% CI) 
 
 
 
 
 
 
 
 
 
 
 
 
5.58 
1.65 
(4.91-
6.24) 
 
 
 
 
6.69 
3.42 
(5.31-
8.07) 
 
 
 
 
8.15 
3.08 
(6.91-
9.40) 
 
 
 
 
 
 
 
 
5.65 
1.34 
(5.07-
6.23) 
 
 
 
 
7.70 
3.42 
(6.22-
9.17) 
 
 
 
 
7.48 
3.38 
(6.02-
8.94) 
 
 
 
 
 
 
 
 
 
3.17 
2.15 
(2.25-
4.1) 
 
 
 
 
2.83 
2.82 
(1.61-
4.05) 
 
 
 
 
4.70 
3.61 
(3.13-
6.26) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.61 
2.08 
(2.71-
4.51) 
 
 
 
 
5.26 
3.40 
(3.79-
6.73) 
 
 
 
 
6.00 
3.45 
(4.51-
7.49) 
 
 
 
 
 
 
 
 
3.25 
2.33 
(2.16-
4.34) 
 
 
 
 
3.70 
3.94 
(1.86-
5.54) 
 
 
 
 
3.95 
4.12 
(2.02-
5.88) 
 
 
 
 
 
 
 
 
3.00 
2.36 
(1.89-
4.11) 
 
 
 
 
2.90 
3.43 
(1.29-
4.51) 
 
 
 
 
3.90 
4.41 
(1.84-
5.96) 
 
 
 
 
 
 
 
 
2.57 
1.89 
(1.71-
3.43) 
 
 
 
 
2.24 
3.21 
(0.78-
3.70) 
 
 
 
 
4.38 
4.41 
(2.37-
6.39) 
 
 
 
 
 
 
 
 
2.63 
2.03 
(1.65-
3.61) 
 
 
 
 
2.16 
2.97 
(0.73- 
3.59) 
 
 
 
 
3.74 
4.01 
(1.80-
5.67) 
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 T1 T2 F1 F2 
 MBCI 
 
N=12 
SAT 
 
N=12 
MBCI 
 
N=11 
SAT 
 
N=12 
MBCI 
 
N=9 
SAT 
 
N=11 
MBCI 
 
N=9 
SAT 
 
N=10 
Self-rating of 
psychotic 
symptoms 
(Voices) 
 
Frequency 
(1-7)  
 
Mean 
S.D 
(95% CI) 
 
 
Distress 
(0-10) 
 
Mean 
S.D 
(95% CI) 
 
 
Believability 
(0-10)  
 
Mean 
S.D 
(95% CI) 
 
 
HPSVQ  
(0-36) 
 
(Hamilton 
Program for 
Schizophrenia 
Voices 
Questionnaire) 
 
Mean 
S.D 
(95% CI) 
 
 
 
 
 
 
 
 
5.08 
1.62 
(4.06-
6.11) 
 
 
 
 
6.50 
3.03 
(4.57-
8.43) 
 
 
 
 
6.83 
3.24 
(4.77-
8.89) 
 
 
 
 
 
 
 
 
 
 
20.67 
8.49 
 
 
 
 
 
 
 
 
5.58 
1.5 
(4.63-
6.54) 
 
 
 
 
8.42 
2.50 
(6.83-
10.01) 
 
 
 
 
6.17 
3.22 
(4.12-
8.21) 
 
 
 
 
 
 
 
 
 
 
25.5 
4.78 
 
 
 
 
 
 
 
 
4.09 
2.07 
(2.70-
5.48) 
 
 
 
 
3.27 
3.10 
(1.19-
5.36) 
 
 
 
 
4.00 
3.58 
(1.6-
6.40) 
 
 
 
 
 
 
 
 
 
 
16.45 
8.10 
 
 
 
 
 
 
 
 
3.42 
2.11 
(2.08-
4.76) 
 
 
 
 
3.75 
3.82 
(1.32-
6.18) 
 
 
 
 
5.17 
4.26 
(2.46-
7.87) 
 
 
 
 
 
 
 
 
 
 
13.00 
10.87 
 
 
 
 
 
 
 
 
3.00 
2.18 
(1.32-
4.68) 
 
 
 
 
2.22 
3.15 
(0.0021-
4.65) 
 
 
 
 
3.11 
3.98 
(0.05-
6.17) 
 
 
 
 
 
 
 
 
 
 
9.44 
8.99 
 
 
 
 
 
 
 
 
2.73 
2.15 
(1.28-
4.17) 
 
 
 
 
1.18 
2.44 
(0.00- 
2.82) 
 
 
 
 
2.45 
3.75 
(0.00-
4.97) 
 
 
 
 
 
 
 
 
 
 
8.55 
9.13 
 
 
 
 
 
 
 
 
4.22 
2.33 
(2.43-
6.02) 
 
 
 
 
3.00 
4.03 
(0.00-
6.10) 
 
 
 
 
4.78 
4.60 
(1.24-
8.32) 
 
 
 
 
 
 
 
 
 
 
13.6322 
10.66 
 
 
 
 
 
 
 
 
2.30 
1.95 
(0.91-
3.69) 
 
 
 
 
1.80 
2.62 
(0.00-
3.67) 
 
 
 
 
2.90 
4.01 
(0.03-
5.77) 
 
 
 
 
 
 
 
 
 
 
5.70 
7.60 
                                                 
21 Lower Bound Confidence Interval truncated to 0 where calculated value is negative to indicate floor effect  
 
22 N=8 in MBCI group for HPSVQ as 1 participant failed to complete all measures in the F2 assessment 
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 (15.27-
25.06) 
(22.46-
28.54) 
(11.01-
21.90) 
(6.09-
19.91) 
(2.54-
16.4) 
(2.41-
14.7) 
(4.71-
22.5) 
(0.26-
11.14) 
 T1 T2 F1 F2 
 MBCI 
 
N=24 
SAT 
 
N=26 
MBCI 
 
N=23 
SAT 
 
N=24 
MBCI 
 
N=20 
SAT 
 
N=21 
MBCI 
 
N=2023 
SAT 
 
N=20 
Mood 
(DASS-21; 
Depression, 
anxiety & 
stress) 
 
Depression  
(0-42) 
 
Mean 
S.D 
(95% CI) 
 
 
Anxiety 
(0-42) 
 
Mean 
S.D 
(95% CI) 
 
Stress 
(0-42) 
 
Mean 
S.D 
(95% CI) 
 
 
 
 
 
 
 
 
 
 
15.77 
12.44 
(10.75-
20.79) 
 
 
 
 
15.85 
13.25 
(10.49-
21.20) 
 
 
 
19.31 
11.76 
(14.56-
24.06) 
 
 
 
 
 
 
 
 
 
20.75 
14.62 
(14.58-
26.92) 
 
 
 
 
19.75 
11.67 
(14.82-
24.68) 
 
 
 
25.58 
11.57 
(20.7-
30.47) 
 
 
 
 
 
 
 
 
 
9.04 
10.48 
(4.51-
13.57) 
 
 
 
 
10.00 
8.66 
(6.26-
13.74) 
 
 
 
15.04 
9.36 
(11.00-
19.09) 
 
 
 
 
 
 
 
 
 
15.42 
12.28 
(10.23-
20.60) 
 
 
 
 
15.17 
12.17 
(10.03-
20.31) 
 
 
 
17.58 
10.23 
(13.26-
21.90) 
 
 
 
 
 
 
 
 
 
13.7 
10.53 
(8.77-
18.63) 
 
 
 
 
8.5 
8.15 
(4.68-
12.32) 
 
 
 
13.50 
11.20 
(8.26-
18.74) 
 
 
 
 
 
 
 
 
 
11.81 
12.18 
(6.27-
17.35) 
 
 
 
 
9.52 
10.52 
(4.73-
14.31) 
 
 
 
9.62 
11.57 
(4.35-
14.89) 
 
 
 
 
 
 
 
 
 
12.60 
11.86 
(7.05-
18.15) 
 
 
 
 
7.70 
10.61 
(2.74-
12.66) 
 
 
 
11.40 
11.75 
(5.90-
16.90) 
 
 
 
 
 
 
 
 
 
13.80 
12.66 
(7.87-
19.73) 
 
 
 
 
10.40 
10.21 
(5.62-
15.18) 
 
 
 
12.40 
9.37 
(8.01-
16.79) 
  
                                                 
23 1 MBCI participant failed to complete all questionnaire measures in the F2 assessment 
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 T1 T2 F1 F2 
 MBCI 
 
N=24 
SAT 
 
N=26 
MBCI 
 
N=23 
SAT 
 
N=24 
MBCI 
 
N=20 
SAT 
 
N=21 
MBCI 
 
N=20 
SAT 
 
N=20 
Recovery 
(0-88) 
 
(QPR; 
Questionnaire 
about the 
Process of 
Recovery) 
 
Mean 
S.D 
(95% CI) 
 
 
 
 
 
 
 
 
 
65.31 
13.25 
(69.96-
70.66) 
 
 
 
 
 
 
 
 
 
60.58 
18.75 
(52.67-
68.5) 
 
 
 
 
 
 
 
 
 
67.09 
13.94 
(61.06-
73.11) 
 
 
 
 
 
 
 
 
 
61.00 
13.20 
(55.42-
66.58) 
 
 
 
 
 
 
 
 
 
63.40 
15.04 
(56.36-
70.44) 
 
 
 
 
 
 
 
 
 
63.52 
15.26 
(56.58-
70.47) 
 
 
 
 
 
 
 
 
 
62.20 
20.45 
(53.49-
68.51) 
 
 
 
 
 
 
 
 
 
61.00 
16.06 
(53.49-
68.51) 
 
 MBCI 
 
N=24 
SAT 
 
N=26 
MBCI 
 
N=23 
SAT 
 
N=23 
MBCI 
 
N=20 
SAT 
 
N=21 
MBCI 
 
N=20 
SAT 
 
N=1924 
Mindfulness 
(0-96) 
 
(SMQ; 
Southampton 
Mindfulness 
Questionnaire) 
 
Mean 
S.D 
(95% CI) 
 
 
 
 
 
 
 
 
 
 
56.27 
14.96 
(50.23-
62.31) 
 
 
 
 
 
 
 
 
47.25 
14.67 
(41.05-
53.45) 
 
 
 
 
 
 
 
 
58.13 
12.28 
(52.82-
63.44) 
 
 
 
 
 
 
 
 
53.26 
14.08 
(47.17-
59.35) 
 
 
 
 
 
 
 
 
57.50 
11.88 
(51.94-
63.06) 
 
 
 
 
 
 
 
 
57.57 
16.52 
(50.05-
65.09) 
 
 
 
 
 
 
 
 
55.00 
11.81 
(49.47-
60.53) 
 
 
 
 
 
 
 
 
57.05 
12.84 
(50.86-
63.24) 
 
 
Data for each questionnaire measure are presented in graphical form in Figure 13 to Figure 
18 in the following section. 
 
  
                                                 
24 1 participant in the SAT group did not complete the SMQ at F2 
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Figure 13  Psychotic Symptoms (Beliefs); error bars 95% CI 
 
 
Figure 14  Psychotic Symptoms (Voices); error bars 95% CI 
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Figure 15 Hamilton Voices Questionnaire; error bars 95% CI 
 
As shown in Figure 13, ratings of frequency, distress and believability for delusions all 
reduced from baseline (T1) to end of therapy (T2) which would be as expected as the crisis 
resolves and the person’s mental state improves over the course of their admission.  In the 
MBCI group, the 95% error bars are non-overlapping from T1 to T2 for frequency, distress 
and believability, whereas this is only the case for frequency within the SAT group.  Within 
both groups, the 95% error bars all overlap for time-points T2-F2, indicating that there may 
not be any reliable difference in scores between these time-points.  This pattern of results is 
mirrored in the data for voices (Figure 14), however as data are available for a smaller 
number of participants, the 95% error bars have larger margins, and so the data are harder to 
interpret.   Small numbers also limit interpretation of the HPSVQ scale (Hamilton Program 
for Schizophrenia Voices Questionnaire).  In general, scores reduce over time from T1 to F1, 
before levelling off between F1 and F2 (Figure 15).  In the MBCI group, the 95% error bars 
overlap across all 4 time points.  However, in the SAT group, the 95% error bars are non-
overlapping between T1 and T2.  In general, the psychotic symptom data are consistent with 
a pattern of recovery and improvement over the course of the inpatient admission (T1-T2), 
but there is not much evidence of additional gains over the follow-up period 6 months post-
discharge. 
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Figure 16 Mood (DASS21); error bars 95% CI 
 
For the mood data (depression, anxiety and stress), the general pattern of improvement from 
T1-T2 was also seen, with a flattening-off effect between T2 and F2 (Figure 16).  For the 
MBCI group, 95% error bars were over-lapping between all time points across depression, 
anxiety and stress.  However, in the SAT group the 95% error bars were non-overlapping 
between T1 (baseline) and F1/F2 (follow-up), for anxiety and stress, although not for 
depression.  For both groups, average depression scores were in the moderate range (14-20) 
at Tl (baseline) and in the mild range (10-13) at F2 (6-month follow-up).  Average anxiety 
scores were in the severe range (15-19) at T1 for both groups, and this dropped to the normal 
range (0-7) at F2 in the MBCI group and the moderate range (10-14) for the SAT group.  
Average stress scores were in the moderate range (19-25) at T1, and dropped to the normal 
range (0-14) at F2 in both groups. 
 
 
0
5
10
15
20
25
30
35
40
Dep Anx Str Dep Anx Str
MBCI SAT
T1 T2 F1 F2
149 
 
 
 
Figure 17 Recovery (QPR); error bars 95% CI 
 
Interestingly, there was no evidence of any change over time in people’s self-rated recovery 
(Figure 17).  Error bars are overlapping within and between both groups over each time point 
from T1-F2.  There are no formal categories of scores for the QPR.  However, the authors of 
the scale quote a mean average score of 50.13 (standard deviation 11.56, range 15-75) in a 
sample of 335 people with experience of psychosis (Law et al., 2014).  In this study, the T1 
score (baseline) was higher than 50 for both the MBCI and SAT group (65 & 60 
respectively), with higher scores indicating better subjective recovery.  Mean scores in both 
groups were above 60 at all 4 assessment points. 
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Figure 18 Mindfulness (SMQ); error bars 95% CI 
 
A similar pattern is seen for the Mindfulness scores, with little change in either group across 
all time points (Figure 18). Error bars are overlapping within and between both groups over 
each time point from T1-F2.  Previous studies have reported scores on the SMQ in clinical 
psychosis samples of mean=37 (N=122, Chadwick et al. (2008)) and mean=47 (N=83; Peters 
et al. (2016)).  Participants in both MBCI and SAT groups scored above this (indicating 
greater mindfulness of thoughts or images).   In the MBCI group, the mean score was 56 at 
T1 (baseline), and 55 at F2 (6-month follow-up).  In the SAT group, the mean score was 47 at 
T1, and 57 at F2. 
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7.3.2 Adjusting for baseline score 
 
In line with the statistical analysis plan, a secondary analysis on the clinical measures was 
calculated using the general linear model, co-varying for baseline score and treatment 
condition. The dependent variable in each case was score at F2 (6 month-follow-up), with 2 
independent variables: treatment condition (MBCI vs. SAT) as a fixed factor and score at T1 
(baseline score) as a co-variate.  Co-efficient estimates (B) of the differences in means 
between treatment condition at F2, with 95% confidence intervals, are reported in Table 19.   
 
Table 19 Coefficient estimates (B) of difference in group means at 6-month follow-up 
 MBCI25 (N=21) 
SAT (N=19) 
Self-rating of psychotic 
symptoms (Beliefs) 
 
Frequency 
 
Coefficient estimate (B) 
(95 % CI) 
 
Distress 
 
Coefficient estimate (B) 
(95 % CI) 
 
Believability 
 
Coefficient estimate (B) 
(95 % CI) 
 
 
 
 
 
 
-0.02 
-1.18 to 1.15 
 
 
 
-0.46 
-2.27 to 1.34 
 
 
 
-0.38 
-2.69 to 1.93 
 MBCI (N=9) 
SAT (N=10) 
 
Self-rating of psychotic 
symptoms (Voices) 
 
Frequency 
 
Coefficient estimate (B) 
(95 % CI) 
 
 
 
 
 
 
 
-2.612 
-4.76 to -0.48 
 
                                                 
25 Reference category for comparison in group means is MBCI (i.e. positive values favour 
MBCI) 
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Distress 
 
Coefficient estimate (B) 
(95 % CI) 
 
Believability 
 
Coefficient estimate (B) 
(95 % CI) 
 
HPSVQ 
 
(Hamilton Program for 
Schizophrenia Voices 
Questionnaire) 
 
Coefficient estimate (B) 
(95 % CI) 
 
 
 
 
 
 
-2.00 
-5.39 to 1.38 
 
 
 
-2.33 
-5.46 to 0.81 
 
 
 
 
 
 
 
-11.85 
-20.82 to -2.89 
 
 
 MBCI (N=20) 
SAT (N=20) 
Mood 
 
(DASS-21; Depression, 
anxiety & stress) 
 
Depression  
 
Coefficient estimate (B) 
(95 % CI) 
 
Anxiety 
 
Coefficient estimate (B) 
(95 % CI) 
 
Stress 
 
Coefficient estimate (B) 
(95 % CI) 
 
 
 
 
 
 
 
1.27 
-6.73 to 9.27 
 
 
 
2.23 
-4.17 to 8.63 
 
 
 
0.71 
-6.39 to 7.81 
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 MBCI (N=20) 
SAT (N=20) 
Recovery 
 
(QPR; Questionnaire about 
the Process of Recovery) 
 
Coefficient estimate (B) 
(95 % CI) 
 
 
 
 
 
 
 
1.06 
-10.56 to 12.69 
 MBCI (N=20) 
SAT (N=19) 
Mindfulness 
(0-96) 
 
(SMQ; Southampton 
Mindfulness 
Questionnaire) 
 
Coefficient estimate (B) 
(95 % CI) 
 
 
 
 
 
 
 
3.92 
-4.57 to 12.42 
 
As can be seen in Table 19, there are only small differences in mean scores between the 
MBCI and SAT groups at 6 month-follow-up, after controlling for baseline score.  The 
confidence intervals cross 0 for most measures indicating no significant difference between 
groups.  The only exception to this is for some of the voice measures (self-rated frequency of 
voices and HPSVQ score).  As the sample size is smaller for the voice measures, since only 
about half of participants reported hearing voices at baseline, these results should be 
interpreted with caution, but may indicate that the MBCI group in fact reported more frequent 
voices at 6-month follow-up compared to the SAT group.  However, it is important to note 
that in the MBCI group, voice frequency and HPSVQ scores were still lower at 6-month 
follow-up than at baseline and discharge. 
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7.4 Summary of key findings on the pilot outcome measures 
 
 The total re-admission rate at 6-month follow-up was 22%, and the number of re-
admissions in each group was similar (6 in the MBCI group and 5 in the SAT group). 
 The relapse rate (6 in the MBCI group and 7 in the SAT group) was similar to the re-
admission rate, indicating a documented relapse in psychotic symptoms without a 
subsequent inpatient admission was relatively rare. 
 A third of participants had psychological therapy in the 6 months following discharge, 
and the rates were slightly higher in the MBCI group compared to the SAT group (10 
vs. 6 people). 
 Symptom measures showed an improvement in scores from baseline to post-therapy, 
but little evidence of additional gains over the 6-month follow-up period. 
 After adjusting for baseline score, there was little difference in mean scores at 6-
month follow-up between groups on any measures, except for higher ratings of voice 
frequency in the MBCI group.   
 Neither group showed increased recovery or mindfulness scores over the course of the 
study. 
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 Discussion 
 
8.1 Overview 
 
This chapter first re-caps the aims and objectives of the study, before summarising the main 
findings, relating to both feasibility and pilot outcome measures.  Strengths and limitations of 
the study are considered, relating to the design of the study, and the generalisability of the 
findings. The results of this study are then discussed in relation to previous inpatient studies, 
including both UK and US trials.  Finally, the implications for planning of future trials to 
further evaluate MBCI are discussed, as well as implications for inpatient and crisis research 
in general. 
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8.2 Evidence before this study – Systematic Review Findings 
 
There is an established evidence base for psychological therapies for psychosis, including 
CBT for psychosis and Family Intervention.  However, current guidelines are based mainly 
on studies conducted in community, not inpatient settings.  Therapies are often adapted for 
delivery within inpatient settings from standard protocols, or are based on untested novel 
protocols.  The evidence base for the added value of psychological therapies for psychosis on 
acute psychiatric wards is unclear.  A systematic scoping review of psychological therapies 
for psychosis on acute psychiatric wards was therefore conducted (Chapter 2).  It was found 
that many different types of therapies have been evaluated with varying study quality.  There 
were significant sources of heterogeneity in the existing literature, including the types of 
outcome assessments used.  Only a minority of studies specifically focused on evaluating 
impact on readmission/relapse.  Promising pilot trials from the US on the use of brief 
inpatient therapies to reduce short-term readmission rates had not yet been replicated in UK 
NHS settings. 
 
8.3 Aims and objectives of study 
 
The amBITION study was a feasibility randomised controlled trial (RCT) of a manualised 
brief talking therapy on acute inpatient wards (Mindfulness-Based Crisis Intervention; 
MBCI).     Inpatients were eligible for the study if they reported at least one positive 
psychotic symptom, and were willing and able to engage in a talking therapy.  In addition to 
treatment as usual (TAU), participants were randomly allocated to receive either MBCI or a 
control intervention (Social Activity Therapy; SAT) which was based on doing activities on 
the ward with the therapist. Participants received between 1 and 5 sessions of therapy during 
their inpatient admission.  The primary objective of this study was to find out whether it was 
possible to carry out this kind of trial successfully within UK NHS  inpatient settings and 
whether patients found it an acceptable intervention (i.e. high satisfaction ratings and low 
drop-out during therapy).  The secondary objective was to collect pilot data on clinical 
outcomes, including hospital readmission and symptom measures.  Participants were 
followed up 3 and 6 months after discharge. 
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8.4 Summary of findings 
 
8.4.1 Feasibility outcomes 
 
Fifty participants were randomised into the trial over a 15-month recruitment period (83% of 
pre-set target).  There was no pre-set recruitment window, however recruitment rate was 
mainly limited by resource issues (i.e. PJ as the single trial therapist with no additional staff 
to carry out the research assessments).   All participants received at least one therapy session, 
and no-one dropped out during the intervention stage.  The average number of sessions 
completed was 3 in both arms of the trial.  At 6-month trial end-point, only one participant 
was completely lost to follow-up as they moved abroad immediately upon discharge.  Data 
on hospital re-admission was available for the remaining 49 participants (98% follow-up).  
Follow-up rate for clinical outcomes (self-report questionnaires) was 86%, which exceeded 
the 80% benchmark set in the trial protocol.  Three participants experienced adverse events, 
none of which were judged to be related to their participation in the trial.  Satisfaction with 
therapy was high in both the MBCI and SAT groups.  Forty participants (80%) completed 
feedback questionnaires at the end of the study, and five participants (10%; three SAT, two 
MBCI) went on to complete an interview with a service user researcher.  Eight members of 
staff (three ward managers, two staff nurses and three consultant psychiatrists) completed 
feedback interviews with two independent assistant psychologists. Qualitative feedback 
highlighted reasons for people wanting to take part in the study, what they found helpful 
about an inpatient talking therapy, and what staff thought was helpful about talking therapies 
being offered on wards. 
 
8.4.2 Pilot outcome measures 
 
The overall re-admission rate at 6-month follow-up was 22% (11/49), and there was little 
difference between groups (6 readmissions in the MBCI group (24%) vs. 5 (21%) in the SAT 
group).  Readmission rate based on psychiatric admission alone (for any reason), was similar 
to relapse rate based on clinical note review.  Just over a third of participants were discharged 
under the care of an early intervention service (18/48) and almost all participants were still 
under the care of secondary mental health services at 6-month follow-up (46/48).  A third of 
participants had at least one session of Cognitive Behavioural Therapy or Family intervention 
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during the 6-month follow-up period.  The number of people who had psychological therapy 
post-discharge was slightly higher in the MBCI group compared to the SAT group (10 vs. 6).  
On the clinical measures, in general symptom scores followed a pattern of improvement from 
baseline to post-therapy, but with little evidence of additional gains over the 6-month follow-
up period after discharge.  After adjusting for baseline score, there was little difference in 
mean scores at 6-month follow-up between groups on any measures, except for some of the 
voices measures, which favoured SAT. Measures of recovery and mindfulness showed no 
change for either group over the course of the study.  
 
8.5 Comparison to previous studies 
 
8.5.1 Feasibility outcomes 
 
The current findings confirm the results of previous studies that it is possible to recruit and 
retain people in therapy trials within inpatient settings.  A direct comparison between this 
study and the US pilot trials of brief therapies (Bach and Hayes, 2002, Gaudiano and Herbert, 
2006) on key feasibility outcomes is limited by the information available in the previous trial 
reports.  The current trial identified 65 eligible participants from 590 consecutive acute 
admissions (of whom 302 met initial eligibility criteria). Bach and Hayes randomised 80 
participants, and reported that 1 in 5 people approached agreed to participate (suggesting that 
400 people in total were approached).  However, it is not clear to what degree patients were 
pre-screened for eligibility, for example by consultation with the team or clinical note review.  
The Gaudiano study reports that 40 people were recruited from a total of 60 people who were 
assessed for eligibility, suggesting in contrast a high level of pre-screening (as 67% of people 
approached agreed to take part, compared to 20% in the Bach study).  Treatment drop-out 
was low in the Gaudiano study, with 1 drop-out in each treatment arm. Treatment drop-out is 
not reported in the Bach study, and the absence of a CONSORT diagram also limits 
understanding of drop-out in the follow-up stage.  The average (3) and range (1-5) of therapy 
sessions completed in this study matches exactly the results of the Gaudiano study.  
Comparable data on average number of sessions, and proportion of people completing all 4 
offered sessions, are not reported in the Bach study.  However, overall the findings of the 
current study that the treatment is highly acceptable to inpatients in terms of low drop-out 
rates during therapy, is consistent with these previous findings.  This contrasts with findings 
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from some of the previous UK inpatient studies offering longer courses of treatment. For 
example, in the North Wales trial (Startup et al., 2004), 45% of people discontinued treatment 
prematurely when up to 25 sessions were offered (with a minimum of 12 planned sessions).   
 
Retention in this trial was slightly higher than in previous studies.  At 6-month trial end-
point, 1 (2%) participant was lost to follow-up for the main service use outcome 
(readmission), and 7 (14%) participants were lost to follow-up for clinical outcomes 
(questionnaire measures).  In the Bach study, the loss to follow-up at the 4-month trial end-
point was 12.5% for the primary outcome (readmission); this was mainly due to people 
moving out of the area.  This might suggest a more mobile population in the area where the 
study was conducted (Reno, in the US state of Nevada).  Questionnaire measures were also 
completed with participants at the 4-month follow-up, but it is unclear how many people 
completed these measures, and whether this number was lower than for the number of people 
for whom readmission data were available.  In the Gaudiano study, loss to follow-up was 
only 5% for readmission data at 4-month follow-up.  Questionnaire measures were not taken 
at follow-up, only at baseline and immediately post-treatment. 
 
8.5.2 Pilot outcome measures 
 
This study found no difference between readmission rates at 6-month follow-up, which is in 
direct contrast to the findings of the previous US pilot trials.  Bach and Hayes report that 20% 
of the participants in the treatment arm were re-admitted to hospital at 4-month follow-up, 
compared to 40% in the control arm.  Gaudiano and Herbert report similar re-admission rates 
(28% in the treatment group vs. 45% in the control).  The most obvious difference between 
the current trial, and the US trials, is that the US baseline re-admission rate seems to be much 
higher.  This is likely to be linked to shorter admissions in the US, and differences in 
community care, as the health-care system is funded differently than in the UK.  Length of 
stay is not reported in the Bach study; however, it is reported that the 4 therapy sessions took 
place at 2-3 day intervals, suggesting a therapy envelope of around 2 weeks.  Average length 
of stay in the Gaudiano study was 10 days, which was considerably shorter than in the current 
trial (31 days).  It is possible that this kind of brief intervention has a demonstrable effect on 
readmission rates only in a care context in which admissions are short, therapy sessions are 
therefore closer together, and the baseline readmission rate is high.  Another factor to 
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consider is that both the US studies used TAU (or a slightly ‘enhanced’ TAU in the Gaudiano 
study) as the control condition, which was a less robust control for non-specific therapy 
factors than the social activity therapy (SAT) used in this trial.  It is possible MBCI would 
have shown a reduced re-admission rate compared to a TAU comparator, but no advantage 
over an ‘active’ therapy control condition.  Future studies could test this by adding a TAU 
arm to the design (as in the SOCRATES study, which had 3 treatment arms, including CBT, 
supportive counselling and TAU).  The only subsequent trial which attempted to directly 
replicate the Bach/Gaudiano trials was done by Tyrberg et al. (2016) in Sweden.  This was a 
small study however, with only 22 participants (12 in the ACT condition and 10 in TAU).  
One person was re-admitted in the ACT group at 4-month follow-up, and four in the TAU 
group.  Although the proportion re-admitted was much lower in the ACT condition compared 
to the TAU condition (9% vs. 40%), the 95 % confidence intervals were very wide for the 
odds ratio given the small sample size, and the results were not statistically significant.  The 
average length of admission in the Swedish study was reported to be approximately three 
weeks. 
 
Direct comparison of re-admission rates with the UK inpatient studies discussed in Chapter 1 
is not possible. This is because they all used much longer courses of therapy than 5 sessions, 
and report re-admission to hospital over longer time periods than 6 months.  In the 
SOCRATES trial, they report readmission rates of 33% in the CBTp group and 36% in the 
TAU group at 18-month follow-up (Tarrier et al., 2004).  The North Wales trial reported 
readmission rates of 61% in the CBTp and 70% in the TAU group at 2-year follow-up 
(Startup et al., 2005).  The higher rates in the latter study are partly due to the longer follow-
up period, but are also likely attributable to a difference in clinical sample (early intervention 
in the SOCRATES trial vs. a more mixed, chronic group in the North Wales study).  Drury 
and colleagues report 5-year readmission data for their trial, but do not give numbers for the 
proportion of people in each group experiencing at least one re-admission (the average 
number of admissions was just over 1 per participant; Drury et al. (2000)).   
 
The findings on the clinical outcome measures will be briefly considered here.  There was a 
general trend for improvement in symptom scores over time (psychotic symptoms and 
mood), which would be an expected consequence of admission.  Most of the improvement 
appeared to happen between baseline (T1) and end of therapy/discharge (T2) with a general 
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flattening out in scores over the 6-month follow-up period.  There was little indication of a 
significant difference between the MBCI and SAT groups on any symptom measures, 
although formal significance testing was not applied due to the trial not being powered for 
efficacy.  After adjusting for baseline score, the only measures on which the 95% confidence 
interval of the parameter estimate did not include 0 at 6-month follow-up, was for frequency 
ratings of voices, and total Hamilton Questionnaire score (HPSVQ), both favouring SAT.  
This finding is difficult to interpret, however, due to small numbers (N=9 in the MBCI group, 
N=10 in SAT group), and even in the MBCI group, scores at 6 months were below those for 
baseline and discharge.  However, it is interesting to note that Bach and colleagues also 
report that more people in the Acceptance and Commitment Therapy (ACT) group reported 
symptoms (both voices and delusions) at 4-month follow-up compared to the TAU group 
(55% vs. 16% for voices specifically).  Given that fewer people in the ACT group were re-
admitted to hospital, despite reporting more symptoms, they interpreted the findings as 
indicating that frequency might in fact be an indirect measure of acceptance.  They suggest:- 
“If participants were more accepting of symptoms that occurred, they presumably would be 
more likely to acknowledge than deny them” (p. 1133, Bach and Hayes (2002)).  However, 
distinguishing between true improvement/deterioration in symptoms, and confounding shifts 
in willingness to report symptoms, remains a challenge. 
 
Finally, neither the recovery measure (QPR) nor the mindfulness measure (SMQ) 
distinguished between groups, and neither group showed any change over time on these 
measures.  The QPR has not been widely used in previous clinical trials, so prior evidence on 
its sensitivity to change over time is limited.  However, it was used as a secondary measure in 
the ADAPT trial of acceptance and commitment therapy for post-psychosis depression 
(Gumley et al., 2017).  The authors similarly report that they found it did not discriminate 
between groups at follow-up, although they do not give the actual scores, precluding direct 
comparison between studies.  One interpretation of the findings of the current study is that 
much of the recovery had already taken place by the time the person was enrolled into the 
trial.  All participants had been in hospital for at least 3 days by the time they completed the 
baseline measures, and 80% of participants had been in hospital for at least a week by 
baseline.  They were no longer at the peak of their crisis, and were receiving care in hospital, 
which they may have perceived as helpful to their recovery (even for people under section), 
and therefore they scored quite highly on the measure.  Finally, participants also scored quite 
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highly on the SMQ (higher than previous clinical groups as outlined in Chapter 7).  It is 
difficult to know how best to interpret this finding.  It could simply be measurement error due 
to small sample size. As above, it could be that recovery and perhaps decentring from 
distressing experiences was underway by the time baseline data were taken.  It could also 
reflect a response to demand characteristics in a therapy trial context, rather than a cross-
sectional study as in previous studies (Chadwick et al., 2008, Peters et al., 2016).   It is also 
important to note that on average participants received only 15 minutes of mindfulness 
practice during their admission (5 mins per session, with an average of 3 sessions per 
participant), and therefore it would not be expected that much change would be shown on 
mindfulness.  Furthermore, participants were not given any audio files of guided practises or 
other resources to support home practice, so a group difference 6 months post-discharge is 
not to be expected.  
 
8.6 Strengths and limitations 
 
In order to better inform the interpretation of the findings of the study, the main strengths and 
limitations will be considered in this section.   
 
The question this trial was designed to answer related primarily to feasibility; can this trial be 
done in a UK NHS setting?  The answer, based on good recruitment and retention within the 
trial, is clearly yes.  However, generalisation to the wider NHS acute services is unknown. 
This trial was completed successfully using a single trial therapist, who did not conduct the 
therapy as part of routine practice, but rather whose time was funded to provide ‘extra’ 
therapy sessions as part of the research study.  Whether the trial could be done using ward 
psychologists to provide all the therapy sessions within routine practice is not yet known.  
Likewise, all participants were recruited from a single site, at a teaching hospital with close 
research links to its partner university, which provided a favourable research environment for 
the trial.  Whether the trial could be done at a different hospital, with a different clinical and 
research environment, is not known.  The impact of the intervention on short-term outcomes 
after discharge is also likely to be highly sensitive to the care context.  For example, the 
baseline rate of re-admissions within 6 months post-discharge may vary across geographical 
location, due to factors such as varying bed numbers and differing availability of follow-up 
care in the local area.  One example of this is the varying access to talking therapies in the 
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community post-discharge across different parts of the country.  The overall rate of therapy in 
the 6 months post-discharge for this trial (18/48; 33%) is consistent with the general rate in 
the London NHS trust in which the trial was conducted (Colling et al., 2017).  However, rates 
of NICE-recommended psychological therapy for psychosis varies widely across the country.  
For example, Haddock and colleagues report only a 5% rate for service user receipt of such 
therapies in the North-West of England (Haddock et al., 2014). The impact on re-admission 
rates found at any one site may not therefore be readily generalisable to other sites.  It should 
also be noted that relapse was defined for the purposes of the trial as a documented 
exacerbation in psychotic symptoms, followed by a change in clinical management.  Using 
this definition therefore means that relapse is partly defined by the response of clinical 
services, i.e. the system around the service user, rather than purely the individual’s 
experience and self-reported difficulties.  The impact of the intervention on short-term 
relapse will also therefore be highly sensitive to the care context, and the system as a whole, 
rather than being solely mediated through changes in the individual’s well-being. 
 
Again, a common criticism of clinical trials is that over-restrictive eligibility criteria leads to 
unrepresentative patient samples, limiting the generalisability of such trials to routine clinical 
practice.  This is particularly relevant to trials within challenging clinical settings such as 
psychiatric wards.  People requiring inpatient care often have complex and chronic 
difficulties, in the context of highly adverse social environments.  The eligibility criteria for 
this trial were therefore designed to be as broad and inclusive as possible.    For example, 
there were no exclusions made for people who were homeless, or in temporary housing, even 
though these people are more challenging to follow-up and may be more likely to drop-out of 
the study.  In fact, 14 participants (28%) were identified as having housing issues at baseline 
(including homelessness, rent arrears, threat of eviction etc.), indicating that this is a 
commonly occurring social difficulty for people on admission.  Likewise, there was no 
exclusion for co-morbid substance use, which is also a common characteristic of this clinical 
group.  However, detailed information on substance use was not assessed at baseline, nor 
were participants asked about problems during the follow-up period, so the impact of 
substance use on outcomes cannot be determined from the data collected for this trial.   
 
All consecutive admissions were screened for eligibility, and data were collected on the 
reasons for not participating in the trial (including distinguishing between people who did not 
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meet eligibility criteria, and people who met criteria but did not take part for other reasons).  
These rich and detailed data are very helpful for assessing feasibility.   They give a baseline 
rate for how many admissions in general fit the eligibility criteria, which is important for 
assessing whether the intervention is addressing a common, or rare, clinical presentation.  In 
fact, almost 50% of all acute admission screened met the initial eligibility criteria.  Just under 
20% of eligible patients ended up taking part in the study, which again gives a helpful 
estimate of how many people would have to be screened overall to achieve a certain sample 
size in a later efficacy trial.   
 
As is usual with psychological therapy trials, participants were not blind to condition, in that 
they were told whether they had been randomly assigned to either therapy 1 (SAT) or therapy 
2 (MBCI).  A brief explanation of what each therapy involved was given within the study 
information sheet, and was repeated immediately after randomisation.  The two therapy 
conditions were labelled neutrally (therapy 1 vs. therapy 2) on both patient and staff 
information sheets, in an attempt to engender clinical equipoise (a belief that there is not one 
better intervention between those on offer in the trial).  This seems to have been successful as 
the treatment credibility scores were high in both conditions, and did not differ significantly 
between those in the MBCI group and those in the SAT group.  
 
Ward staff were blinded to treatment condition as they were not explicitly told whether 
participants had been randomised to MBCI or SAT.  Standard templates were used for all 
therapy notes and letters, which were added to electronic patient notes, and shared with staff.  
These standard templates did not contain any information about the content of the sessions, 
which might have accidentally unblinded staff to treatment condition.  However, participants 
were not explicitly forbidden to share with staff what they were doing in the therapy sessions.  
This was with the aim of assessing whether participant disclosure was a significant threat to 
unblinding staff.  Based on feedback interviews with ward staff (nurses and psychiatrists), it 
appears that participant disclosure was not a significant threat to blinding, as most staff 
reported that they had no discussions about the content of any of the sessions with 
participants.  Furthermore, although all staff interviewed said they understood it was a 
randomised trial with an active control arm, they displayed little interest in which treatment 
arm participants were in, suggesting they perhaps did not think one was probably superior to 
the other.  However, this was not systematically tested, for example by asking ward staff to 
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make a guess as to which treatment arm each participant had been in.  Staff were also not 
asked to make therapy credibility ratings in the same way as participants were, so it is 
possible that they may not have regarded the 2 therapies as equally helpful in the same way 
as participants.    
 
There was also no attempt to measure or control for ‘contamination’ between therapy arms 
(in which trial participants receive aspects of the intervention to which they were not 
randomised, through contact with participants in the other treatment arm).  It is challenging to 
define and detect contamination in therapy trials.  For example, if two participants in separate 
therapy arms just talk about their respective therapies, does this constitute contamination, or 
does it require active sharing of therapy resources such as handouts or skills learned within 
therapy?  If so, how common is it that participants share therapy resources with one another 
in this way, and how can it best be quantified?  These remain unanswered questions.  One 
solution to avoid therapy contamination is to use a cluster randomised design, in which 
participants in different treatment conditions do not come into contact with each other 
because they are on different wards, or at different sites.  However, randomising by ward or 
hospital site raises additional methodological challenges, such as accounting for systematic 
differences between clusters (i.e. different levels of TAU between different sites). 
 
As the trial therapist, PJ was of course not blind to therapy condition, and she also conducted 
all the research assessments, from baseline to 6-month follow-up.  Although all the 
questionnaire measures used were self-report, there was still potential risk of bias from PJ’s 
involvement in the follow-up measures due to a conflict between the role of therapist and 
researcher.  For example, participants might have responded to demand characteristics and 
under-reported symptoms due to an implicit expectation that they would have benefitted from 
the therapy.  The main service use data (readmission and relapse rates) were however rated 
by an independent clinician who was blind to treatment condition (and who was otherwise 
not involved in the study). 
 
8.7 Implications for planning of subsequent trials 
 
Progression to a further trial is warranted given feasibility was clearly demonstrated according 
to all pre-set benchmarks.  In order to address some of the limitations of the trial as discussed 
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above, it would be helpful to design the next trial to address some of the key issues, before 
progression to a full efficacy trial would be warranted.  The appropriate next step would be to 
move from single-site to multi-site, and also from a single trial therapist, to delivery by ward 
psychologists in routine practice with independent assessors.  
 
Looking ahead to a future efficacy trial - what should the primary outcome be?  Selection of 
an appropriate outcome measure, which genuinely reflects real-world concerns of service 
users and clinicians, is probably one of the most important decisions in trial design 
(Heneghan et al., 2017).  Reducing short-term readmission rates is certainly of concern to the 
NHS given the economic cost of frequency hospital admission.   However, perhaps we need 
to understand more about the personal, social and occupational costs of hospital readmissions 
from a service user perspective.  Therefore, further work to understand the impact of short-
term re-admission to hospital would be valuable, including ascertaining an appropriate trial 
end point.  For example, is 6 months an appropriate trial end point, or should the follow-up 
period be shorter or longer?  Even the definition of ‘relapse’ is contentious.  This trial found 
very little difference between readmission rate, and relapse rate from clinical note review.  
This might reflect the fact that most people who require a change in clinical management 
arising from an exacerbation in psychotic symptoms tend to go on to require hospital 
admission.  Only two participants in the trial had an episode of care with the home treatment 
team (HTT), and avoided subsequent hospital admission.  However, differences between 
readmission and relapse rate is also likely to be context-sensitive (for example, it might 
depend on how over-burdened HTTs are or how severe bed shortages are locally). 
 
8.8 General directions for future research 
 
This is an exciting time for inpatient research in psychosis, with several pilot trials currently 
testing brief interventions within this setting.   For example, Lisa Wood and colleagues 
adapted a CBT intervention for internalised stigma into a brief intervention and successfully 
piloted it with acute inpatients with psychosis (Wood, 2017).  Daniel Freeman and colleagues 
have highlighted the importance of sleep disruption in psychosis (Waite et al., 2016), and 
have recently completed a pilot trial of a brief CBT for sleep intervention for people with 
psychosis during an inpatient admission (Sheaves et al., 2017).  These innovations in the field 
lead to the possibility that in the future, when someone is admitted to hospital during a mental 
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health crisis, there could be a menu of choices available to them of brief, evidence-based 
interventions.  Brevity of admission, or concerns that ‘now is not the right time’, should no 
longer be used as an excuse for withholding talking therapies in inpatient setting.  There is 
clear emerging evidence that brief inpatient interventions are feasible, safe and acceptable to 
both service users and ward staff.  However, much more work is needed to further evaluate 
such interventions in larger, robustly designed and adequately powered trials.  Looking to the 
future, the challenge of how to measure and quantify the benefit of inpatient therapies looms 
large on the horizon.  A shift away from symptom measures, to a greater focus on functional 
outcomes guided by service user priority, may be a productive direction. The use of 
questionnaires as process measures (e.g. psychological flexibility) will continue to play an 
important role in evaluating whether hypothesised mechanisms change as predicted over the 
course of treatment.  This will help us to understand the active ingredients of any 
intervention, which is essential for refinement and improvement of interventions over time.  
 
8.9 The Final Word 
 
Although analysis of the qualitative data gathered as part of the trial is not reported within 
this thesis, it feels appropriate to give the final word back to the trial participants.  An 
admission to hospital can be one of the worst experiences someone ever goes through, and 
the fact that so many people were willing to take part in this research to improve services for 
the future is truly humbling.   The following quote from one of the participants who was in 
the MBCI group encapsulates some of the wisdom many participants expressed about what 
they learnt from their experience of engaging with therapy at such a difficult time. 
 
“We actually, erm, recomposing yourself and… erm, how can I say it, recomposing 
yourself and just taking the moment out from that environment to… you know what I mean, to 
just be at peace with yourself.  Yeah, and just staying sort of focused even though there’s 
noise all around.  There’s always going to be noise and stuff…in life, you know what I 
mean?” 
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10.2 Letter of favourable opinion from ethics committee 
 
  
London - Camberwell St Giles Research Ethics Committee  
Level 3, Block B  
Whitefriars  
Lewins Mead  
Bristol  
BS1 2NT  
  
Telephone: 
01173421330 29 September 2015  
  
Dr Pamela Jacobsen  
NIHR Clinical Doctoral Research Fellow  
King's College London  
Department of Psychology (PO 78)  
Institute of Psychiatry, Psychology & Neuroscience  
De Crespigny Park  
London  
SE5 8AF  
  
  
Dear Dr Jacobsen  
  
Study title:  MINDFULNESS-BASED CRISIS INTERVENTIONS (MBCI)  
FOR PSYCHOSIS WITHIN ACUTE INPATIENT  
PSYCHIATRIC SETTINGS; A FEASIBILITY RANDOMISED 
CONTROLLED TRIAL  
REC reference:  15/LO/1338  
Protocol number:  N/A  
IRAS project ID:  177667  
  
Thank you for your letter of 14 September 2015. I can confirm the REC has received 
the documents listed below and that these comply with the approval conditions 
detailed in our letter dated 01 September 2015  
  
Documents received  
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The documents received were as follows:  
  
Document    Version    Date    
Participant information sheet (PIS) [Participant information sheet  
v.1.8_14.09.15]   
1.8   14 September 2015  
  
Approved documents  
  
The final list of approved documentation for the study is therefore as follows:  
  
Document    Version    Date    
Covering letter on headed paper [Covering letter]      30 June 2015   
Evidence of Sponsor insurance or indemnity (non NHS Sponsors only) [KCL 
insurance policy]   
      
GP/consultant information sheets or letters [Letter to GP/community care 
team]   
1   30 June 2015   
Interview schedules or topic guides for participants [Patient feedback topic 
guide]   
1.4   07 July 2015   
Interview schedules or topic guides for participants [Staff feedback topic 
guide]   
1.4   07 July 2015   
IRAS Checklist XML [Checklist_21072015]      21 July 2015   
Letter from funder [NIHR funding letter]      16 September 2014  
Letter from statistician [Letter from statistician]      16 July 2015   
Non-validated questionnaire [Therapy Credibility]   1   16 July 2015   
Non-validated questionnaire [Self-rating of psychotic symptoms - voices]   1   16 July 2015   
Non-validated questionnaire [Self-rating of psychotic symptoms - Beliefs]   1   16 July 2015   
Non-validated questionnaire [Stress bubbles]   1   16 July 2015   
Other [CV 2nd supervisor]      16 July 2015   
Other [Assessment plan]   1   14 July 2015   
Participant consent form [Patient consent form]   1.4   25 June 2015   
Participant consent form [Patient consent form - Audio-taping feedback 
interview]   
1   22 June 2015   
Participant consent form [Staff consent form_feedback interview]   1   04 June 2015   
Participant information sheet (PIS) [Brief participant leaflet]   1.4   25 June 2015   
Participant information sheet (PIS) [Brief clinician leaflet]   1.3   25 June 2015   
Participant information sheet (PIS) [Staff information sheet for trial 
feedback]   
1.3   16 July 2015   
Participant information sheet (PIS) [Participant information sheet  
v.1.8_14.09.15]   
1.8   14 September 2015  
REC Application Form [REC_Form_16072015]      16 July 2015   
Research protocol or project proposal [Trial protocol]   1.7   14 July 2015   
184 
 
 
Summary CV for Chief Investigator (CI) [Chief Investigator CV]      16 July 2015   
Summary CV for supervisor (student research) [CV 1st supervisor]      16 July 2015   
Summary, synopsis or diagram (flowchart) of protocol in non technical 
language [Study Plan]   
1   16 July 2015   
Validated questionnaire [DASS-21]         
Validated questionnaire [HPSVQ]         
Validated questionnaire [SMQ]         
Validated questionnaire [QPR]         
  
You should ensure that the sponsor has a copy of the final documentation for the study.  
It is the sponsor's responsibility to ensure that the documentation is made available to 
R&D offices at all participating sites.  
  
  
  
Yours sincerely  
  
Aliki Sifostratoudaki REC Assistant  
  
  
E-mail: nrescommittee.london-camberwellstgiles@nhs.net   
  
  
Copy to:  Mr Keith Brennan, King’s College London   
Ms Jennifer Liebscher, South London and Maudsley NHS Foundation 
Trust  
  
  
  
15/LO/1338  Please quote this number on all correspondence  
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10.3 Sample Case Report Form (CRF) 
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CASE REPORT 
FORM 
MINDFULNESS-BASED CRISIS INTERVENTIONS (MBCI) FOR 
PSYCHOSIS WITHIN ACUTE INPATIENT PSYCHIATRIC 
SETTINGS; A FEASIBILITY RANDOMISED CONTROLLED TRIAL 
BrIef Talking therapIes ON wards (amBITION study)  
ISRCTN37625384 
Participant ID:   
 
Hospital Site:    
 
Ward:   
 
 
 
  
  
amBITION 
study 
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INSTRUCTIONS FOR COMPLETION 
Complete all sections.  Do not leave any boxes blank. Write NK for "not 
known” where applicable. 
Write legibly, in black ink, and in block capitals. 
Do not write outside of the designated boxes. Write BRIEF comments within 
free space boxes where provided. 
 
Completely fill in each box using leading ‘0’ if needed. 
 
Use DDMMYY for all date formats 
 
Ensure that the participant ID is completed in the header on each page. 
 
If a mistake is made, never obliterate or over-write an entry.  Corrections will be 
made as follows: 
 Cross out the incorrect entry with a single line so that the incorrect 
entry should still be readable.  Never use correction fluid. 
 Enter the correct data. 
 Initial and date the correction 
 
CRFs will be kept in a secure location during the course of the trial. Once the 
trial has closed the CRFs will then be archived with all other essential 
documentation. 
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Section 1: SCREENING INITIAL ELIGIBILITY SCREEN 
 
Identified by clinical team as i) 
experiencing distressing psychotic 
symptoms AND Iii)F20-39 diagnosis 
YES  ☐ 
NO  ☐ 
Trial therapist has capacity for new 
participant 
YES  ☐ 
NO  ☐ 
Primary/allocated nurse gives 
permission for researcher to 
approach 
YES  ☐ 
NO  ☐ 
 
If no, specify reason below: 
  
 
 
 
Participant given brief information 
leaflet 
YES  ☐ 
NO  ☐  
Date given:   
                            (DDMMYY) 
Participant gives consent for 
researcher to access clinical notes for 
further eligibility screen 
YES  ☐ 
NO  ☐  
Date given:   
                            (DDMMYY) 
DEMOGRAPHICS  
DATE OF BIRTH                          
(DDMMYY) 
  
ETHNICITY 
CODE 
 
LABEL 
 
 
 
 
 
 
SEX 
 
MALE              ☐ 
FEMALE          ☐ 
DIAGNOSIS 
ICD-10 CODE 
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The following criteria MUST be answered YES for participants 
to be included in the trial 
YES NO 
1. Aged 18 or above ☐ ☐ 
2. Current psychiatric inpatient on a working-age adult 
ward 
☐ ☐ 
3. Diagnosis of schizophrenia-spectrum disorder or 
psychotic symptoms in the context of an affective 
disorder (ICD-10 codes F20-39) 
☐ ☐ 
4. Reports at least one current distressing positive 
psychotic symptom 
☐ ☐ 
5. Able to give informed consent to participate in trial, as 
assessed by consultant psychiatrist/responsible clinician 
☐ ☐ 
6. Willing and able to engage in psychological therapy ☐ ☐ 
If any of the above criteria is answered NO, the participant is NOT eligible for 
the trial and must not be included in the study.  Please list reason(s) for 
ineligibility for screen failure on Participant Eligibility Review page. 
Section 1: SCREENING INCLUSION/EXCLUSION CRITERIA 
The following criteria MUST be answered NO for participants to 
be included in the trial 
YES NO 
7. Diagnosis of learning disability, or major cognitive 
impairment arising from underlying medical condition  
☐ ☐ 
8. Unable to engage in a talking therapy in English, or to 
complete simple written questionnaires in English 
☐ ☐ 
9. Primary diagnosis of substance misuse ☐ ☐ 
10. Does not report any current distressing psychotic 
symptoms 
☐ ☐ 
11. Lacks capacity to consent to participation in research 
trial 
☐ ☐ 
12. Unable to take part in individual therapy due to risk of 
aggression/violence 
☐ ☐ 
13. Mental state precludes possibilty of engaging in a talking 
therapy, e.g. significant thought disorder 
☐ ☐ 
If any of the above criteria is answered YES, the participant is NOT eligible for 
the trial and must not be included in the study.  Please list reason(s) for 
ineligibility for screen failure on Participant Eligibility Review page. 
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Is the participant eligible to take part in the trial? 
 
 
Investigator’s Signature:________________________ 
 
Investigator’s Name:_________________________ 
 
Date:    
 
                       (DDMMYY) 
 
YES ☐ 
 
NO ☐ 
 
 
  
Section 1: SCREENING PARTICIPANT ELIGIBILITY REVIEW 
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Participant given information sheet 
 
YES  ☐ 
NO  ☐  
Date given:   
                                   (DDMMYY) 
Participant agreed to participate 
 
 
 
 
 
 
 
 
 
YES  ☐ 
NO  ☐  
If no, give reason: 
Not interested ☐ 
Not feeling well enough ☐ 
Not wanting talking therapy ☐ 
Not agreeing to randomisation ☐ 
Other:_________________________ 
 
                        
Participant gave written informed 
consent 
YES  ☐ 
NO  ☐  
Date:   
                                   (DDMMYY) 
Patient was randomised YES  ☐ 
Date:  
                                    
                                  (DDMMYY)      
NO  ☐  
If no, give reason: 
Discharged ☐ 
Lost capacity ☐ 
Changed mind ☐ 
Transferred out of SLaM ☐ 
Other:________________________ 
Patient randomised to condition 
 
Therapy credibility score   (0-10) 
 
Therapy 1 ☐  
 
Therapy 2 ☐ 
Section 1: SCREENING INFORMED CONSENT AND 
RANDOMISATION 
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Section 2: BASELINE DATA DEMOGRAPHIC DATA 
1. Relationship status 
☐Not currently in a relationship 
☐In a relationship, but not living with 
partner 
☐In a relationship and living with 
partner 
4.   Highest level of education            
☐No formal qualifications 
☐GCSE (or equivalent) 
☐A-Levels (or equivalent) 
☐Graduate 
☐Post-graduate 
☐Other (specify)________________           
 
2a. Where they live 
☐Supported accommodation 
☐Temporary accommodation 
☐Rented (council) 
☐Rented (private) 
☐Own property 
☐In family home 
2b. Live alone? 
☐Yes 
☐No (tick all that apply) 
Partner/spouse ☐ 
Parents ☐ 
Children under 18 ☐ 
Children over 18 ☐ 
Siblings ☐ 
Other family ☐ 
Friend ☐ 
Flatmates ☐ 
Other:______________________ 
5. Employment status (tick all that 
apply) 
☐Working part-time 
☐Working full-time 
☐Studying 
☐Volunteering 
☐Retired 
☐Looking after family 
☐Unemployed 
☐Claiming DLA/ESA 
3. Housing problems identified on 
admission? 
☐No 
☐Yes (tick all that apply) 
Homeless ☐ 
Unsuitable accommodation ☐ 
Rent/mortgage arrears ☐ 
Threat of eviction ☐ 
Other:____________________ 
6a. Migrated to the UK? 
☐Yes  
☐No 
6b. Asylum-seeker/refugee status? 
☐Yes 
☐No 
6c. English as first language? 
☐Yes 
☐No 
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1. Psychiatric Diagnoses (list ICD-10 
code) 
 
 
 
 
 
 
5a. Open to CMHT on admission? 
☐Yes 
☐No  
5b. On Care Programme Approach 
(CPA)? 
☐Yes 
☐No 
 
2a. Date of admission  
                                                 
                                                
(DDMMYY) 
2b. Legal status on admission 
☐Informal 
☐MHA (section________) 
2c. Date of discharge 
                                              
                                               (DDMMYY) 
 
5c. If open to CMHT, date and nature 
of last contact: 
                                               
                                              (DDMMYY) 
☐In person 
☐Phone 
☐Letter 
3. Previous admissions? 
☐No 
☐Yes (if yes, specify no.)__________ 
    (no. in past 12 months)_________ 
 
6. Psychological therapy in past 5 
years 
☐None 
☐Offered (type)_________________ 
☐Received (type)________________ 
4a. Date first presented to services 
 
                                               (DDMMYY) 
4b. Date first presented to SLaM 
                                                
                                                
(DDMMYY) 
7a.Suicidality in lead-up to crisis? 
☐Yes 
☐No 
7b. Suicide attempts in past 12 mths? 
☐Yes 
☐No 
Section 2: BASELINE DATA CLINICAL DATA 
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SECTION 3: OUTCOMES CHECKLIST FOR COMPLETION 
T1: BASELINE  
 
    (    (                         Date 
(DDMMYY) 
 
T2: POST-THERAPY  
 
                                       Date 
(DDMMYY) 
F1: 3 MONTH FOLLOW-UP 
 
                                     Date 
(DDMMYY) 
F2: 6 MONTH FOLLOW-UP 
 
                                     Date 
(DDMMYY) 
Self-report measures 
completed: 
PSRS -V   Y ☐          N ☐ 
PSRS-B    Y ☐          N ☐ 
HPSVQ    Y ☐          N ☐ 
DASS-21  Y ☐          N ☐ 
SMQ         Y ☐          N ☐ 
QPR          Y ☐          N ☐ 
Self-report measures 
completed: 
PSRS -V   Y ☐          N ☐ 
PSRS-B    Y ☐          N ☐ 
HPSVQ    Y ☐          N ☐ 
DASS-21  Y ☐          N ☐ 
SMQ         Y ☐          N ☐ 
QPR          Y ☐          N ☐ 
Self-report measures 
completed: 
PSRS -V   Y ☐          N ☐ 
PSRS-B    Y ☐          N ☐ 
HPSVQ    Y ☐          N ☐ 
DASS-21  Y ☐          N ☐ 
SMQ         Y ☐          N ☐ 
QPR          Y ☐          N ☐ 
Self-report measures 
completed: 
PSRS -V   Y ☐          N ☐ 
PSRS-B    Y ☐          N ☐ 
HPSVQ    Y ☐          N ☐ 
DASS-21  Y ☐          N ☐ 
SMQ         Y ☐          N ☐ 
QPR          Y ☐          N ☐ 
Medication log completed: 
Y  ☐                  N ☐ 
Adverse events log 
completed: 
Y    ☐               N  ☐ 
Medication log completed: 
Y  ☐                  N ☐ 
Adverse events log 
completed: 
Y    ☐               N  ☐ 
Medication log completed: 
Y  ☐                  N ☐ 
Adverse events log 
completed: 
Y    ☐               N  ☐ 
Medication log completed: 
Y  ☐                  N ☐ 
Adverse events log 
completed: 
Y    ☐               N  ☐ 
 TAU in addition to trial:- 
Attended therapy groups  ☐ 
1:1 therapy input  ☐ 
Service use data completed: 
Y ☐                      N ☐ 
  
Service use data completed: 
Y ☐                      N ☐ 
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SECTION 3: OUTCOMES SELF-REPORT MEASURES 
 PSRS-V PSRS-B HPSVQ 
(0-36) 
DASS-21 
 
SMQ 
(0-96) 
QPR 
(0-88) 
 
T1: BASELINE 
Frequency (1-7)   
 
Distress (0-10)  
 
Believability (0-10) 
 
Frequency (1-7)   
 
Distress (0-10)  
 
Believability (0-10) 
 
 Dep (0-42)   
 
Anx (0-42)  
 
Str (0-42) 
 
  
T2: POST-THERAPY Frequency (1-7)   
 
Distress (0-10)  
 
Believability (0-10) 
 
Frequency (1-7)   
 
Distress (0-10)  
 
Believability (0-10) 
 
 Dep (0-42)   
 
Anx (0-42)  
 
Str (0-42) 
 
  
 
F1: 3 MONTH 
FOLLOW-UP 
 
Frequency (1-7)   
 
Distress (0-10)  
 
Believability (0-10) 
 
Frequency (1-7)   
 
Distress (0-10)  
 
Believability (0-10) 
 
 Dep (0-42)   
 
Anx (0-42)  
 
Str (0-42) 
 
  
F2: 6 MONTH 
FOLLOW-UP 
Frequency (1-7)   
 
Distress (0-10)  
 
Believability (0-10) 
 
Frequency (1-7)   
 
Distress (0-10)  
 
Believability (0-10) 
 
 Dep (0-42)   
 
Anx (0-42)  
 
Str (0-42) 
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SECTION 4: THERAPY LOG 
Session 
No. 
Date scheduled 
(DD/MM/YY) 
Attended? Audio-recorded? Session 
duration 
(mins) 
Breaks Session ended 
early (EE) OR 
interrupted (I)? 
Risk issues? 
                              ☐Yes 
☐No (if no, give reason) 
☐Therapist cancelled 
☐Pt declined 
☐Pt asleep 
☐Pt in other meeting 
☐Pt not on ward 
☐Yes 
☐No (if no, give reason) 
☐Pt declined 
☐Recorder not available 
☐Equipment failure 
 
 
 
Adequate 
engagement? 
☐Yes 
☐No 
No. of 
breaks  
 
Duration 
(total in mins) 
 
☐Yes – EE 
☐Yes - I  
(specify who by) 
 
 
☐No 
☐Yes (if so, specify) 
 
 
 
 
☐No 
  
 
 
☐Yes 
☐No (if no, give reason) 
☐Therapist cancelled 
☐Pt declined 
☐Pt asleep 
☐Pt in other meeting 
☐Pt not on ward 
☐Yes 
☐No (if no, give reason) 
☐Pt declined 
☐Recorder not available 
☐Equipment failure  
 
 
 
Adequate 
engagement? 
☐Yes 
☐No 
No. of 
breaks  
 
Duration 
(total in mins) 
 
☐Yes – EE 
☐Yes - I  
(specify who by) 
 
 
☐No 
☐Yes (if so, specify) 
 
 
 
 
☐No 
  
 
 
☐Yes 
☐No (if no, give reason) 
☐Therapist cancelled 
☐Pt declined 
☐Pt asleep 
☐Pt in other meeting 
☐Pt not on ward 
☐Yes 
☐No (if no, give reason) 
☐Pt declined 
☐Recorder not available 
☐Equipment failure  
 
 
 
Adequate 
engagement? 
☐Yes 
☐No 
No. of 
breaks  
 
Duration 
(total in mins) 
 
☐Yes – EE 
☐Yes - I  
(specify who by) 
 
 
☐No 
☐Yes (if so, specify) 
 
 
 
 
☐No 
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☐Yes 
☐No (if no, give reason) 
☐Therapist cancelled 
☐Pt declined 
☐Pt asleep 
☐Pt in other meeting 
☐Pt not on ward  
 
☐Yes 
☐No (if no, give reason) 
☐Pt declined 
☐Recorder not available 
☐Equipment failure  
 
 
 
Adequate 
engagement? 
☐Yes 
☐No 
No. of 
breaks  
 
Duration 
(total in mins) 
 
☐Yes – EE 
☐Yes - I  
(specify who by) 
 
 
☐No 
☐Yes (if so, specify) 
 
 
 
 
☐No 
  
 
 
☐Yes 
☐No (if no, give reason) 
☐Therapist cancelled 
☐Pt declined 
☐Pt asleep 
☐Pt in other meeting 
☐Pt not on ward  
 
☐Yes 
☐No (if no, give reason) 
☐Pt declined 
☐Recorder not available 
☐Equipment failure  
 
 
 
Adequate 
engagement? 
☐Yes 
☐No 
No. of 
breaks  
 
Duration 
(total in mins) 
 
☐Yes – EE 
☐Yes - I  
(specify who by) 
 
 
☐No 
☐Yes (if so, specify) 
 
 
 
 
☐No 
  
 
 
☐Yes 
☐No (if no, give reason) 
☐Therapist cancelled 
☐Pt declined 
☐Pt asleep 
☐Pt in other meeting 
☐Pt not on ward  
 
☐Yes 
☐No (if no, give reason) 
☐Pt declined 
☐Recorder not available 
☐Equipment failure  
 
 
 
Adequate 
engagement? 
☐Yes 
☐No 
No. of 
breaks  
 
Duration 
(total in mins) 
 
☐Yes – EE 
☐Yes - I  
(specify who by) 
 
 
☐No 
☐Yes (if so, specify) 
 
 
 
 
☐No 
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 STRESS (1-6) INTERFERENCE (1-6) HOPEFULNESS (1-6) 
Session No. Pre Post Pre Post Pre Post 
1  
 
 
     
2  
 
 
     
3  
 
 
     
4  
 
 
     
5  
 
 
     
 
  
SECTION 5: WITHIN-SESSION MEASURES – STRESS BUBBLES 
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 Re-admission? Days to 1st re-
admission 
Number of re-
admissions 
Total no. 
OBDs 
Episodes with 
HTT 
Relapse No. of 
contacts with 
CMHT 
Reference to 
therapy goal 
in notes? 
F1: 3 MONTH 
FOLLOW-UP 
 
 
☐YES 
☐NO 
 
 
 
 
    
☐YES 
☐NO 
 
If yes, no. of 
episodes: 
 
 
☐Type 1 
(true relapse) 
☐Type 2 
(exacerbation) 
☐Non-relapse 
☐Unable to 
rate 
 
In person 
 
 
Phone 
 
 
Letter 
 
 
☐YES 
☐NO 
F2: 6 MONTH 
FOLLOW-UP 
 
 
 
 
☐YES 
☐NO 
 
 
 
 
 
 
    
 
☐YES 
☐NO 
 
If yes, no. of 
episodes: 
 
 
☐Type 1 
(true relapse) 
☐Type 2 
(exacerbation) 
☐Non-relapse 
☐Unable to 
rate 
 
In person 
 
 
Phone 
 
 
Letter 
 
 
 
 
☐YES 
☐NO 
SECTION 6: SERVICE USE DATA AT FOLLOW-UP 
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SECTION 7: PSYCHIATRIC MEDICATION LOG T1: BASELINE 
No. Medication name 
(specify generic or brand) 
Dose  
(specify units) 
Route Frequency 
Record if PRN 
(specify units) 
Compliance – self-
report 
Compliance – collateral 
source  
(specify:                          ) 
1.  
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
2.  
 
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
3.  
 
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
4.  
 
 
 
   ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
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SECTION 7: PSYCHIATRIC MEDICATION LOG T2: END OF THERAPY 
No. Medication name 
(specify generic or brand) 
Dose  
(specify units) 
Route Frequency 
Record if PRN 
(specify units) 
Compliance – self-
report 
Compliance – collateral 
source  
(specify:                          ) 
1.  
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
2.  
 
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
3.  
 
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
4.  
 
 
 
   ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
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SECTION 7: PSYCHIATRIC MEDICATION LOG F1: 3 MONTH FOLLOW-UP 
No. Medication name 
(specify generic or brand) 
Dose  
(specify units) 
Route Frequency 
Record if PRN 
(specify units) 
Compliance – self-
report 
Compliance – collateral 
source  
(specify:                          ) 
1.  
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
2.  
 
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
3.  
 
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
4.  
 
 
 
   ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
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SECTION 7: PSYCHIATRIC MEDICATION LOG F2: 6 MONTH FOLLOW-UP 
No. Medication name 
(specify generic or brand) 
Dose  
(specify units) 
Route Frequency 
Record if PRN 
(specify units) 
Compliance – self-
report 
Compliance – collateral 
source  
(specify:                          ) 
1.  
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
2.  
 
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
3.  
 
 
 
 
 
 
  ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
4.  
 
 
 
   ☐  Yes 
☐  No 
☐  Partial 
☐  Yes 
☐  No 
☐  Partial 
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SECTION 8: ADVERSE EVENTS LOG: DEFINITIONS 
Related to Study? 
 
1 (Highly Likely) – temporal relationship is reasonable and there is no other cause to explain event   
2 (Likely) - temporal association is reasonable and event is more likely to be due to study intervention than other cause  
3 (Unlikely) - temporal relationship unlikely or event likely to be better explained by another cause  
4 (Highly Unlikely) - temporal relationship not reasonable or event explained in isolation by another cause  
 
Classification 
 
Serious: 
Class A: Incidents that result in death (they include, but are not limited to, homicide, suicide, death by accidental causes, 
sudden/unexpected death) 
Class B: Incidents which acutely jeopardise the health or psychological well-being of the individual, resulting in injury requiring 
immediate hospital admission and/or permanent disability. 
Class C: Incident which acutely jeopardise the health or psychological well-being of the individual, resulting in injury requiring 
medical attention and/or, for staff, more than 3 days sick leave. 
Non-Serious 
Class D: These are incidents which result in minor injury, and, for staff, requiring less than 3 days sick leave. 
Class E: Incidents, which result in no injury. 
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SECTION 8: ADVERSE EVENTS LOG 
Has the participant experienced any adverse events for the duration of the trial?                                 
 NO  ☐               YES  ☐  (If yes, complete log below) 
No. Description of event Start Date 
(DD/MM/YY) 
End Date 
(DD/MM/YY) 
Related to study? Classification If applicable: 
Date reported  
(DD/MM/YY) 
 
1.  
 
 
 
 
 
 ☐1(Highly Likely) 
☐2 (Likely) 
☐3 (Unlikely) 
☐4 (Highly unlikely)      
☐A      
☐B      
☐C 
☐D 
☐E 
 
2.  
 
 
 
 
 
 
 ☐1(Highly Likely) 
☐2 (Likely) 
☐3 (Unlikely) 
☐4 (Highly unlikely)      
☐A      
☐B      
☐C 
☐D 
☐E 
 
3.  
 
 
 
 
 
 
 ☐1(Highly Likely) 
☐2 (Likely) 
☐3 (Unlikely) 
☐4 (Highly unlikely)      
☐A      
☐B      
☐C 
☐D 
☐E  
 
4.  
 
 
 
  ☐1(Highly Likely) 
☐2 (Likely) 
☐3 (Unlikely) 
☐4 (Highly unlikely)      
☐A      
☐B      
☐C 
☐D 
☐E  
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Did participant complete the trial? ☐    YES, please provide date of last 
visit:- 
 
 
                       (DDMMYY) 
 
☐    NO, please provide date of 
withdrawal and give reason below:- 
 
 
 
                         (DDMMYY) 
 
Early withdrawal – please tick the most appropriate reason for participant 
not completing the trial:- 
 
 ☐  Adverse events related, specify AE:  
   
 ☐ Participant’s decision, specify:  
   
 ☐ Investigator’s decision, specify:  
   
☐  Sponsor’s decision, specify: 
   
 ☐ Lost to follow-up, specify reason if known: 
   
☐  Other, specify:  
 
 
 
  
SECTION 9: TRIAL COMPLETION 
   Page 207 of 279 
Brief talking therapies on wards   V.2   16.09.15 
 
 
Principal Investigator’s Signature Statement: 
I have reviewed this CRF and confirm that, to the best of my knowledge, it 
accurately reflects the study information obtained for this participant.  All 
entries were made either by myself or by a person under my supervision 
who has signed the Delegation and Signature Log. 
Principal Investigator’s Signature: 
 
 
 
Principal Investigator’s Name: 
 
 
 
 
 
Date of Signature: 
 
 
                      (DDMMYY) 
ONCE SIGNED, NO FURTHER CHANGES CAN BE MADE TO THIS CRF 
WITHOUT A SIGNED DATA QUERY FORM 
 
SECTION 10: PRINCIPAL INVESTIGATOR SIGN-OFF 
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10.4 Therapy Manual (MBCI)
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MINDFULNESS-BASED CRISIS 
INTERVENTIONS (MBCI) FOR 
PSYCHOSIS WITHIN ACUTE 
INPATIENT PSYCHIATRIC 
SETTINGS; A FEASIBILITY 
RANDOMISED CONTROLLED 
TRIAL  
 
Mindfulness-Based Crisis Interventions (MBCI) 
Therapy Manual  
 210 
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1. INTRODUCTION/ENGAGEMENT 
 
1.1 Therapist role and introductions 
First session and re-cap at subsequent sessions: - 
 
 
1.2 Format of sessions/ overall intervention 
First session and re-cap at subsequent sessions:- 
 
 
 
 
 
1.3 Frequency/duration of sessions 
First session and re-cap at subsequent sessions: -  
 
 
 
 
 
1.4 Confidentiality 
First session and re-cap at subsequent sessions: - 
 
 
 
 
 
  
Hello, my name is [give first name and last name] and I’m a [give professional 
background].  I’ll be your therapist for these sessions.  My role is to work together with 
you to ffer some help at this difficul  time.   
 
At the beginning of each session we’ll decide together how we want to use the time we 
have. At the end of the session we’ll also discuss together something you might want to 
practice, or a small goal you want to achieve, before the next session.  We’ll check in with 
how this “homework” went at the beginning of the next session. 
 
We have up to an hour to meet today. You can take a break, or stop early anytime you 
need.  This is your [insert session number] session.  We can have anywhere from 1- 5 
sessions together while you are an inpatient here on the ward, and the sessions will stop 
whenever you get discharged.  We can decide together when and how often you would 
like to have your therapy sessions. 
 
I’d also just like to explain how confidentiality works for the purposes of these sessions.  I 
will let your care team both here on the ward and in the community know that you are 
attending sessions, but I won’t share any details about the content of what we discuss.  
However, with your agreement, I would like to be able to share any goals we have come 
up with together with your community team so that they can help support you in working 
towards those goals.  If you tell me anything that makes me concerned for your safety, or 
for the safety of others I will have to share that straight away with your care team.  If you 
are unhappy with anything on the ward relating to your care in general, I am happy to 
help you discuss that with your primary/allocated nurse if you would like but I’m afraid I 
won’t be able to address any of those problems myself. 
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1.5 Consent for taping 
First session (and re-check at subsequent sessions):- 
 
 
 
 
 
 
 
 
 
 
  
Before we start I’d like to ask whether you would be happy for me to record these sessions 
using this digital voice recorder.  One reason is that it would help you and me to remember 
what we talked about in the sessions, because it’s easy to forget things when there is a lot 
to think about and a lot going on at the moment.  Another reason is that it can be helpful 
for my supervisor to be able to listen to the tape to check that I am doing things properly.  
All the recordings will be stored securely and anonymously and will be destroyed after the 
study has been written up, unless you give consent for them to be kept for 
educational/training purposes.  If you like, you can have a copy of the recording of each 
session to listen to between the sessions and keep for the future.  You can also ask me to 
turn the recorder off at any time.  How does that sound to you?  Do you have any more 
questions about recording the sessions? 
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2. SESSION PLAN 
Each session should follow a set format as below:- 
2.1 Brief mindfulness practice 
2.2 Check-in with how the client has been since the last session 
2.3 Set agenda collaboratively with client 
2.4 Review homework 
2.5 Discuss agreed topic(s) 
2.6 Set homework/practice activities collaboratively (client and therapist take 
written note) 
2.7 Therapist to ask for client feedback on session, including any concerns or 
confusion that may have arisen 
2.8 Set the time and date of the next session (recorded on appointment card for 
client)  
Reminder of what happens next in case of unexpected discharge before next 
meeting 
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3. SESSION CONTENT 
3.1 Adaptations to working in acute settings 
MBCI is delivered between 1 and 5 sessions, of up to an hour in duration.  Sessions may be 
scheduled daily as a maximum frequency, and weekly as a minimum frequency.   Each 
session is designed to be “stand-alone” and contains the key components of the intervention. 
The therapist should therefore approach each session as if it were the only session.  However, 
for clients who do take part in more than 1 session, any given session can of course refer back 
to previous sessions, with the aim of building and expanding on ideas and skills that have 
already been discussed, modelled and practised.  All sessions take place on the ward. 
There are 3 key components which each session should include, in the suggested order within 
each session:- 
i. Developing mindfulness skills (guided practice) 
ii. Making sense of crisis using mindfulness model 
iii. Identifying values and committed action 
The therapist should aim to begin each session with a brief guided mindfulness practice.  For 
the 1st session, this can be simply introduced as a way to “arrive” in the present moment of 
starting the session.  Formulation of the crisis using the mindfulness model is likely to take 
up more of session 1 than in later sessions.  Given the time constraints of the setting, this may 
require more of a psycho-educational than a fully socratic approach as might be more 
appropriate in longer-term therapy.   
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3.2 MBCI Key components 
3.2.1 Developing mindfulness skills 
The therapist should aim to introduce the concept of mindfulness in an accessible and 
understandable way.   
 
 
 
 
 
The therapist should explain why it’s important to practice mindfulness skills.   
 
 
 
 
 
 
 
The therapist should lead a guided mindfulness meditation in line with mindfulness for 
psychosis guidelines (e.g. brief practices, with frequent grounding and use of everyday, 
concrete language). See section 4 – THERAPY RESOURCES for examples of different 
mindfulness meditations which can be used flexibly, to best meet the individual’s needs.   
After each practice, the therapist should lead a brief enquiry into the client’s experiences 
during the practice.   
 
  
Have you heard of mindfulness before?  Is this something you have tried out for yourself 
before? 
Mindfulness means being aware of our experience in the current moment, whatever that 
might be, without needing to fix or change things.  For example, you might just notice 
what your mind is up to without needing to get caught up in the thoughts or voices which 
might be around in that moment. 
 Mindfulness is a skill that takes time to learn.  It’s a bit like learning to ride a bike, it’s 
something you have to try out for yourself, you can’t just read about it in a book!  It also 
takes time to learn and you get most out of it if you practice regularly.  In these sessions, 
I’d like to try out some simple mindfulness practices with you, which you can also practice 
by yourself between sessions and after the therapy has finished. 
I’m curious to know what you noticed during that practice.  Remember we’re just 
practicing being with our experience in the moment, just as it is, whatever that might be.   
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Key insights might include noticing the mind’s tendency to wander away from the present 
moment, what the mind habitually wanders away to, noticing how thoughts/voices/bodily 
sensations come and go over time, and noticing habitual reactions such as trying to push 
away unwanted experiences.  
 
 
 
 
 
 
 
 
It is very common for people to confuse being mindful with being relaxed, emptying the 
mind or having a focusing attention like a laser.  If this comes up the therapist can gently 
remind the client that this isn’t the intention behind mindful meditation, whilst also 
acknowledging how helpful it is to notice such judgements or expectations coming up in the 
mind.  
 
 
 
 
 
 
  
Isn’t it interesting when we practice mindfulness how our minds often get caught up in 
expectations of how we think things should be, or judgements of how well we’re doing?  
When we practice mindfulness, we can thank our minds for these expectations and 
judgements, without needing to buy into them.  Mindfulness isn’t about emptying the mind, 
getting relaxed or stopping the mind from wandering.  It’s just about noticing, with 
kindness and curiosity, what’s in our experience in the present moment. 
That’s really interesting how you were able to notice sensations in the soles of your feet, 
and how these were changing from moment to moment.  It’s also great that you were able 
to be aware that your mind often wandered away from the sensations in the soles of your 
feet.  It sounds like your mind got quite busy with voices at a certain point, but you were 
then gently able to direct your awareness to come back to sensations in the soles of the feet 
at other times. 
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3.2.2 Making sense of crisis using mindfulness model 
The therapist should aim to develop a collaborative understanding with the client of what has 
brought them into crisis on this occasion, focussing on how the person usually tries to cope 
with difficult thoughts, feelings and experiences and how well these strategies are working 
for the person.  The crisis formulation template (therapy resource 4.1) should be completed 
together with the client if possible.  The starting point for the formulation is always with the 
identifying and naming of the overwhelming emotions at the heart of the crisis.  
 
 
 
 
 
 Recent stressors to the crisis should then be identified such as social (e.g. housing, finances) 
and personal problems (e.g. relationships).  More distal factors which the client identifies as 
vulnerability factors may be appropriately named and validated, without being discussed in 
detail (e.g. childhood abuse). 
 
 
 
 
This then leads on to a discussion of how the client was trying to deal with these difficult 
thoughts, emotions and psychotic symptoms.  Given time constraints, therapists will share a 
formulation and example strategies (e.g. Chadwick, 2006), asking the client to connect with 
and provide examples of his or her own habitual reactions. In line with the formulation, the 
therapist should pay particular attention to attempts to either block out, suppress or otherwise 
escape from unwanted internal experiences, or reactions that mean getting caught up in 
struggling with internal experiences (rumination, fighting).  Mindfulness is located as a 
middle way between these two reactive styles.  
 
 
 
 
We’re going to start by naming some of those really difficult emotions that were around 
for you, and putting them in the centre here in the jagged hole.  This sharp, spiky shape 
represents how painful these emotions can be to be in contact with. 
What has been going on for you recently?  Has anything in particular been upsetting you 
or worrying you lately? 
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Finally, the therapist should also help the client to identify their existing strengths and 
adaptive coping skills (e.g. seeking support from friends) which can be built on, and these 
should be noted on the formulation. 
 
 
 
 
 
3.2.3 Identifying values and committed action 
The therapist should work with the client to identify their values (e.g. family, work, health, 
society), and discuss specific behavioural goals consistent with these values.   
 
 
 
 
 
The valued living questionnaire (resource 4.5) can be used to help the client to identify their 
values. The therapist should then discuss with client the difference between values and goals, 
using a metaphor to illustrate (section 4.6).   
 
 
 
It sounds like things have been really difficult for you, and you’ve been trying to cope 
with things as best you can.  It also sounds like some of the things you did to try and cope 
(e.g. drinking alcohol to block out voices) sometimes helped at the time, but other times 
the voices just got louder or they came back to bother you later on.  This is typical of 
what happens to a lot of people who are trying to cope with difficult experiences.  It 
sounds very frustrating and I’d like to work together with you to help find other ways of 
relating to your experiences, which might work out better for you.  Mindfulness is one 
approach we’ll be exploring together in these sessions.  It’s kind of like a middle way 
between these 2 extremes – not running away from experiences, but not getting caught up 
in fighting against them either. 
What other things do you try and do to help you cope?  Do you do other things which you 
feel work better for you?    What would you say are your personal strengths?  What about 
someone who knew you well as a person – what would they say? 
I’d be interested in knowing more about your values.  By this I mean, the things that really 
mean something to you deep down.  The things that you would like your life to stand for.  
This is about the values you have freely chosen, rather than what other people have told 
you about what you should want in life.   
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Clients should be encouraged to set a small, achievable goal for homework at the end of each 
session which can be reviewed at the beginning of next session (and recorded using record 
form 4.7).  In preparation for discharge, longer-term goals can also be identified (e.g. starting 
a college course) and should be shared with the client’s community care team at the end of 
therapy, with their permission.  This can then act as a bridge to carrying on committed action 
post-discharge and helping the person to build up a valued life in the community. 
  
Values are like the direction you are heading in, and goals are like the destinations you 
reach along the way.  I’d like to start thinking with you about setting some goals which are 
consistent with your values.  What sort of things would you be doing, how would you be 
spending your time, if you weren’t struggling with (e.g. voices, worries, anxiety)? 
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4 THERAPY RESOURCES – Index 
 
4.1 Making sense of crisis  - formulation template 
4.2 Applying mindfulness to distressing symptoms handout 
4.3 Mindfulness meditations (5 mins, frequency guidance, use of everyday concrete 
language) 
4.3.1  Meditation on the soles of the feet on the floor 
4.3.2  Mindfulness of the breath 
4.3.3  Body scan 
4.3.4  Hearing/seeing meditation 
4.3.5  Eating/drinking meditation 
4.3.6  Walking meditation 
4.3.7  Movement meditation 
4.4 Mindfulness metaphors 
4.4.1 Leaves on a stream/clouds in the sky 
4.4.2 Passengers on a bus 
4.4.3 Unwelcome party quest 
4.4.4 Finger cuff 
4.5 Valued Living Questionnaire (Wilson et al., 2010) 
4.6 Values, goals & actions sheet 
4.7 Goals/values metaphors 
4.7.1  Compass metaphor 
4.7.2  Skiing metaphor 
4.7.3  Path up the mountain metaphor 
4.7.4  Swamp metaphor 
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THE PAST 
 
STRENGTHS & ALTERNATIVE 
COPING 
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Step 1: Name the horrible feelings 
• Stick to emotion words (e.g. angry, sad, scared) 
• OK to be flexible and use people’s own words 
• Validate!! Don’t get drawn into fixing/challenging…. 
• Empathise and normalise  
• Be patient and gently persevere – both therapist and client can be guilty of wanting to 
avoid talking about emotions  
Step 2: The past 
• Identify triggering factors to horrible feelings  
• Start with most recent factors e.g. relationship problems, financial worries 
• If appropriate, can also name more distant factors 
• Can name and acknowledge past trauma without needing to go into detail  
Step 3: Identify maintaining factors 
• What are the behaviours that have brought someone into hospital? 
• How is the person trying to cope? 
• Remember people do things for understandable reasons  
• Validate not judge  
Step 4: Identify strengths and alternative coping strategies 
• Identify strengths – personal qualities, values, resilience in the face of adversity, what 
is important to the person? 
• Alternative coping – let the person tell you!! 
• Social support, maintaining well-being, religious/spiritual practices, coping strategies 
(existing or need to be developed)  
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10.5 Therapy Manual (SAT)
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MINDFULNESS-BASED CRISIS 
INTERVENTIONS (MBCI) FOR 
PSYCHOSIS WITHIN ACUTE 
INPATIENT PSYCHIATRIC 
SETTINGS; A FEASIBILITY 
RANDOMISED CONTROLLED 
TRIAL  
 
Social Activity Therapy (SAT)26 
Therapy Manual  
                                                 
26 Based on protocol developed by Haddock et al (2009) for the PICASSO project 
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4. INTRODUCTION/ENGAGEMENT 
 
4.1 Therapist role and introductions 
First session and re-cap at subsequent sessions: - 
 
 
4.2 Format of sessions/ overall intervention 
 
 
 
First session and re-cap at subsequent sessions: - 
 
 
 
 
 
4.3 Frequency/duration of sessions 
First session and re-cap at subsequent sessions: -  
 
 
 
 
  
Hello, my name is [give first name and last name] and I’m a [give professional 
background].  I’ll be your therapist for these sessions.  My role is to work together with 
you to offer some help at this difficult time.   
 
At the beginning of each session we’ll decide together how we want to use the time we 
have. At the end of the session we’ll also discuss together something you might want to 
practice, or a small goal you want to achieve, before the next session.  We’ll check in with 
how this “homework” went at the beginning of the next session. 
 
We have up to an hour to meet today. You can take a break, or stop early anytime you 
need.  This is your [insert session number] session.  We can have anywhere from 1- 5 
sessions together while you are an inpatient here on the ward, and the sessions will stop 
whenever you get discharged.  We can decide together when and how often you would 
like to have your therapy sessions. 
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4.4 Confidentiality 
First session and re-cap at subsequent sessions: - 
 
 
 
 
 
  
I’d also just like to explain how confidentiality works for the purposes of these sessions.  I 
will let your care team both here on the ward and in the community know that you are 
attending sessions, but I won’t share any details about the content of what we discuss.  
However, with your agreement, I would like to be able to share any goals we have come 
up with together with your community team so that they can help support you in working 
towards those goals.  If you tell me anything that makes me concerned for your safety, or 
for the safety of others I will have to share that straight away with your care team.  If you 
are unhappy with anything on the ward relating to your care in general, I am happy to 
help you discuss that with your primary/allocated nurse if you would like but I’m afraid I 
won’t be able to address any of those problems myself. 
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4.5 Consent for taping 
First session (and re-check at subsequent sessions): - 
 
 
 
 
 
 
  
Before we start I’d like to ask whether you would be happy for me to record these sessions 
using this digital voice recorder.  One reason is that it would help you and me to remember 
what we talked about in the sessions, because it’s easy to forget things when there is a lot 
to think about and a lot going on at the moment.  Another reason is that it can be helpful 
for my supervisor to be able to listen to the tape to check that I am doing things properly.  
All the recordings will be stored securely and anonymously and will be destroyed after the 
study has been written up, unless you give consent for them to be kept for 
educational/training purposes.  If you like, you can have a copy of the recording of each 
session to listen to between the sessions and keep for the future.  You can also ask me to 
turn the recorder off at any time.  How does that sound to you?  Do you have any more 
questions about recording the sessions? 
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5. SESSION PLAN 
Each session should follow a set format as below:- 
5.1 Check-in with how the client has been since the last session 
5.2 Set agenda collaboratively with client 
5.3 Review homework 
5.4 Discuss agreed topic(s) 
5.5 Set homework/practice activities collaboratively (client and therapist take 
written note) 
5.6 Therapist to ask for client feedback on session, including any concerns or 
confusion that may have arisen 
5.7 Set the time and date of the next session (recorded on appointment card for 
client)  
Reminder of what happens next in case of unexpected discharge before next 
meeting 
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6. SESSION CONTENT 
SAT is delivered between 1 and 5 sessions, of up to an hour in duration.  Sessions may be 
scheduled daily as a maximum frequency, and weekly as a minimum frequency.   Each 
session is designed to be “stand-alone” and contains the key components of the intervention. 
The therapist should therefore approach each session as if it were the only session.  However, 
for clients who do take part in more than 1 session, any given session can of course refer back 
to previous sessions, building on activities and interests that have already been identified. 
The purpose of SAT is to collaboratively work with the client to identify activities they enjoy 
and which they can engage in during sessions, and, between sessions as they wish. The aim is 
to provide a supportive environment with a therapist using non-specific aspects of therapy 
(e.g. agenda setting, collaboration, feedback, empathy).  All sessions take place on the ward. 
 
Key aspects include: 
 Review and discussion around activities which the client currently engages in (using 
interest/activity checklist if helpful) 
 Discussion of activities which the client has enjoyed previously 
 Discussion of any activities which the client would like to engage with during the 
therapy sessions e.g. playing games, puzzles, arts & crafts, reading magazines etc. 
(subject to risk management issues) 
 Collaborative setting of homework to carry out enjoyable and achievable activities 
between sessions (using homework/apt card to record the agreed activity).  Only a 
small and realistic goal should be set as homework e.g. read for 20 mins after dinner. 
The therapist should aim to be supportive, collaborative and empathic at all times and to 
adhere in general to all non-specific therapy factors in cognitive-behavioural therapy (CBT), 
as defined by the Cognitive Therapy Scale for Psychosis (CTS-PSY; Haddock et al, 2001).  
However, the therapist should not employ any therapy techniques specific to any model of 
therapy, including CBT for psychosis or mindfulness-based therapies. The therapist should 
aim to keep the sessions activity focussed.  If the client raises any emotional difficulties 
during the sessions, or becomes distressed, the therapist should aim to validate and contain 
the client’s distress rather than offer advice or counselling.  The therapist can sign-post to 
other sources of support, including staff on the ward and the client’s community care team if 
required.  
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7. THERAPY RESOURCES – Index 
 
- Interest/activity checklist 
- Homework/apt card 
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10.6 Fidelity and Adherence Scale 
 
BrIef Talking therapIes ON wards (amBITION study) 
MBCI = Mindfulness Based Crisis Interventions/SAT = Social Activity Therapy 
Therapist:     
Client ID number:                         
Session Number:  
Rater: 
Date of Rating:  
(After rating completed) Which therapy do you think is being delivered?     MBCI ☐ SAT ☐ 
INSTRUCTIONS 
The scale consists of 4 sub-scales, as follows:- 
A: Non-specific Cognitive Therapy Scale (essential to MBCI & SAT) - pgs. 2-3 
B: MBCI-specific Therapy Scale (unique to MBCI) - pg.4 
C: SAT-specific Therapy Scale (unique to SAT) - pg.4 
D: CBT for psychosis Therapy Scale (proscribed for both MBCI & SAT) - pg.5 
Within each sub-scale each key component is rated on Adherence (A) and Competence (C). 
Adherence:  For each key component, assess whether this was demonstrated by the therapist during 
the session.  Where relevant, examples of relevant behaviours are listed below each component.  
Focus on what the therapist attempted to do, whether or not those attempts were successful or not.  If 
the component is present, score the item as ‘1’ (present).  Any components which are not 
demonstrated should be scored as ‘0 (absent)’. Enter either ‘0’ or ‘1’ in the adherence column for each 
key component. 
0= Absent 1= Present 
Competence:  For each component which has been identified as present (i.e. scored 1 in the 
adherence column), rate how well the therapist carried out the particular component.  Use the following 
scale to rate each component and enter that number in the competence column.  The competence 
column should be left blank for any components which were not demonstrated (i.e. which are rated 
absent under the adherence column). 
Always consider the whole session when rating each item. 
Rating scale for assessing competence 
0 1 2 3 4 5 6 
Poor Barely 
Adequate 
Mediocre Satisfactory Good Very Good Excellent 
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 A: Non-specific Cognitive Therapy Scale27 
Adherence Competence Key components 
  1) Agenda 
 
Did the therapist set an agenda? 
 
Examples of relevant  therapist behaviours include:- 
 - The therapist noted client’s current emotional status regarding agenda 
setting 
- Therapist and patient established agenda for session 
- Priorities for agenda items were established 
- Agenda was appropriate for time allotment (neither too ambitious nor 
too limited) 
- The agenda that provided an opportunity for the client to discuss salient 
events or problems occurring during the time since the last session 
- The agenda was adhered to during the session where appropriate 
  2) Feedback 
 
Did the therapist ask for and respond to feedback? 
 
Examples of relevant therapist behaviours include:- 
 - Therapist asked for feedback regarding previous session 
- Therapist asked for feedback and reactions to present session 
- Therapist asked client specifically for any negative reactions to 
therapist, content, problem formulation, etc. 
- Therapist attempted to respond to client’s feedback 
- Therapist checked that the client clearly understood the therapist’s role 
and/or the purpose and limitations of sessions 
- Therapist checked that s/he had fully understood the client’s 
perspective by summarising and asking client to fine-tune as 
appropriate 
  3) Understanding 
 
Did the therapist express warmth, respect and empathy for the client? 
 
Examples of relevant therapist behaviours include:- 
 
 
 
 
- Therapist conveys understanding by rephrasing or summarising what 
the client had said 
- Therapist shows sensitivity e.g. by reflecting back feelings as well as 
ideas 
- Therapist’s tone of voice was empathic 
- Therapist acknowledged client’s viewpoint as valid and important 
- Therapist did not negate client’s point of view 
- Where differences occurred, they were acknowledge and respected 
  
                                                 
27 Taken from Cognitive Therapy Scale for Psychosis (CTS-PSY); Haddock et al, 2001 
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Adherence Competence Key Components 
  4) Interpersonal Effectiveness 
 
Did the therapist communicate effectively during the session? 
 
Examples of relevant therapist behaviours include:- 
 - Therapist seemed open rather than defensive, shown by not holding 
back impressions or information, nor evading client’s questions 
- Content of what therapist said communicated warmth, concern and 
caring rather than cold indifference 
- The therapist did not criticise, disapprove or ridicule the client’s 
behaviour or point of view 
- The therapist responded to, or displayed, humour when appropriate 
- Therapist made clear statements without frequent hesitations or 
rephrasing 
- Therapist was in control of the session, s/he was able to shift 
appropriately between listening and leading 
  5) Collaboration 
 
Did the therapist collaborate effectively with the client? 
 
Examples of relevant therapist behaviours include:- 
 - Therapist asked client for suggestions on how to proceed and offered 
choices when feasible 
- Therapist ensured that client’s suggestions and choice were 
acknowledged 
- Therapist explained rationale for intervention(s) 
- Flow of verbal interchange was smooth with a balance of listening and 
talking 
- Therapist worked with client even when using a primarily educative role 
- Discussion was pitched at a level and in a language that was 
understandable by the client 
  6) Homework 
 
Did the therapist set and review homework? 
 
Examples of relevant therapist behaviours include:- 
 - Therapist explicitly reviewed previous week’s homework 
- Therapist summarised conclusions derived, or progress made, from 
previous homework 
- Appropriate homework was assigned 
- Therapist explained rationale for homework assignment 
- Homework was specific and details were clearly explained  
- Therapist asked patient if s/he anticipated problems in carrying out the 
homework 
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B: MBCI-specific Therapy Scale 
Adherence Competence Key components 
  1) Making sense of crisis using mindfulness model28 
 
Did the therapist work together with the client to build up a shared 
understanding of what has brought them into crisis, including 
identifying habitual responses to internal experiences, and formulating 
this within the mindfulness model? 
 
  2) Developing mindfulness skills29 
 
Did the therapist lead a brief mindfulness practice in line with 
mindfulness for psychosis guidelines?  
 
  3) Identifying values and committed action30 
 
Did the therapist help the client to identify (and distinguish between) 
values and goals, and to identify achievable short terms goals in line 
with their values? 
 
 
C: SAT-specific Therapy Scale31 
Adherence Competence Key components 
  1) Within-session activities 
 
Did the therapist discuss with the client which activities they would like 
to engage with during the session, and carry these out? 
 
  2) Response to emotional distress 
 
Did the therapist respond to any distress expressed by the client ONLY 
by validation and containment? 
 
 
  
                                                 
28 Adapted from Durrant, Clarke, Tolland, & Wilson (2007) 
29 Following Chadwick (2006) 
30 Hayes, Strosahl & Wilson (2011) 
31 Taken from Haddock et al (2009) – PICASSO project 
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D: CBT for psychosis Therapy Scale32 
Adherence Competence Key components 
  1) Columbo style 
 
Did the therapist help the client to explain their reasons for holding a 
belief by apologizing for being confused but then carefully questioning 
to gain the details? 
 
  2) Evidence for delusional beliefs 
 
Did the therapist assess the evidence that the client uses to support 
his/her delusional beliefs? 
 
  3) Verbal challenge of delusions 
 
Did the therapist challenge the client’s beliefs through discussion? 
 
  4) Validity Testing 
 
Did the therapist encourage the client to 1) engage in specific 
behaviours for the purpose of testing the validity of their beliefs, OR 2) 
make explicit predictions about external events so that the outcomes of 
those events could serve as tests of those predictions OR 3) review the 
outcome of previous validity tests? 
 
  5) Schemas 
 
Did the therapist assess and formulate underlying schemas and 
dysfunctional assumptions OR intervene on the basis of previous 
assessment of such schemas? 
 
 
                                                 
32 Taken from Rollinson et al. (2008)- Revised Cognitive Therapy for Psychosis Adherence Scale (R-CTPAS) 
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10.7 Self-rating of psychotic symptoms (beliefs) 
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10.8 Self-rating of psychotic symptoms (voices) 
 
  
 237 
 
10.9 Stress Bubbles 
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10.10 Therapy Credibility 
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10.11  Hamilton Program for Schizophrenia Voices Questionnaire (HSPVQ) 
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10.12 Depression, anxiety and stress scales (DASS-21) 
 
  
 241 
 
10.13 Questionnaire about the Process of Recovery (QPR) 
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10.14 Southampton Mindfulness Questionnaire; SMQ 
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10.15 Participant Feedback Topic Guide 
 
 (Suggestions in italics can be used as prompts in interviews/focus groups)  
Taking part in the study 
1) At the time, did you feel that you were given enough information about the study? 
(e.g. too much, too little, use of jargon) 
2) Was there anything in particular that almost put you off taking part? 
(e.g. concerns about taking part in research, unsure about therapy) 
3) Was there anything in particular that made you keen to take part? 
(e.g. boredom on ward, wanting someone to talk to) 
4) Did you understand why you were randomly allocated to either therapy 1 or 2 (rather 
than being able to choose yourself?) 
(e.g. concerns about randomisation, was the process explained well) 
5) What did you think of the questionnaires you were asked to fill out?  
(e.g. too few, too many, did they seem relevant?) 
 
Experiences of therapy 
6) How did you find having therapy sessions within the ward environment? 
(e.g. problems with noise, lack of privacy?) 
7) What did you think about the timing and frequency of therapy sessions? 
(e.g. convenience, sessions too often/not often enough) 
8) What did you think about the number of sessions you were offered? 
(e.g. too many/few, about right?) 
9) Have you ever been offered any therapy like this before, either in hospital or in the 
community? 
(e.g. was offer taken up, how did this compare with previous experiences?) 
10) a. What was the most helpful thing about the therapy? 
(e.g. understanding experience, chance to talk, coping skills, sharing goal with 
team) 
b. What was the least helpful thing about the therapy? 
(e.g. difficult to concentrate, too much to take in at that time) 
11) Have you done any mindfulness practice, or attended a mindfulness group in the past 
6 months?  If so, where did you do this?  
 
Overall Satisfaction 
On scale of 0 to 10, how satisfied were you with the therapy overall? 
Please circle a number. 
(0 means not satisfied at all, and 10 means completely satisfied). 
 
 
  
Not satisfied 
at all 
Completely 
satisfied 
Somewhat 
satisfied 
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10.16 Staff Feedback Topic Guide 
 
(Suggestions in italics can be used as prompts in interviews/focus groups)  
Views on the study 
1) Was the information you were provided about the study easy to understand? 
(e.g. too much, too little, use of jargon) 
2) Was there anything that made you reluctant to allow patients to take part in the study? 
(e.g. concerns about research procedures, unsure whether therapy would 
help) 
3) Was there anything that made you keen for patients to take part in the study? 
(e.g. promoting research on ward, potential benefits of therapy) 
4) Did you understand why patients were randomly allocated to either therapy 1 or 2 
(rather than being able to choose themselves?) 
(e.g. concerns about randomisation, was the process explained well) 
5) a. Could you guess which therapy was the control condition? 
b. Could you guess (or did patients tell you) which therapy condition they had been 
randomised to? 
6) What outcome measures did you think the study should be focussing on?  
(e.g. symptom measures, functioning, well-being, recovery) 
 
Views on therapy 
11) What did you think about the therapy sessions taking place within the ward 
environment? 
(e.g. problems with room space, lack of privacy?) 
12) What did you think about the timing and frequency of therapy sessions that were 
offered? 
(e.g. sessions too often/not often enough) 
13) What did you think about the number of sessions that were offered? 
(e.g. too many/few, about right?) 
14) What therapy are patients normally offered on your ward? 
(e.g. who offers this, is it normally taken up by patients?) 
15) a. Did patients tell you anything that was helpful about the therapy? 
(e.g. understanding their experiences, chance to talk, coping skills) 
b. Did patients tell you anything that was unhelpful about the therapy? 
(e.g. difficult to concentrate, too much to take in at that time) 
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10.17 Patient Information Sheet  
 
  
Participant Information Sheet  
BrIef Talking therapIes ON wards (amBITION study) 
  
You are being invited to take part in a research study. Before you decide whether you would 
like to take part or not, it is important that you understand why the research is being done and 
what it will involve. Please read this information sheet carefully and decide if you would like 
to take part or not.  
  
What is the study about?  
We know that people having distressing experiences 
sometimes come into hospital in crisis.  The aim of this study 
is to develop brief talking therapies which might be helpful for 
people when they are in hospital.  Everyone  
in the study will be offered one of two possible talking 
therapies, allocated at random.  This will either involve doing activities on the ward, or 
talking about how you are coping with things.  
  
Why have I been asked to take part in this study?   
You have been invited to take part because the Consultant Psychiatrist in charge of your care 
on the ward has identified you are experiencing some distress and might be willing to try out 
a talking therapy.  
  
Do I have to take part?   
No.  Participation is entirely voluntary, which means it is up to you whether you want to take 
part.  If you do decide to take part, but later change your mind, you are free to withdraw at 
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any time without giving a reason.  If you decide not to take part in the study, or later 
withdraw from the study, this will not in any way affect the normal care you receive.  
  
What will happen to me if I take part?  
• If you decide to take part, you will be asked to sign a consent form (you will be given a 
copy to keep along with this information sheet).  
• You will complete a brief research assessment, completing questionnaires about your 
current difficulties and your general well-being.  This should take no longer than 20 
minutes.  
• You will then be randomly allocated to one of the two therapies and be given your first 
appointment for therapy. This will be done by computer.  Random allocation means by 
chance, a bit like flipping a coin. This is to make sure the study is a fair  
 
test .   
  
  
  
  
  
    
Random Allocation  
THERAPY 2   
  -  1 -  sessions  5   
  -  Therapist working  
with you 1:1    
  -  Helping you with  
coping  skills  
  -  Goals for the future   
THERAPY 1   
  -  1 -  sessions 5   
  -   Therapist working  
with you 1:1   
  -   Helping you to do  
activities     
-  Planning activities    
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• You will be asked your permission for the therapy sessions to be 
audio-taped.   You can ask for a copy of the  
recordings. You can still take part in the study even if you do not 
agree for the sessions to be recorded.    
  
• After you have finished the therapy sessions the researchers will ask you to complete the 
same questionnaires as before you started therapy. We will then  
contact you again at 3 and 6 months from when you leave 
hospital to ask you to complete the questionnaires again. We 
will also be interested in your views about taking part in the 
study and how you found the therapies.  We will  
ask you if you would be willing to take part in a feedback 
interview, or a focus group, but you do not have to if you do not want to.  
   
• Some of the information we would like to collect about your contact with services in the 
Trust before and after therapy will be recorded in your clinical notes. We will ask your 
permission to gather this information from your notes, even if you decide to withdraw early 
from the study, and do not want to be contacted further by the researchers.  
  
• Throughout your involvement in the study all other care / treatments will remain the same 
unless changed by your care team.  
    
Will I be compensated for my time?  
You will be compensated £10 for your time to complete each research assessment.  If you 
choose to take part in a feedback interview or focus group, you will be reimbursed £20 to 
cover your time and travel expenses.   
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What are the possible disadvantages and risks of taking part?  
The main disadvantage is that the talking therapies may not be helpful. Talking therapies can 
sometimes involve talking about feelings, thoughts or experiences which may be upsetting at 
times. This is a completely normal part of therapy and the therapist is very experienced in 
keeping this to a level you can manage.  It is always possible to stop a therapy session or 
indeed to stop therapy altogether.  For the research assessments, there are no right or wrong 
answers and you do not have to answer any questions you do not want to.  You are free to ask 
the interviewer to move on to another subject or to stop the session altogether if you find any 
of the questions upsetting.  
  
What are the possible advantages or benefits of taking part?  
Both therapies are likely to have some benefit.  However, this will vary from person to 
person. The information we collect during the study will help us to decide on whether brief 
talking therapies will be helpful for people on wards in the future.  
  
    
Will my responses be confidential?  
Yes.  All data collected will be kept confidential, and identified 
only by an anonymous identification code that will not personally 
identify you. No names will be used when the  
results of the study are published or talked about so your identity 
will never be revealed in any reports based on this study. Some quotes may be used from 
feedback interviews or focus groups to illustrate themes in the research report, but these will 
all be anonymised and not used in a way that could personally identify you.  
  
The researchers will let your care team on the ward and in the community (including your 
GP) know that you are attending therapy sessions as part of the study, and a brief entry will 
be made in your clinical notes after each session.  This will not include any details about the 
content of what is discussed in the sessions.    
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If you tell the therapist something that makes them concerned 
for your safety, or the safety of others they will have to share 
this information with your care team on the ward and other 
professionals involved in your care as appropriate.  
  
What will happen to the results of the research study?  
The research should be completed by the end of 2017 and the results of the study will be 
published in an academic journal.  You are welcome to have a copy of the results of the study 
once it is completed, if you wish.   
  
Who is organising and funding the research?  
This research is being funded by the National Institute for Health 
Research (NIHR).  King’s College London is the lead sponsor of 
the research.  South London and Maudsley NHS  
Foundation Trust (SLaM) is the co-sponsor for the research.  
  
Who has reviewed the study?  
This research was reviewed and funded by the NIHR. People with experience of using local 
mental health services have provided advice on study procedures and documents so that the 
study will be carried out in the best possible way. All research in the NHS is also looked at by 
an independent group of people, called a Research Ethics Committee, to protect your safety, 
rights, wellbeing and dignity. This study has been reviewed and given a favourable opinion 
(approved) by the London-Camberwell St Giles Research Ethics Committee on 29th Sep, 
2015.  
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What should I do if I have questions or concerns about the research?  
If you have any concern about any aspect of this study, you should ask to speak 
to the researcher who will do their best to answer your questions (Dr. Pamela 
Jacobsen, Chief Investigator, 07541 736129). If you would rather speak to 
someone else then you can contact the project supervisors Professor Paul 
Chadwick or Dr. Emmanuelle Peters at King’s College London on 020 7848 
0033. If you wish to complain formally, you can do this through the NHS 
Complaints Procedure. You can call the Patient Advice and Liaison Service 
(PALS) freephone on 0800 731 2864 for information on how to do this.   
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10.18 Patient Consent Form 
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Consent Form – Part 1 
BrIef Talking therapIes ON wards (amBITION study) 
 
Consent for initial screening: 
Do you consent to your electronic/written records being screened to ensure you are 
eligible to take part in the study? (witness should sign for verbal consent)  
Signature (participant/witness):-                 Signature (researcher):- 
Date:-                                                               Date:- 
 
1. I confirm that I have read the information sheet dated .................... (version.....) 
for the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without my medical care or legal rights being 
affected. 
 
3. I understand that the researchers will access relevant sections of my electronic 
records to record my contact with services for follow-up data after I leave hospital.  I 
understand that if I withdraw early from the study I will not be contacted further by 
the researchers but this follow-up data will still be collected from my records. 
 
4. I understand that the key members of my care team will be told that I am taking 
part in this study (this will include, if relevant, my community consultant, care co-
ordinator, GP and any therapists working with me). 
 
5. I agree to take part in the above study.  
 
            
Name of Participant  Date    Signature 
 
            
Name of Person  Date    Signature 
taking consent 
  
amBITION 
study 
 
 253 
 
  
 
 
Consent Form – Part 2 
BrIef Talking therapIes ON wards (amBITION study) 
 
Additional consent for audio-taping of therapy sessions: 
 
1. I agree to audio-taping of my therapy sessions for use by my therapist and 
their clinical supervisor to ensure a high quality of therapy. I understand that 
all recordings will be stored securely and identified only by anonymous 
identification code.  I understand I can request a copy of the recordings to 
keep. 
 
2. I agree to audio recordings to be used for purposes of checking how well the 
therapy was delivered at the end of study. 
 
 
 
Signature (participant):-                                Signature (researcher):- 
Date:-                                                               Date:- 
 
 
 
 
 
  
amBITION 
study 
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10.19 Trial Steering Committee Meeting Minutes 
 
Trial Steering Committee (TSC) Meeting 28/04/16 – Minutes 
 
1. Welcome, introductions and apologies 
Attended:  Katherine Berry (Independent Chair) 
  Pamela Jacobsen (Chief Investigator) 
  Paul Chadwick (PhD Supervisor) 
  (Service User Advisory Group representative) 
Apologies: Emmanuelle Peters (PhD Supervisor) 
  Emily Robinson (Trial Statistician) 
 
2. Review Trial Report 
 
PJ gave a summary of the trial protocol and the intervention.  KB asked about the 
qualitative component of the study.  PJ clarified this was to get participants and staff 
views on the trial procedures and intervention. The plan is to invite participants to 
give feedback via an individual interview or small focus group, led by a member of 
the Service User Advisory Group.  KB suggested thinking about whether we have 
enough resources to interview everyone, and being realistic about the amount of 
qualitative data we could reasonably analyse.  We could instead aim to interview a 
small number of people (e.g. 10%, N=6) but in more depth. 
 
PJ summarised recruitment so far.  Recruitment started at the Maudsley Hospital on 1 
of the male wards in November 2015 (AL3), and recruitment was extended to 1 of the 
female wards (AL2) at the end of February 2016.  Recruitment has been 2-3 
participants a month so far. In order to achieve a rate of 5-6 participants a month, 
another male ward will be added in May (ES2) and PJ will have some extra help with 
recruitment from the local Clinical Research Network (CRN) who have just assigned 
2 clinical studies officers (CSOs) to the study.  CSOs can check patient’s notes for 
eligibility and also do the initial approach to patients on wards to see if they are 
interested in participating. 
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Retention within the trial is good so far.  All participants have received at least 1 session of 
therapy (which is defined as the minimum ‘dose’), and no-one has been lost to follow-up.  
Data completeness is also high, with 100% of participants having complete baseline 
assessments, and 92% having complete post-therapy measures.  The first wave of 3 month 
follow-ups have just begun.  PC queried how we define “lost to follow-up” and PJ suggested 
this should be based on whether data on the primary outcome is available (re-admission to 
hospital) rather than completion of questionnaire measures, as these are secondary  outcomes.  
Service-data will available for all participants from their SLaM electronic records, however 
we might not know about admissions to other trusts if someone has moved away or spent 
time out of the area during the follow-up period.  PJ will therefore record admissions to 
SLaM inpatient wards, and also any collateral information on admissions elsewhere for 
participants who move out of area.  It is possible that this information may not be available 
for participants who move away and cannot be contacted further. 
 
PJ reported that 1 participant had been withdrawn from the trial due to risk to 
therapist (but is still open to follow-up).  This led on to a discussion on how we define 
‘discontinued intervention’, given that participants have varying number of sessions 
anyway depending on the length of admission.  PJ suggested this should be defined on 
whether more sessions could have been offered had the participant not been 
withdrawn.   
 
There have 2 adverse events (1 in each arm), neither of which was considered to be 
related to participation in the trial.  
 
3. Any other business 
 
No other business to discuss 
 
4. Date and time of next meeting 
 
We agreed it would be helpful to meet again in about 6 months’ time, towards the end 
of the recruitment window.  PJ will send round some suggested dates in November 
via a doodle poll. PJ will also send round a recruitment update in the interim period, 
in 3 months’ time. 
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Trial Steering Committee (TSC) Meeting 13/03/17 – Minutes 
 
1. Welcome, introductions and apologies 
Attended:  Katherine Berry (Independent Chair – via skype) 
  Pamela Jacobsen (Chief Investigator) 
  Paul Chadwick (PhD Supervisor) 
  Emmanuelle Peters (PhD Supervisor) 
Emily Robinson (Trial Statistician) 
(Service User Advisory Group representative) 
 
 
2. Review Trial Report 
 
PJ gave a summary of the trial report.  Recruitment has now finished (N=50).  Everyone in 
the trial received at least 1 session of therapy (defined as the minimum dose).  The strategy of 
randomising at the beginning of session 1 was therefore a very successful way of eliminating 
any drop-out between randomisation and the start of therapy.  Follow-ups will continue over 
the next 6 months until August 2017.  Retention in the trial remains good.  Follow-up rates 
are over 95% for the primary outcome (readmission rate) and over 85% for the secondary 
outcomes (self-report clinical measures).  The trial will be written up according to the new 
CONSORT extension guidelines for pilot and feasibility trials.  There was a suggestion to 
separate out those assessed further for eligibility from those not assessed further for eligibility 
on the CONSORT diagram to improve clarity.  The ward teams and consultants are currently 
being asked to give some qualitative feedback on the trial, via individual interviews and focus 
groups.  These will be conducted by assistant psychologists who work in the trust, but who 
were not directly involved in the trial.  Garry and Christine have conducted service-user led 
feedback interviews with 4 trial participants so far, and the plan is to conduct between 4-6 
more over the next few months. 
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3. Any other business 
 
KB suggested thinking about sources for funding for a subsequent trial to build on this work.  
This could include a HTA programme grant from the NIHR or a post-doctoral fellowship 
award for PJ.  
 
4. Date and time of next meeting 
 
The suggested date of the next meeting will be Oct 2017.  All follow-ups will have been 
completed by this time, and the main feasibility outcome data will be available for review.  PJ 
will send out some dates via an online poll closer to the time. 
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Trial Steering Committee (TSC) Meeting 02/11/17 – Minutes 
 
1. Welcome, introductions and apologies 
Attended:  Katherine Berry (Independent Chair) 
  Pamela Jacobsen (Chief Investigator) 
  Paul Chadwick (PhD Supervisor) 
  Emily Robinson (Trial Statistician) 
(Service User Advisory Group representative) 
   (Service User Advisory Group representative) 
  Nancy Carney-Holland (Psychology BSc student) 
Apologies: Emmanuelle Peters (PhD Supervisor) 
 
2. Review Trial Report 
 
PJ gave a summary of the trial report, highlighting that most of the data is the same as 
presented in the last meeting.  However, we now have final figures on retention in the trial, as 
all follow-ups have been completed.  Retention in the trial is very good, and exceeds the pre-
set benchmark of no more than 20% loss to follow-up at trial end-point of 6 months post-
discharge.  The follow-up rate was 98% for service use data (from clinical notes) and 86% for 
self-report questionnaire measures.  KB asked about any factors we felt were important in 
being able to achieve good retention in the trial.  PJ commented that she felt flexibility and 
persistence were important in following people up, as sometimes people would be difficult to 
contact, or might miss appointments.  However, in general people were very committed to the 
trial, and were sometimes willing to meet with her for the follow-up, even if they were not 
engaging with their community team in general.  This is also seemed to reflect the fact that 
people valued the therapy they received as part of the trial, regardless of which arm of the 
trial they were in. 
 
3. Trial close-up and dissemination plans 
PJ and CA presented their draft of the feedback summary for participants.  A parallel version 
can be written to feedback to ward staff.  PC suggested reminding people about 
confidentiality and anonymity.  ER also suggested some re-wording to make clear that the 
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main trial paper would be open access, and therefore accessible online to everyone, not just 
health professionals.   
We briefly discussed the publication plan for the trial.  PJ suggested two separate papers, a 
main report focussing only on the feasibility outcomes, and then a secondary paper reporting 
on the clinical outcomes.  PJ will apply for HRA approval to collect service use data (from 
clinical notes only) for a further 6 months, so we have data on readmissions/relapse for up to 
12 months post-discharge. The final 12-month follow-up window would be in Feb 2018. 
We also talked about ideas for broader dissemination.  GE suggested it might be possible to 
go to community meetings on the acute wards, where they have slots for external speakers, 
and which are attended by staff and patients.  We agreed it might be a good idea to contact 
local mental health charities such as Rethink and Mind, and see whether they might be 
interested in including the study in their newsletters or online.  We should also consider a 
press release when the trial paper is published, given the novelty of the study, and the 
potential impact on improving inpatient care for the future. 
 
4. Any other business 
As the trial is completed, this was the final TSC.  PJ thanked all members of the committee 
for all their hard work and input over the course of the trial.  PJ particularly thanked KB for 
giving her time and expertise as Chair of the TSC, and to GE and CA who have been with the 
project throughout the whole three years, and also conducted some of the follow-up 
interviews with participants. 
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10.20 Data Management Plan 
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Appendix 1: Data Extraction Template (incorporating MMAT) 
 
Form version/date Version 2/03.01.17 
Review Title Psychological therapies for psychosis within acute 
psychiatric inpatient settings; A systematic review of 
current evidence 
PROSPERO ID CRD42015025623 
Name of review author 
completing this form 
 
Date form completed  
Reference of record being 
reviewed 
 
Notes (Unpublished – for 
own use) 
E.g. References to be followed up, source of 
information (especially if multiple reports of same 
trial, or unpublished data/personal communication 
included).   
 
METHODS 
Aim of intervention (as stated in the trial report/s.  What was the 
problem that this intervention was designed to 
address?) 
Aim of study (as stated in the trial report/s.  What was the trial 
designed to assess?) 
Study design (Case study/case series/observational 
study/uncontrolled trial/RCT etc.) 
Methods of recruitment of 
participants 
(how were potential participants approached and 
invited to participate?) 
Inclusion/exclusion criteria 
for participation in study 
 
Informed consent 
obtained? 
(Yes / No / Unclear) 
Ethical approval? (Yes / No / Unclear) 
Funding (including source, amount, if stated) 
Statistical methods and 
their appropriateness 
(if relevant - just brief overview required) 
RCTs ONLY: Power 
calculation? 
(Yes / No / Unclear) 
CLINICAL SETTING 
How ward is described e.g. acute, triage 
Characteristics of wards e.g. gender mix, no. of beds 
Country  
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PARTICIPANTS 
Clinical details (e.g. 
diagnosis, no. of 
admissions) 
 
Number participated: Total and number in each group if applicable 
 
RCTs ONLY: appropriate 
CONSORT diagram 
included? 
Yes (state if significant elements missing)/No 
 
Age: range, mean 
(standard deviation) 
 
Gender  
Ethnicity  
Other health problem/s (if 
relevant) 
 
Stage of problem/illness (if 
relevant) 
 
Treatment 
received/receiving 
Description of TAU if relevant 
 
Other social/demographic 
details (e.g. literacy or 
reading level) 
 
INTERVENTIONS 
Details of intervention 
 
Brief description of therapy as described in paper.  
(Capture this information for each arm of the study, 
eg. Intervention A, Intervention B…)   
 
CBT or non-CBT based? 
 
State if unclear or therapy model not described 
 
Sub-type of therapy (if 
relevant) 
 
e.g. ACT, compassion-focused 
 
Mode of delivery 
 
  
e.g. individual, group, family 
 
Details of control/usual or 
routine care 
 
 
Delivery of intervention  
 
(eg. stages, timing, frequency, duration) (for each 
intervention included in the study, e.g. Intervention 
A; Intervention B…) 
 
Details of providers  
 
  
(Who delivers the intervention? Number of 
providers; training of providers in delivery of 
intervention; specify profession and role).  
 
Intervention quality (if 
relevant):  
(record any information on the quality of the 
intervention - assessed by study authors, others, or 
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 by you - such as the evidence base of the 
intervention, or the quality of staff training for 
intervention delivery) 
 
Fidelity/integrity 
 
(Was the intervention delivered as intended? Record 
any assessment of this). 
 
Did therapy continue post-
discharge? 
 
 
Adaptations to standard 
protocols/procedures 
 
 
OUTCOMES 
Principal and secondary 
outcome measures 
 
As stated in paper - note if not explicitly stated or 
unclear  
 
Questionnaires/ 
assessment tools used 
 
(give reference for standard measures or state if 
unvalidated or new measure) 
 
Methods of assessing 
outcome measures  
 
 
  
(eg. Phone survey, questionnaire, physical 
measurements (for each outcome)) 
 
Methods of follow-up for 
non-respondents 
 
 
Timing of outcome 
assessment  
 
(including frequency, length of follow up (for each 
outcome))  
 
Data for meta-analysis 
could be extracted from 
paper for primary 
outcome measure 
(Dichotomous or 
Continuous?)? 
 
Yes/No/Partial (state what missing if relevant) 
 
Any mention of Adverse 
events? 
 
Yes/No e.g. whether formally monitored or not, 
mention of incidents which would be considered an 
adverse event (whether or not explicitly labelled as 
such) 
 
Details of any Adverse 
events? 
 
(eg. Complaints, levels of dissatisfaction, adverse 
incidents, side effects) 
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QUALITY ASSESSMENT (MMAT, 2011) 
Types of mixed 
methods study 
components or 
primary studies 
Methodological 
quality criteria 
(see tutorial for 
definitions and 
examples) 
Responses 
Yes No Can’t tell Comments 
Screening 
questions 
(for all types) 
Are there clear 
qualitative and 
quantitative 
research questions 
(or objectives), or 
a clear mixed 
methods question 
(or objective)? 
 
    
Do the collected 
data address the 
research question 
(objective)?  E.g. 
consider whether 
the follow-up 
period is long 
enough for the 
outcome to occur 
(for longitudinal 
studies or study 
components) 
 
    
Further appraisal 
may not be 
feasible or 
appropriate when 
the answer is 'no' 
or 'can't tell' to 
one or both of the 
screening 
questions 
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Types of mixed 
methods study 
components or 
primary studies 
Methodological 
quality criteria 
(see tutorial for 
definitions and 
examples) 
Responses 
Yes No Can’t tell Comments 
1. Qualitative 1.1  Are the sources 
of qualitative data 
(archives, 
documents, 
informants, 
observations) 
relevant to address 
the research 
question 
(objective)? 
 
    
1.2  Is the process 
for analyzing 
qualitative data 
relevant to address 
the research 
question 
(objective)? 
 
    
1.3  Is appropriate 
consideration given 
to how findings 
relate to the 
context, e.g. the 
setting in which the 
data were 
collected? 
 
    
1.4 Is appropriate 
consideration given 
to how findings 
relate to 
researchers' 
influence e.g. 
through their 
interactions with 
participants? 
 
    
2. 
Quantitative 
randomized 
controlled 
(trials) 
2.1 Is there a clear 
description of the 
randomization (or 
an appropriate 
sequence 
generation?) 
 
    
2.2 Is there a clear 
description of the 
allocation 
concealment (or 
blinding when 
applicable?) 
 
    
2.3 Are there 
complete outcome 
data (80% or 
above?) 
 
    
2.4 Is there low 
withdrawal/drop-
out (below 20%)? 
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Types of mixed 
methods study 
components or 
primary studies 
Methodological 
quality criteria (see 
tutorial for 
definitions and 
examples) 
Responses 
Yes No Can’t tell Comments 
3. 
Quantitative 
non-
randomised 
3.1 Are participants 
recruited in a way 
that minimizes 
selection bias? 
    
3.2 Are 
measurements 
appropriate (clear 
origin, or validity 
known, or standard 
instrument; and 
absence of 
contamination 
between groups when 
appropriate) 
regarding the 
exposure/intervention 
and outcomes? 
    
3.3 In the groups 
being compared 
(exposed vs. non-
exposed; with 
intervention vs. 
without; cases vs. 
controls) are the 
participants 
comparable, or do 
researchers take into 
account (control for) 
the difference 
between these 
groups? 
    
3.4 Are there 
complete outcome 
data (80% or above), 
and when applicable, 
an acceptable 
response rate (60% 
or above), or an 
acceptable follow-up 
rate for cohort 
studies (depending 
on the duration of 
follow-up?) 
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Types of mixed 
methods study 
components or 
primary studies 
Methodological 
quality criteria (see 
tutorial for 
definitions and 
examples) 
Responses 
Yes No Can’t tell Comments 
4. 
Quantitative 
descriptive 
4.1 Is the sampling 
strategy relevant to 
address the 
quantitative research 
question (quantitative 
aspect of the mixed 
methods question)? 
    
4.2 Is the sample 
representative of the 
population 
understudy? 
    
4.3 Are 
measurements 
appropriate (clear 
origin, or validity 
known, or standard 
instrument?) 
    
4.4 Is there an 
acceptable response 
rate (60% or above?) 
 
    
5. Mixed 
Methods 
 
Criteria for 
the 
qualitative 
component 
(1.1. to 1.4), 
and 
appropriate 
criteria for 
the 
quantitative 
component 
(2.1 to 2.4, or 
3.1 to 3.4, or 
4.1 to 4.4) 
must also be 
applied 
5.1 Is the mixed 
methods research 
design relevant to 
address the 
qualitative and 
quantitative research 
questions (or 
objectives), or the 
qualitative and 
quantitative aspects 
of the mixed methods 
question (or 
objective?) 
 
    
5.2 Is the integration 
of qualitative and 
quantitative data (or 
results) relevant to 
address the research 
question (objective?) 
 
    
5.3 Is appropriate 
consideration given 
to the limitations 
associated with this 
integration e.g. the 
divergence of 
qualitative and 
quantitative data (or 
results) in a 
triangulation design? 
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Appendix 2: Paper Publication of Trial Protocol in Pilot and Feasibility Trials 
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